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Abstract 
 
Background: Gestational diabetes mellitus (GDM) is defined as any degree of 
glucose intolerance that occurs or is first recognised during pregnancy. The 
prevalence of GDM is 1-28% globally and 11% in China. Although GDM can cause 
severe maternal and neonatal outcomes, there is no consensus worldwide as to 
whether universal or selective screening of expectant mothers should be 
recommended. In 2010, The International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) recommended that all pregnant women should be screened 
via a one-step universal screening approach for GDM, using a 75g oral glucose 
tolerance test (OGTT) with reduced thresholds. Despite ongoing debate over the 
efficacy and use of the IADPSG approach, China was the first country to adopt the 
new screening approach. A number of observational studies have shown that the new 
IADSPG approach is clinically more effective. However, reservations exist as to the 
associated increase in health costs and inconvenience to pregnant women. 
 
Aim: To assess and explore the best screening approach for GDM both globally and 
in China. 
 
Methods: The research involved three projects. Project I (Chapter 3) was a 
systematic review of the effectiveness and cost-effectiveness of universal versus 
selective screening for GDM, which followed a standard systematic review 
procedure for Diagnostic Test Accuracy studies. Project II (Chapter 4) was a Q 
methodology study to investigate the pregnant women’s attitudes towards and 
experience of the IADPSG one-step screening approach for GDM in China. A total 
of 30 pregnant women who visited the hospital for antenatal care in 2014 were 
recruited to participate in the study. The Q methodology study was undertaken using 
the FlashQ software and were analysed using the PQMethod software. Project III 
(Chapter 5) was a case-control study to establish and assess a risk score algorithm in 
order to improve the IADPSG approach for GDM screening in China. Medical 
records of 550 pregnant women (272 GDM cases and 278 controls) who had given 
birth in the year 2013 at the Chengdu First People’s Hospital were retrospectively 
collected and analysed. Univariable analysis and multiple logistic regression analysis 
were used to identify GDM risk factors and to formulate the risk score algorithm. A 
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Receiver Operating Characteristic (ROC) curve was employed to assess the 
effectiveness of the risk score algorithm for GDM screening. 
 
Results: The systematic review (Chapter 3) included 28 effectiveness studies, four 
cost studies and one cost-effectiveness study. Seven out of the 28 effectiveness 
studies and the cost-effectiveness study favoured selective screening. The Q 
methodology study (Chapter 4) suggested that the participants agreed as to the 
importance and necessity of the IADPSG one-step GDM screening for all pregnant 
women. However, the non-GDM women felt somewhat burdened in undertaking the 
fasting and 2-hour oral Glucose Tolerance Test (OGTT) for GDM under the 
IADPSG approach. The participants also desired more information on GDM and 
OGTT both before and after the test. The case-control study (Chapter 5) identified 
age, height, body mass index (BMI), family history of diabetes, waist circumference, 
previous deliveries and blood pressure before 24
th
 week of gestation to be risk 
factors for GDM in the Chinese population. Subsequently, a risk score algorithm was 
established, whereby the use of the risk score to select high-risk women for 
screening could help to exclude nearly half (45%) of non-GDM women from the 
OGTT while still diagnosing 80% of the GDM cases. 
 
Conclusion: Universal screening for GDM is recommended for areas where GDM 
prevalence is relatively high and where economic constraints circumscribing 
implementation of the approach do not exist. For areas where GDM prevalence is 
low, it is recommended that current practice, whether it is universal or selective 
screening, should be retained until more robust evidence emerges. The IADPSG one-
step universal screening was viewed positively in terms of importance and necessity 
by participants of the study, and they felt that GDM screening is necessary to be 
undergone by every pregnant woman. At the same time, the non-GDM women also 
felt strongly that the two-hour OGTT requiring 3 blood samples over the test period 
was inconvenient and burdensome. Alternatively, the use of a risk score-based 
selective IADPSG approach was observed to be conducive to the exemption of 
nearly half (45%) of non-GDM women from the OGTT test while still diagnosing 
80% of the GDM cases in China. A future validation cohort from other parts of 
China is required to affirm the effectiveness of this risk scoring algorithm. 
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Executive Summary 
 
GDM is the onset or first recognition of glucose intolerance during pregnancy. GDM 
can lead to severe maternal and neonatal outcomes including pre-eclampsia, 
caesarean section delivery, shoulder dystocia, macrosomia and stillbirth. GDM 
screening can facilitate early treatment and reduce negative outcomes. However, 
whether all pregnant women should be screened (universal screening) or only high-
risk women should be screened (selective screening) for GDM is a widely debated 
issue. In 2010, the IADPSG suggested a new universal screening approach requiring 
every pregnant woman to undergo the 75g Oral Glucose Tolerance Test (OGTT) for 
GDM diagnosis between the 24
th
 to 28
th 
week of gestation. The thresholds of the 
OGTT were reduced to diagnose more pregnant women with GDM. China was the 
first country to adopt the IADPSG approach, despite the fact that clear consensus 
does not exist as to the best screening approach or adoption of the new IADPSG one-
step approach for GDM. The PhD research assessed the effectiveness and cost-
effectiveness of universal versus selective screening, explored patient perspectives 
on IADPSG and tested a risk score-based selective screening approach under the 
new IADPSG criteria. 
 
Chapter 1: This chapter provides a background to the PhD research, introducing 
GDM as a growing health problem and the role of GDM screening in addressing this 
issue. It describes different GDM screening approaches, the controversies in the 
evidence and implementation across the globe. It highlights the challenges in 
addressing the inconsistency pertaining to the identification of the optimal GDM 
screening approach, identifies the research gaps and justifies the rationale for this 
PhD research. 
 
Chapter 2: This chapter outlines the overall research question and the aims and 
objectives of this research. 
 
Chapter 3: This chapter presents a systematic review of the effectiveness and cost-
effectiveness of selective screening in comparison with universal screening for 
GDM. Four electronic databases were searched, including Medline, Embase, Science 
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Citation Index (SCI) and Social Sciences Citation Index (SSCI) (via Web of Science) 
and the Cochrane database. For effectiveness studies, the outcome measures selected 
were specificity and sensitivity of selective screening in comparison with universal 
screening. Thirty three studies were included in the review, including 28 
effectiveness studies, four cost studies and a single cost-effectiveness study. Only 
seven of the 28 effectiveness studies recommended selective screening for pregnant 
women. These seven studies were conducted in areas with relatively low GDM 
prevalence and included the four studies using their own selection criteria rather than 
standard guidelines for identifying high risk women. The cost-effectiveness study 
and three of the four cost studies found that universal screening was slightly more 
expensive and less cost-effective when compared to selective screening. In 
conclusion, universal screening was recommended for areas with relatively high 
GDM prevalence and absence of economic constraints. In areas where GDM 
prevalence is low, it is recommended that current practices, whether led by universal 
or selective screening, are maintained until stronger evidence in support of either 
emerges. This chapter reports that selective screening with self-developed selection 
criteria for high risk women based on local population could potentially be effective 
and recommends future research in this direction. It discusses the limited evidence as 
to the cost-effectiveness of selective screening in comparison with universal 
screening. 
 
Chapter 4: This chapter presents the findings of a Q methodology study focusing on 
pregnant women’s attitudes, views and experience of the IADPSG universal 
approach for GDM screening in China. In 2011, China adopted the IADPSG 
recommendation and the one-step universal approach, thereby replacing the previous 
two-step universal approach that comprised a screening test followed by OGTT if 
needed. Non-GDM women who would have only received the simple screening test 
(i.e., 50g glucose challenge test) under the two-step approach now had to undertake 
the complicated OGTT test. Also, the number of women diagnosed with GDM was 
estimated to double or triple under the new IADPSG approach. Q methodology is 
used to explore subjective perspectives including participant points of view, 
opinions, beliefs and attitudes. The Q methodology study was conducted to obtain 
the perspectives of pregnant women about the new IADPSG approach in order to 
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improve the approach in accordance with the needs of expectant mothers. A total of 
32 Q statements (Q-set) relevant to attitudes, views and experience of the GDM 
testing approach were developed from a review of literature, consultations with 
pregnant women, expert opinions and online sources. The FlashQ software was used 
for computerising the Q statements to facilitate data collection and to provide a user 
friendly interface. Thirty pregnant women (15 GDM and 15 non-GDM women) from 
the Chengdu First People’s Hospital were recruited (P-set) to participate in the study. 
They were asked to rank-order the 32 Q statements from agree least to agree most (-
3~+3) based on their own viewpoints into a table of normal distribution (Q sorts) and 
provide reasons for the statements they most agreed and disagreed with. The 
PQMethod software was used for Q sorts analysis, and the reasons they provided 
were used for interpretation and illustration. Two distinct shared viewpoints emerged 
from the Q analysis results. In general, pregnant women tended to agree that GDM 
screening was important and necessary and needed to be administered to all pregnant 
women. However, the non-GDM women felt strongly that OGTT was inconvenient 
in terms of the three blood samples required and prolonged duration of two hours 
needed to complete the test, thereby leaving them to feel burdened in undergoing the 
OGTT. Both GDM and non-GDM women wished strongly to be provided with more 
information on GDM and OGTT both before and after undergoing the OGTT. 
 
Chapter 5: This chapter presents a nested case-control study that established and 
assessed the effectiveness of a risk score-based selective screening approach for 
GDM led by IADPSG criteria in China. Studies showed that while the IADPSG 
approach was clinically more effective, there were global concerns about the 
increased costs and burden associated with approach. This study explored the use of 
existing and novel risk factors to generate a risk scoring algorithm to select only the 
high-risk pregnant women for GDM screening. Medical records of 2897 pregnant 
women who gave birth during 2013 while receiving care at the Chengdu First 
People’s Hospital were investigated. The study found that GDM prevalence was 
9.4%. A nested case-control study was conducted involving 272 GDM and 278 non-
GDM. It was identified that age, height, body mass index (BMI), family history of 
diabetes, waist circumference, previous deliveries, systolic and diastolic blood 
pressure during the first trimester represented risk factors for GDM in the Chinese 
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population. A risk scoring algorithm was formulated using the adjusted odds ratios 
of these eight risk factors from the multiple logistic regression result. A Receiver 
Operating Characteristic (ROC) curve was drawn to assess the effectiveness of the 
algorithm, showing that a cut-off score of 0.32 provided an optimal sensitivity of 
80% and a specificity of 45%. This implied that risk score-based selective screening 
would correctly identify 80% of the GDM women as high-risk women through the 
use of the risk scoring algorithm, enabling the mothers-to-be to undergo the OGTT. 
On the other hand, 20% GDM women (2% of the pregnant population) would be 
missed due to this kind of screening. Essentially, 45% of the non-GDM women 
(41% of the pregnant population) would be correctly identified as low risk women, 
thereby avoiding the OGTT. A further cohort from other areas of China is needed to 
affirm the effectiveness of the risk scoring algorithm. 
 
Chapter 6: This final chapter summarises the key findings of this research and 
discusses their implications for practice and for future research. The optimal GDM 
screening approach is “setting dependent”. It is influenced by the population 
characteristics and risks, the different screening tests and criteria used and the patient 
perspectives as well as the wider context of healthcare value and culture. Until more 
evidence emerges, universal screening is recommended for areas where GDM 
prevalence is relatively high and without economic constraints. Whether it is 
universal or selective screening, current practice should be maintained for areas 
where GDM prevalence is low. In China, the new IADPSG universal screening 
approach was generally accepted by pregnant women, although non-GDM women 
largely felt that the IADPSG screening test was inconvenient and burdensome. The 
exploration of a risk score-based selective screening approach under the IADPSG 
criteria showed that nearly half of pregnant women would be exempted from the 
GDM screening test, while 80% of the GDM cases would be identified accurately in 
China. Future research is also needed to provide more evidence as to the cost-
effectiveness of selective versus universal screening. Evaluations on the 
effectiveness of a risk-scoring algorithm and patient perspectives for GDM screening 
within country-specific settings are strongly recommended. 
 
  
 
 
 
 
 
 
 
Chapter 1: Introduction 
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1.1 INTRODUCTION 
 
‘There is an urgent need for universally applicable simple screening and diagnostic 
procedures criteria for GDM – lessons from projects funded by the World Diabetes 
Foundation’.  
(Nielsen et al., 2012) 
 
This quote reflects the global debate as well as the complexity undergirding the 
optimal screening and diagnostic approaches for gestational diabetes mellitus 
(GDM). In the absence of international consensus, different guidelines and 
implementations for GDM screening exist between and even within countries. In 
2010, the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) recommended a universal screening approach for GDM with reduced test 
thresholds, which caused even more debate and controversy worldwide. 
Nevertheless, China was the first and one of the few countries which adopted the 
IADSPG criteria. The evaluation of the effectiveness, cost-effectiveness and user-
perspectives of the IADPSG approach is at its very initial stage. As a Chinese citizen 
and health researcher, I developed a strong interest in this particular area as I was 
keen to evaluate different GDM screening approaches so as to address the 
inconsistency and contribute to the evidence-based recommendations in GDM 
screening approaches. 
 
At present, there are worldwide uncertainties about: 1) whether all pregnant women 
should be screened (universal screening) or only screen women with GDM risk 
factors (selective screening); 2) should the new IADPSG one-step screening 
approach for GDM be adopted; and 3) especially for China, what implications there 
are for adopting the IADPSG approach and what can be improved. This introduction 
summarises and critically appraises the recent debate on and implementation of 
GDM screening approaches and identifies gaps of research in this area. 
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1.2 GDM AS A HEALTH PROBLEM 
 
1.2.1 Definition of GDM and adverse outcomes of the condition 
 
GDM was generally understood to represent “any degree of glucose intolerance that 
occurs or is first recognised during pregnancy” (Metzger & Coustan, 1998). 
Contemporary definitions have evolved to refer to GDM as diabetes diagnosed 
during pregnancy that is not clearly overt diabetes (American Diabetes Association, 
2013). Generally asymptomatic, GDM can nevertheless cause adverse short and 
long-term maternal and fetal outcomes (Langer et al., 2005). The Hyperglycemia and 
Adverse Pregnancy Outcomes (HAPO) study serves as a pivotal clinical study for 
understanding the existence of a continuous relationship between mild 
hyperglycaemia and adverse pregnancy outcomes (Test, 2008).   
 
Adverse consequences to maternal health include spontaneous abortion, gestational 
hypertension, pre-eclampsia and caesarean section, while stillbirth, macrosomia, 
large for gestational age (LGA) babies, birth trauma and shoulder dystocia may be 
any one of the conditions experienced by the babies of mothers with GDM (Ju et al., 
2008; Langer et al., 2005; Odar et al., 2004; Test, 2008; Reece et al., 2009). 
Additionally, women with GDM and their offspring are at increased risk of 
developing type 2 diabetes in the future (Damm et al., 2009; Kim et al., 2002).  
 
1.2.2 Aetiology and pathology of GDM 
 
Pregnancy is a condition characterised by progressive insulin resistance that 
commences close to the midpoint of the gestational period and progressed through 
the third trimester. Insulin sensitivity falls by up to 50% in late pregnancy (Di Cianni 
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et al., 2003). It has been noted that the main contributors to insulin resistance include 
the insulin desensitising effects of hormones produced by the placenta, followed by 
increased maternal adiposity (Perkins et al., 2007). During normal pregnancy, 
resistance to insulin action is observed to increase, as in most pregnancies, pancreatic 
beta cells are able to compensate for increased insulin demands, thereby maintaining 
normoglycaemia. In contrast, women who develop GDM experience deficits in beta-
cell response, thereby leading to insufficient insulin secretion that can compensate 
for increased insulin demands. The risk for GDM is increased by many factors 
including: age, ethnicity, obesity, first-degree relatives with diabetes, previous 
gestational diabetes, gestational weight gain, polycystic ovarian syndrome (PCOS), 
smoking, and many others (Association, 1997; Force, 2008; Walker, 2008; Webber 
et al., 2015; NICE 2015). The high risk ethnic origins include South Asia (India, 
Pakistan, Bangladesh), Black Caribbean and Middle Eastern origin (Saudi Arabia, 
United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, Lebanon, Egypt) 
(Webber et al., 2015). 
 
1.2.3 Epidemiology of GDM 
 
With the increasing global epidemic of obesity and type 2 diabetes, as well as the 
increasing age of conception and child bearing, the prevalence of GDM is rising 
(Aljohani et al., 2008; Anna et al., 2008; Ferrara, 2007; Waugh et al., 2010). 
However, estimating the GDM prevalence is made difficult by a lack of universally 
accepted diagnostic criteria for GDM, a factor which also hinders the consistent 
diagnosis and management of GDM in clinical practice (Reece et al., 2009). GDM 
incidence is expected to further increase with the adoption of the new screening 
criteria proposed by the IADPSG (Panel, 2010).  
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GDM affects 1–28% pregnant women worldwide, with wide variations due to 
ethnicity (Jiwani et al., 2012). In Europe, GDM affects 0.15–4% of pregnant women 
(Baliutaviciene et al., 2002). In the UK, up to 5% of the women giving birth in 
England and Wales were reported to have diabetes, with 87.5% of the expectant 
mothers within this percentage having GDM (NICE, 2015). In China, the GDM 
incidence was reported to range from 8% to 15% calculated according to the new 
IADPSG approach for GDM diagnosis (Shang & Ma, 2011; Wei & Yang, 2011; Hou 
et al., 2012; Lu et al., 2012; Jiang et al., 2013). 
 
1.2.4 Screening for GDM 
 
GDM is detected through screening carried out on pregnant women between the 24
th
 
to 28
th
 gestational week. In 2002, Scott et al. (2002) examined the evidence of GDM 
screening against the 10 criteria identified by the UK National Screening Committee 
(NSC) for determining whether a screening programme should be implemented, and 
they found that GDM screening did not meet all the NSC criteria. Before 2007, the 
benefit of screening pregnant women for GDM was not clear and not adequately 
supported by rigorous scientific evidence (Vidaeff et al., 2003; Russell et al., 2007). 
Studies and reviews carried out subsequently provided increasing evidence in 
support of benefits associated with GDM screening. In 2008, a cost-effectiveness 
study by the UK National Institute for Health and Care Excellence (NICE) 
concluded that it was cost-effective to conduct GDM screening (NICE, 2008). This 
study used data from an earlier Australian Carbohydrate Intolerance Study in 
Pregnant Women (ACHOIS) carried out by Crowther et al. (2005). Recently, the 
U.S. Preventive Services Task Force (USPSTF, 2013) found that there was a 
moderate net benefit associated with screening for GDM after 24
th
 week of gestation 
so as to reduce maternal and fetal complications, including the collective outcomes 
of preeclampsia, macrosomia, and shoulder dystocia. Hence, in light of the support 
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available in literature, it can be concluded that GDM screening is necessary for 
preventing the development of adverse maternal and neonatal outcomes.  
 
The two alternative test(s) for GDM screening currently available are the two-step 
tests or a one-step test. For two-step tests, pregnant women first undergo a screening 
test of 50g glucose challenge test (GCT), women with a positive test result further 
undergo a diagnostic test, a 75g or 100g oral glucose tolerance test (OGTT). For the 
one-step test, pregnant women undergo the OGTT directly for diagnosis. The 50g 
GCT is the most commonly used screening test, wherein the venous plasma glucose 
is tested one hour after drinking 50g of glucose in solution. Other alternative 
screening tests include glycosylated hemoglobin (HbA1c) and fasting plasma 
glucose (FPG) (Hartling et al., 2012). The diagnostic test is 75g or 100g OGTT, 
within which the venous plasma glucose is tested at fasting state, and then 1 hour, 2 
hours, or 3 hours after drinking 75g or 100g of glucose in solution. There are several 
different OGTT criteria prevalent internationally, which are summarised in Table 1. 
 
Table 1. Different diagnostic criteria for GDM screening internationally 
  Diagnostic 
test 
  
Venous plasma mmol/l (mg/dl)   
  fasting 1h 2h 3h 
IADPSG (Panel, 2010) 75g OGTT 5.1 (92) 10.0 (180) 8.5 (153)  
World Health Organization 
(Organization, 1999) 
75g OGTT 7.0 (126)  7.8 (140)  
O'Sullivan and Mahan 
(O'Sullivan & Mahan, 1964) 
100g OGTT 5.0 (90) 9.1 (164) 8.0 (144) 6.9 (124) 
National Diabetes Data Group 
(Group, 1979) 
100g OGTT 5.8 (105) 10.6 (190) 9.2 (165) 8.1 (145) 
Carpenter and Coustan/ 
American Diabetes 
Association (Association, 
2010) 
100g OGTT 5.3 (95) 10.0 (180) 8.6 (155) 7.8 (140) 
 
26 
 
1.2.5 Treatment and management of GDM 
 
Studies have shown that the risk of adverse pregnancy outcomes can be prevented or 
reduced by achieving glycaemic control alongwith lifestyle modifications and/or 
pharmaceutical intervention during pregnancy (Crowther et al., 2005; Landon et al., 
2009). Such lifestyle modifications typically involve dietary changes and exercise, 
whereas pharmacological treatment is reserved for women who are unable to 
maintain an acceptable range of glucose levels despite adjustments in terms of diet 
and exercise (Chirayath, 2006; Holt et al, 2008).  
 
The treatment of GDM has been observed to be effective in reducing macrosomia, 
preeclampsia and shoulder dystocia (Falavigna et al., 2012). A multicenter 
randomised trial conducted in the US demonstrated that it was potentially useful to 
treat pregnant women with mild GDM (Landon et al., 2009). They found that though 
treatment of mild GDM did not significantly reduce the frequency of stillbirth or 
perinatal death and other neonatal complications, it did reduce the risks of fetal 
overgrowth, shoulder systocia, cesarean delivery and hypertensive disorders. 
 
Further, the Australian Carbohydrate Intolerance Study in Pregnant Women 
(ACHOIS) trial showed reductions in perinatal complications among infants born to 
mothers who were provided with more intensive dietary advice, blood glucose 
monitoring and insulin upon requirement (Crowther et al., 2005). In connection with 
the treatment for GDM, the HAPO study showed that women failing to control 
hyperglycaemia in pregnancy by lifestyle measures alone could be safely and 
effectively treated with oral agents, for instance metformin or glibenclamide, rather 
than being directly administered insulin (Test, 2008).  
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Waugh et al. (2010) synthesised evidence pertaining to the risks and benefits of oral 
glucose lowering drugs in comparison with insulin in the treatment of 
hyperglycaemia in pregnancy. The RCT evidence showed little difference in results 
between the drugs and insulin. When comparing metformin with insulin, less 
maternal weight gain was reported with the use of metformin, but insulin evidenced 
better outcomes in terms of age at delivery. When comparing glibenclamide with 
insulin, there was evidence of less maternal hypoglycemia with glibenclamide, but 
insulin was observed to achieve less neonatal hypoglycaemia and lower birthweight. 
The review suggested that both metformin and glibenclamide were effective 
alternatives to insulin. Not surprisingly, some evidence suggested that women 
preferred oral agents to insulin treatment (Waugh et al., 2010).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                          
1.2.6 Postnatal care and follow-up of GDM 
 
Pregnant women with GDM are unlikely to require insulin after the delivery, so all 
hypoglycemic agents (either oral or insulin) should be stopped immediately after 
birth. With the purpose of detecting women with previously undiagnosed pre-
existing diabetes, it is suggested that pregnant women with GDM undergo blood 
glucose monitoring in the early postnatal period (Luesley & Mark, 2016).   
 
Several clinical trials have concluded that lifestyle modifications and/or 
pharmacological intervention have the potential to prevent pregnant women with a 
history of GDM from progressing to type 2 diabetes (Ratner et al., 2008; Xiang et al., 
2006). Postnatal follow-up of GDM and corresponding necessary preventative 
interventions have been of importance to preventing long-term health consequences 
for both the mother and her child. 
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1.3 GDM SCREENING APPROACHES  
 
1.3.1 Controversies over GDM screening approaches 
 
There is continued disagreement and inconsistency regarding the best screening 
strategy (Scott et al., 2002; Waugh et al., 2010). The current evidence is 
inconclusive to make a recommendation on whether universal or selective screening 
should be implemented (Tieu et al., 2010). Universal screening for GDM was 
recommended by the International Workshop Conference on Gestational Diabetes 
Mellitus in 1980, 1984, and 1990 (Baliutaviciene et al., 2002). While in 1997, the 
fourth International Workshop Conference on Gestational Diabetes Mellitus and the 
American Diabetes Association (ADA) recommended selective screening for GDM 
(ADA, 1997). The fifth international workshop conference in 2007 continued to 
recommend selective screening for GDM (Metzger et al., 2007). However, the ADA 
changed its previous recommendation from selective screening (Association, 2010) 
to universal screening in 2011 (Prevention & TYPE, 2011).  Meanwhile, as reported 
in Section 1.2.4, either two-step tests or a one-step test is used for GDM screening. 
Figure 1 illustrates the different screening approaches and tests used. 
 
Figure 1. Different GDM screening approaches and testing methods 
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Under the selective screening approach, women are categorised into high risk and 
low risk individuals. Subsequently, only the high risk women undergo GDM 
screening test under the selective approach. High risk women are identified on the 
basis of their risk factors for developing GDM. Table 2 shows the commonly used 
selection criteria according to the NICE and ADA guidelines, which are also 
mentioned in section 3.1.1. If a pregnant woman presents one of these risk factors, 
she is classified as a high risk woman and undergoes the screening test.  
 
Table 2. Selection criteria for high risk women for GDM screening 
 
 
In 2010, the International Association of Diabetes in Pregnancy Study Group 
(IADPSG) recommended a one-step universal screening approach with reduced 
OGTT thresholds for GDM. This recommended a 75g OGTT at 24–28 weeks for all 
women not previously diagnosed with diabetes by random or fasting plasma glucose 
testing at the first antenatal visit (Panel, 2010). The thresholds of 75g OGTT were 
reduced to diagnose more GDM women who might develop adverse maternal and 
neonatal outcomes. The lowered thresholds were ≥5.1 mmol/l at fasting, 10 mmol/l 
at 1 hour and 8.5 mmol/l at 2 hours. A diagnosis of GDM was made if at least one 
abnormal value was identified. Before the IADSPG recommendation, the commonly 
used criterion was that GDM diagnosis was confirmed with at least two abnormal 
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values from four measurements (blood glucose ≥5.8mmol/l at fasting, 10.6mmol/l at 
1 hour, 9.2mmol/l at 2 hours, and 8.1 mmol/l at 3 hours). 
 
Though the one-step universal approach for GDM was suggested by the IADPSG, 
there were many concerns related to implementing the approach. Vandorsten et al. 
(2012) have indicated that there is no clear evidence to demonstrate improvements in 
the health and patient-centered outcomes through the adoption of the one-step 
approach. They have voiced reservations about the increased patients costs, life 
disruptions and psychological burdens result from increase in the number of women 
diagnosed with GDM under the new approach. Langer et al. (2013) have pointed out 
that the IADPSG criteria has not been analysed systematically for medical, social, 
and economic ramifications, and caution should be exercised in promoting the new 
approach until associated outcomes have been rigorously evaluated.  
 
The American Diabetes Association (ADA) adopted the IADPSG recommendation 
in 2010 (Association, 2010) and then rejected it in December 2013 (Association, 
2013). The National Institutes of Health (NIH) Consensus Group rejected IADPSG 
in March 2013 (NIH, 2013). However, the World Health Organization (WHO) 
endorsed IADPSG in August 2013 (WHO, 2013). Worldwide debate continues over 
whether or not to adopt the IADPSG approach for GDM. In the context of China, the 
IADPSG one-step universal approach was adopted in July 2011 (Chinese Ministry of 
Health, 2011).   
 
1.3.2 Different implementations among countries  
 
Due to the lack of evidence and consensus on the IADPSG approach and the optimal 
approach for GDM screening, countries are implementing different screening 
practices (Figure 2). In the United States, universal screening with two-step tests is 
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commonly used with criteria proposed by the National Diabetes Data Group (NDDG) 
(Group, 1979) or Carpenter and Coustan (Carpenter & Coustan, 1982). Many 
developing countries are also implementing the universal screening approach, 
including Brazil, India, Mexico, and Ethiopia (Moyer, 2014; Tsatsoulis et al., 2009). 
In the United Kingdom, there are variations in practice among different areas and 
hospitals, however, most of the hospitals conduct selective screening with a one-step 
75g OGTT according to the NICE guideline (NICE, 2015). France and New Zealand 
are implementing selective screening with two-step tests (Vambergue, 2010; 
Simmons et al., 2009). China has adopted the new IADPSG one-step universal 
approach since 2011 (Chinese Ministry of Health, 2011), and the new approach was 
implemented by the majority of hospitals in China. Previously, China recommended 
universal screening with two-step tests (Le, 2008). Italy adopted the IADPSG criteria 
in 2011 and Australia adopted it in 2014 (Wong, 2014).  
 
Figure 2. Global implementation of the different GDM screening approaches  
 
1.3.3 Evidence on selective and universal screening approaches 
 
It is still internationally unclear whether to conduct a universal or selective screening 
approach for GDM, or whether to adopt the IADPSG one-step universal approach. 
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The following sections aim to summarise the literature addressing these issues, and 
to present the current state of development in these areas. 
 
Several reviews have been published, which partially addressed the issue of 
universal versus selective screening for GDM. In the review by Scott et al. (2002) 
for assessing GDM screening methods and costs, it identified two studies with direct 
comparison between routine universal screening and selective screening (Bebbington 
et al., 1999; Casey et al., 1997) and several studies of subgroups of women at higher 
risk of GDM, with a view to having selective rather than universal screening. It 
found that low sensitivities and specificities had been reported using risk factors 
alone as a screening test.  
 
One recent systematic review (Tieu et al., 2010) evaluated the screening, diagnosis 
and treatment of GDM, addressing the issue of universal versus selective screening. 
The review included only randomised and quasi-randomised trials, and identified 
one quasi-experimental study (Griffin et al., 2000) which suggested universal 
screening was superior to selective screening and resulted in higher detection rate, 
earlier diagnosis, and better pregnancy outcomes. However, due to the risks of bias 
in the trial, the systematic review did not reach a definite conclusion about which 
screening approach should be recommended. As pointed out by Tieu et al. (2010), 
the trial had high risk in randomisation, allocation concealment and outcome data 
report, outcome data were analysed by GDM diagnosis rather than by original group 
allocation, affecting interpretation of outcome data. Another recent systematic 
review (Hieronimus & Le Meaux, 2010) also assessed studies relevant to selective 
versus universal screening. It concluded that the benefits of GDM screening and 
treatment had only been proven for women with GDM risk factors, their relevance in 
women without risk factors remained controversial because of the number of 
unnecessary tests and the cost-effectiveness ratio. However, the review (Hieronimus 
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& Le Meaux, 2010) only searched Medline and Cochrane Databases and did not 
conduct quality assessment for the studies included therein. Further information 
about systematic reviews in this area will be discussed in chapter 3. 
 
1.3.4 Evidence on the new IADPSG universal screening approach 
 
1.3.4.1 International studies on the clinical and cost implications of the new 
IADPSG approach  
 
In 2008, the HAPO study investigated whether maternal hyperglycaemia less severe 
than that in diabetes mellitus is associated with increased risks of adverse pregnancy 
outcomes (Test, 2008). A total of 25,505 pregnant women at 15 centers in nine 
countries were involved. The HAPO study found strong, continuous associations of 
maternal glucose levels below the diagnosis of diabetes with increased birth weight 
and increased cord-blood serum C-peptide levels. This indicated that adverse 
maternal and neonatal outcomes appeared across a wider range of maternal glucose 
levels than previously thought. Having reviewed the result from the HAPO study, in 
2010, the IADPSG Consensus Panel recommended a major change in GDM 
screening, promoting a one-step 75g OGTT for all pregnant women from 24
th
 to 28
th
 
week of gestation with lower OGTT threshold values than had been used previously 
(Panel, 2010). Under the new regimen of one-step universal screening approach, 
GDM diagnosis is confirmed if there is at least one abnormal value registered from 
the three that have been measured (fasting glucose ≥5.1 mmol/l, 10 mmol/l at 1 hour, 
and 8.5 mmol/l at 2 hours). In line with this, the new IADPSG approach was 
expected to substantially increase the GDM incidence, potentially doubling or 
tripling the incidence (Panel, 2010). 
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One issue with the IADPSG criteria was that it is only based on observational 
datasets, including the large observational HAPO study (Test, 2008). No randomised 
controlled trial has been conducted to test the effectiveness of the IADPSG approach, 
which prevents a definitive conclusion of the superiority of IADPSG (Cundy et al., 
2014). However, following the observational study of HAPO (Test, 2008), there 
have been increasingly more observational studies (i.e., case-control studies) 
undertaken supporting the notion that the IADPSG is clinically more effective 
(Lapolla et al., 2011; Benhalima et al., 2013). These retrospective studies have found 
that the women classified as normal in accordance with the old criteria but re-
classified as GDM by the IADPSG criteria (i.e., new GDM women) had significantly 
higher incidences in clinically important adverse outcomes (e.g., caesarean section 
delivery, large for gestational age, shoulder dystocia). This implied that diagnosing 
and treating these women would have improved the outcomes. In China, the 
conducted observational studies also showed the IADPSG approach was more 
clinically effective (Shang & Ma, 2011; Wei & Yang, 2011; Lu et al., 2012; Jiang et 
al., 2013). 
 
Two recent studies evaluated the cost-effectiveness of the IADPSG one-step 
approach compared with the two-step approach currently used in many countries 
(Mission et al., 2012; Werner et al., 2012). Mission et al. (2012) found that the 
IADPSG approach was more expensive and more effective but cost-effective at 
$61,503/ quality-adjusted life year (QALY). However, Werner et al. (2012) 
suggested the IADPSG recommendation was cost-effective only when post-delivery 
care reduced diabetes incidence. Thus far, no cost-effectiveness study has been 
conducted in China. Vandorsten et al. (2012) have concluded that available studies 
do not provide clear evidence that a one-step approach is more cost-effective 
compared with the current two-step approach. 
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Concerns over the costs and cost-effectiveness are among the key reasons that 
countries hesitate to adopt the IADPSG approach. The NIH panel stated that they 
were particularly concerned about the increase of corresponding costs and 
interventions by adopting the IADPSG approach (NIH, 2013). The increased costs 
are comprised of the increased diagnosis costs by conducting OGTT among all 
pregnant women, and the increased healthcare costs by treating the additional 
women diagnosed as GDM. If, as concluded by all the observational studies, the 
IADPSG approach is more clinically effective, it will be necessary to spend the 
additional treatment expenditure on these GDMs. However, there is still a need to 
explore whether the diagnosis costs of conducting the OGTT could be reduced 
without compromising the clinical effectiveness, which would improve the cost-
effectiveness of the IADPSG approach.  
 
1.3.4.2 Chinese studies on the clinical and cost implications of the new IADPSG 
approach 
 
The new IADPSG recommendation was based on the HAPO study that did not 
include data from China. To explore the applicability of the approach to China, 
several Chinese studies investigated the clinical effectiveness of the new IADPSG 
approach in comparison with other approaches. These are summarised below.  
 
Three studies (Shang & Ma, 2011; Lu et al., 2012; Cai & Yang, 2012) compared the 
IADPSG one-step universal approach with the previous two-step universal approach 
for GDM. Shang & Ma (2011) and Lu et al. (2012) evaluated the clinical outcomes 
of the "over-diagnosed" GDM cases that were picked up by the IADPSG criteria but 
not by the previous two-step tests. Shang & Ma (2011) divided the additionally 
diagnosed GDM cases into treatment and non-treatment group, and found the 
treatment group had better clinical outcomes, indicating it was important to diagnose 
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and treat these additional GDM women. Lu et al. (2012) compared the outcomes of 
the "over-diagnosed" cases with non-GDM women and found that, if left untreated, 
the additionally diagnosed GDM cases were characterised by significantly higher 
rates of maternal and neonatal complications than women without GDM. Both 
findings suggested that IADPSG approach was clinically more effective in China. 
The other study by Cai & Yang (2012) was biased in study design. It found that if 
treatment were provided, the GDM diagnosed against the IADPSG criteria had 
significantly fewer adverse outcomes than GDM women diagnosed with the older 
criteria, thus leading to the conclusion that IADPSG criteria was better. However, 
this might simply have transpired because the GDM cases diagnosed by the IADPSG 
criteria were milder cases due to reduced OGTT thresholds.   
 
Jiang et al. (2013) compared the one-step 75g OGTT universal approach using the 
IADPSG cut-offs (reduced thresholds) and the older cut-offs. The additional women 
who were diagnosed by the IADPSG cut-offs (8.14% GDM incidence) but not by the 
older cut-offs (4.57% GDM incidence) were divided into treatment and non-
treatment groups. It was shown that the maternal and neonatal outcomes were 
significantly better in the treatment group, thereby suggesting that the reduced cut-
offs of the IADPSG criteria improved clinical outcomes. However, no published cost 
or cost-effectiveness study for the IADPSG screening approach in China has been 
identified.  
 
1.3.5 User perspectives on GDM screening and diagnosis 
 
Patient-centred healthcare is increasingly emphasised in current research and 
guidelines (Bauman et al., 2003; Stiggelbout et al., 2012). Therefore, it is essential to 
understand the perspectives of pregnant women in GDM screening. As GDM 
screening involves pregnant women who are a special and vulnerable user group, 
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evidence from user perspectives and experience plays an important role in the design, 
implementation, and evaluation of a quality healthcare service. Patient attitudes, 
views, and experiences of GDM screening need to be considered and explored in the 
process of identifying and implementing the optimal GDM screening and diagnostic 
approach. 
 
One Australian study has examined women’s attitudes towards a universal one-step 
GDM screening with modified OGTT (Griffiths et al., 1993). The OGTT involved 
two blood glucose tests at fasting state and after 2 hours; in the fasting state, a 75g 
glucose load is taken either at home or in a collection center. The study showed 
generally positive results. However, this study is somewhat dated having been 
conducted more than 20 years ago, and there is a lack of recent research on 
understanding women’s attitudes or experiences of GDM screening, especially using 
the new IADPSG universal one-step screening approach for GDM, which is globally 
recommended and increasingly adopted. Under the IADPSG approach, the OGTT 
involved three blood glucose tests at fasting state, after one hour, and after two hours 
(Panel, 2010). Evidences showed that the new IADPSG approach has the benefit of 
overlooking fewer women in probable need of treatment (HAPO, 2008; Lapolla et 
al., 2011; Benhalima et al., 2013) and enabling diagnosis during the course of one 
visit rather than two for the GDM women (the minority) as compared to the two-step 
screening approach (Shang & Ma, 2011; Wei & Yang, 2011). However, under the 
new approach, a more complicated OGTT test (fasting, two hours, three blood 
samples required) has to be carried out for all pregnant women. Earlier, the non-
GDM pregnant women (the majority) needed only a relatively simple 50g GCT 
screening test (non-fasting, one hour, one blood sample required) under the two-step 
screen approach or needed only a simpler OGTT (two blood samples required) under 
the older OGTT criteria.  
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There is gap in literature as to what pregnant women think of the IADPSG screening 
approach. Therefore, it is necessary to explore women’s perspectives on the one-step 
universal approach for GDM in order to fill this gap and to provide evidence for 
identifying and optimising the best GDM screening approach. 
 
1.4 RATIONAL OF THE RESEARCH 
 
1.4.1 A summary of the current situation 
 
Inconsistent recommendations and research evidences exist as to whether universal 
screening or selective screening is the best screening approach. The interest of 
screening for patients with no risk factors remains controversial; however, if only 
screening the high risk women, low sensitivities and specificities have been reported. 
Clear consensus does not present on whether or not to adopt the IADPSG one-step 
screening approach for GDM. There is no RCT evidence for the intervention of the 
IADPSG criteria, although several observational studies have shown the clinical 
effectiveness of this approach. However, the new IADPSG approach results in 
increased costs for the healthcare system and greater burden for non-GDM pregnant 
women. No study has explored the attitudes or experiences of pregnant women with 
reference to the new IADPSG approach, thereby failing to provide a clear user 
perspective.  
 
1.4.2 Gaps and implications for further research and practice 
 
When there is no conclusive answer as to the optimal GDM screening approaches, 
countries might be suggested to continue with their current practice before future 
evidence emerges. Compared to universal screening, the selective screening 
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approach could be beneficial in terms of reduced testing, less cost, more cost-
effective and better risk stratification (Hieronimus & Le Meaux, 2010; Waugh et al., 
2010). Reduced testing would mean that patients would experience potentially less 
anxiety and discomfort. At the same time, better cost-effectiveness and risk 
stratification would allow resources to be better allocated to the care needed the most 
by the patients. However, this strategy also has the disadvantage of overlooking a 
certain proportion of GDM cases as it routinely excludes low risk women from the 
screening test by operating under the assumption that they will not have GDM (Scott 
et al., 2002). Hence, assessment of the effectiveness and cost-effectiveness of 
selective screening as well as the best selection criteria for identifying high risk 
women are urgently needed. In this regard, a cutting-edge comparative systematic 
review might be needed to provide high quality evidence for addressing this issue 
under discussion. 
 
The new IADPSG one-step universal screening approach for GDM has been 
recommended since 2010 (Panel, 2010). Recent studies have also favourably 
appraised the IADPSG criteria in terms of short-term clinical outcomes (Lapolla et 
al., 2011; Shang & Ma, 2011; Lu et al., 2012; Benhalima et al., 2013; Jiang et al., 
2013). However, current evidence is still limited, reflecting a lack of evaluation as to 
the cost-effectiveness of the approach or insights into user perspectives. The 
adoption of the new approach has yet to be fully investigated. Changes to the current 
approach might need to be made if new evidence comes into sight. 
 
1.4.3 Rationale of the current PhD research  
 
The current PhD research aimed to assess and explore the optimal screening 
approaches for GDM in order i) to address the uncertainty of current evidence and 
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controversies of implementations in GDM screening approaches, and ii) to fill the 
research gap in terms of the IADPSG screening approach. 
 
This study used a mixed method approach to address the research question. Firstly, a 
systematic review was undertaken to synthesise evidence on the effectiveness and 
cost-effectiveness of universal versus selective screening. This aimed to appraise and 
evaluate the relevant literature and to identify further research needs. Secondly, the 
perspectives of pregnant women about GDM screening were investigated using Q 
methodology to address the limited evidence available on user viewpoints. 
Specifically, the study aimed to provide timely evidence of pregnant women’s 
attitudes towards the new IADPSG approach being adopted. Thirdly, to address the 
controversy between the clinical effectiveness and the increased cost of the IADPSG 
approach, the final study explored and assessed a risk score-based selective 
screening approach for IADPSG. 
 
 
1.5 Summary 
 
GDM prevalence has been rising with the increasing global epidemic of obesity and 
type 2 diabetes, as well as the increasing age of conception and child bearing. 
Screening for GDM after 24th week of gestation is beneficial in reducing maternal 
and neonatal complications. There is no agreement as to the best screening 
approaches for GDM. Controversies exist in whether universal screening or selective 
screening should be recommended. A comprehensive systematic comparative review 
of selective screening versus universal screening will help to address the issue. 
Although the adoption of the new IADPSG one-step universal approach for GDM is 
widely debated, China has been implementing the IADPSG approach since 2011. 
Therefore, it is worthwhile to investigate the adoption of the IADPSG approach as 
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well as user attitudes in China where research gaps in the literature related to the 
screening approach exist.  
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Chapter 2：Aims and Objectives 
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2.1 Research question 
 
The main purpose of this thesis is to address the inconsistent evidence and research 
gap on selective versus universal screening for GDM as well as the adoption of the 
new IADPSG universal screening approach for GDM. The overall research question 
framing the research was to evaluate and explore the most appropriate screening 
approach for GDM. 
   
2.2 Aims 
 
1) To comparatively assess selective screening versus universal screening approach 
for GDM.  
2) To explore patient perspectives on the new IADPSG universal screening approach 
for GDM. 
2) To establish and evaluate a risk score-based selective screening approach under 
the new IADPSG criteria for GDM.  
 
2.3 Objectives 
 
1) To assess the effectiveness and cost-effectiveness of selective screening in 
comparison with universal screening for GDM. 
2) To explore the pregnant women’s attitudes, views, and experiences of the 
IADPSG universal screening approach for GDM within a Chinese context. 
3) To investigate the risk factors for GDM and establish a risk scoring algorithm for 
the identification of high risk women for a selective screening approach under the 
new IADPSG criteria within a Chinese context. 
4) To evaluate the effectiveness of the risk score-based selective screening approach 
under the new IADPSG criteria within a Chinese context. 
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Chapter 3: A Systematic Review of the Effectiveness and 
Cost-effectiveness of Screening for GDM: Universal or 
Selective Screening? 
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3.1 BACKGROUND 
 
GDM has been defined as the onset or first recognition of glucose intolerance during 
pregnancy (IWCGDM, 1985). Screening and diagnosis for GDM are usually 
conducted in pregnant women between the 24
th
 to 28
th
 weeks of gestation. There has 
been debate over the best screening approach for GDM, and it remains unclear 
whether all pregnant women should be screened through universal screening or only 
those women at high risk should be screened selectively. The effectiveness and cost-
effectiveness of the two approaches are still unclear and require a systematic 
synthesis of the current evidence.  
 
3.1.1 GDM screening and the controversies 
 
The prevalence of GDM has increased over the last 20 years, and ethnic differences 
have been reported (Ferrara, 2007). The U.S. Preventive Services Task Force 
(USPSTF) concluded that there was a moderate net benefit of screening for GDM 
after the 24
th
 weeks of gestation to reduce maternal and fetal complications (Moyer, 
2014). As described in Chapter 1, consensus does not exist as to whether universal or 
selective screening should be recommended, and different countries continue to 
implement different screening approaches worldwide. Universal screening requires 
all pregnant women to undergo the GDM test. On the other hand, selective screening 
selects pregnant women who are at high risk of developing GDM based on existence 
of risk factors, and only these high risk women undergo the GDM test. The 
commonly used GDM risk factors are advanced maternal age, obesity, family history 
of diabetes (amongst first-degree family members), history of GDM, history of 
macrosomia, and certain ethnic/racial group including South Asia (especially India, 
Pakistan or Bangladesh) (Association, 1997; Force, 2008; Walker, 2008; Association, 
2010; NICE, 2015).  
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3.1.2 Current state of evidence on universal versus selective screening 
 
Two systematic reviews (Hieronimus & Le Meaux, 2010; Tieu et al., 2010) and two 
health technology assessment (HTA) reports (Scott et al., 2002; Waugh et al., 2010) 
have been identified, which compare the effectiveness of selective screening versus 
universal screening for GDM.  
 
Hieronimus and Le Meaux (2010) searched only two databases of Medline and 
Cochrane database from 1990 to 2010 and did not assess the quality of the included 
studies. Tieu et al. (2010) evaluated the screening, diagnosis and treatment of GDM, 
including only randomised and quasi-randomised trials. Only one quasi-experimental 
study (Griffin et al., 2000) was identified that compared the two screening 
approaches, which suggested universal screening was superior to selective screening 
and that it resulted in higher detection rate, earlier diagnosis and better pregnancy 
outcomes. However, due to the limitations of this trial, the systematic review by Tieu 
et al. could not arrive at a definite conclusion about which screening approach could 
be recommended.  
 
Scott et al. (2002) and Waugh et al. (2010) conducted Health Technology 
Assessment (HTA) on the treatment and screening for GDM. The review by Scott et 
al. had a particular focus on screening methods and costs as well as an appraisal of 
GDM screening against the criteria set by the UK National Screening Committee 
(NSC). Waugh et al. (2010) updated the report by Scott et al. by examining evidence 
that has emerged since 2002, including the Australian Carbohydrate Intolerance 
Study in Pregnant Women (ACHOIS), the Maternal and Fetal Medicine Units 
Network (MFMUN) trial and the HAPO and reviewed the trends in maternal age and 
obesity and their effect on GDM prevalence. It is important to point out that the 
reports by Scott et al. (2002) and Waugh et al. (2010) did not focus specifically on 
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universal screening versus selective screening approaches. Within each report, 
effectiveness studies on selective screening (or risk factor screening) were subsumed 
under the section reviewing different GDM screening tests. Hence, these were 
limited in number as the analysis was peripheral to the main focus of these two 
studies. 
 
3.1.3 Rationale for conducting the systematic review 
 
The previous two systematic reviews (Hieronimus & Le Meaux, 2010; Tieu et al., 
2010) and two HTA reports (Scott et al., 2002; Waugh et al., 2010) were limited for 
a number of reasons. In the case of Hieronimus & Le Meaux (2010), the limitation 
was due to the databases that had been searched, whereas the types of study included 
in Tieu et al. (2010) were restricted. The key limitation of Scott et al. (2002) and 
Waugh et al. (2010) resided in the focus and quantity of the effectiveness studies 
included therein.  
 
These four reviews also used different outcome measures. Hieronimus and Le 
Meaux (2010) used efficacy outcome measures of sensitivity and specificity for the 
effectiveness studies. In the review by Tieu et al., (2010), clinical outcome measures 
of key maternal and neonatal events for the effectiveness studies were used. While 
Scott et al. (2002) and Waugh et al. (2010) narratively described the sensitivity and 
specificity for the effectiveness studies involved, as a short-section within the HTA 
reports. 
 
The current systematic review extends and updates the previous reviews by using 
broader types of study design, including recent studies published after 2010 and by 
fully searching and assessing the efficacy outcome measures of sensitivity and 
specificity of selective screening as compared to universal screening. This systematic 
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review aimed to produce most up-to-date and comprehensive synthesis of existing 
evidence on selective versus universal screening approach. Data on sensitivity and 
specificity were statistically analysed and meta-analysis was conducted where 
applicable. The findings of the review provide more comprehensive and strong 
evidence for recommendations as to GDM screening approaches, in order to address 
the global debate and lack of consensus over selective versus universal screening.  
 
 
3.2 AIM AND OBJECTIVES 
 
The study aimed to undertake a systematic review on the effectiveness and cost-
effectiveness of selective screening compared to universal screening for pregnant 
women. 
 
The specific objectives were:  
(1) To evaluate the effectiveness (sensitivity and specificity) of selective screening 
compared to universal screening for GDM;   
(2) To assess the cost-effectiveness and cost of selective screening compared to 
universal screening for GDM.   
 
 
3.3 RESEARCH METHODOLOGY 
 
3.3.1 General framework of the systematic review 
 
The systematic review adhered to the PRISMA guidelines (Moher et al., 2009). The 
protocol of the systematic review was registered with the PROSPERO international 
prospective register of systematic reviews. The registration number is 
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CRD42013004241. The proposal can be accessed via: http://www.crd.york.ac.uk/ 
PROSPERO/display_record.asp?ID=CRD42013004241#.VPOBRPmsWe4.  
 
3.3.2 Search strategy 
 
A wide range of electronic databases including Medline, Embase, Web of Science 
(SCI and SSCI) and Cochrane Database were searched. Databases of ongoing trials 
were also searched. These included current Controlled Trials, ClinicalTrials.gov, 
UKCRN Portfolio Database, and WHO International Clinical Trials Registry 
Platform. 
 
Advanced searches were deployed with keywords being mapped into subject 
headings (search terms). Key words were defined from the review question, such as 
"gestational diabetes" and "screening". It was not necessary to define the study 
design, outcome or setting at this early stage. Study design and outcome measure 
were scrutinised at the later screening stage by the researcher, and there was no 
restriction in terms of the study setting.  
 
The search was restricted to the English language and the publication year (1980 to 
present). Year 1980 was chosen because the screening approach was recommended 
at the First Workshop on GDM in 1980 (ADA, 1980). Universal screening was 
recommended by the first three workshops (Association, 1980; Association, 1985; 
Metzger, 1991), and selective screening was recommended by the fourth and fifth 
workshop (Metzger & Coustan, 1998; Metzger et al., 2007). The search was 
undertaken on 14 November 2014. The search history based on the four databases is 
shown in Appendix 1. 
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‘Grey literature’ was searched to reduce publication bias. These involved 
unpublished conference proceedings, guidelines, and other information from key 
relevant organisations in the field of GDM, i.e., ADA (American Diabetes 
Association), British Diabetes Association (BDA) and the National Institute for 
Health and Care Excellence (NICE) in the UK. An ancestry search was conducted to 
check reference lists of relevant articles.  
 
3.3.3 Selection criteria (inclusion and exclusion) for eligible studies 
 
Articles identified in the above search were screened according to the selection 
criteria (inclusion and exclusion) in the order of title, abstract and full text of studies. 
In view of the research question framing this systematic review, the selection criteria 
were developed. These included the types of study, intervention, comparator, 
outcome, population and setting. Table 3 shows the inclusion and exclusion criteria 
for selection of studies. 
 
Table 3. A table of inclusion and exclusion criteria for study selection 
 
 Inclusion Exclusion 
Study design 1. For effectiveness: RCT, quasi-RCT, 
cohort study, cross-sectional study 
2. For cost-effectiveness and cost: cost-
effectiveness study, cost study 
Case-control study (not 
suitable for the research 
question) 
Qualitative study 
Systematic review 
Literature review 
Population Pregnant women 
 
Women who have pre-existing 
diabetes or who have already 
been diagnosed as having 
GDM before screening 
Intervention Selective screening for GDM (screening 
can be screening test followed by 
diagnosis test or one-step diagnosis test) 
Screening only contained 
screening test without 
diagnosis test 
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Comparison Universal screening for GDM (screening 
can be screening test followed by 
diagnosis test or one-step diagnosis test) 
Screening only contained 
screening test without 
diagnosis test 
Outcome 1. For effectiveness: (1) sensitivity 
(percentage of GDM women who were 
correctly diagnosed as having GDM), (2) 
specificity (percentage of non-GDM 
women who avoided GDM screening) 
2. For cost and cost-effectiveness: (1) cost 
studies: cost per identified GDM case; (2) 
cost-effectiveness: ICER 
Studies failed to report the 
outcome indicated in the 
inclusion criteria 
Setting Any setting None 
 
 
(1) Types of studies: For assessing the effectiveness studies, RCT, quasi-RCT, 
cohort study, and cross-sectional study were included. Case-control study design was 
not suitable for the research question, and was excluded. For assessing cost-
effectiveness, cost-effectiveness and cost studies were included. Qualitative study, 
systematic review, and literature review were excluded. 
 
(2) Types of population and the setting: Pregnant women were the target 
population. However, studies in which women had pre-existing diabetes or had 
already been diagnosed as having GDM before screening were excluded. No limit 
was made on population size or study setting.  
 
(3) Types of interventions and comparators: The intervention was the selective 
screening approach, whereas the comparator was universal screening approach. The 
GDM test for the two approaches could be either two-step tests (screening test 
followed by diagnostic test) or one-step test (diagnostic test). Studies which only 
involved a screening test without a diagnostic test would be excluded. 
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(4) Types of outcome measures: For effectiveness studies, the outcome measures 
were sensitivity and specificity of selective screening compared to universal 
screening. For this review, sensitivity is the proportion of GDM cases who are 
correctly screened and diagnosed; specificity is the proportion of non-GDM women 
who can be exempted from the screening and diagnosis. For cost-effectiveness 
studies, the outcome measure was incremental cost-effectiveness ratio (ICER); 
whereas for cost studies, the outcome measure was cost per identified GDM case. 
 
3.3.4 Study selection process 
 
All retrieved records were entered into an Endnote database. Duplicate records were 
identified and removed. Two reviewers pilot-tested a priori screening form based on 
the predefined study eligibility criteria. The two reviewers screened 20% of all 
identified records for title and abstract and then all records for full text independently, 
against the agreed inclusion and exclusion criteria. Level of agreement was tested by 
the Kappa inter-rater reliability comparison. Disagreements over eligibility were 
resolved through discussion between the two reviewers to make consensus or by 
consulting the author of the original studies. The selection process was documented 
using a PRISMA diagram. Reasons for exclusion of full text papers were 
documented.  
 
3.3.5 Quality assessment strategy 
 
For effectiveness studies, the Downs and Black quality assessment tool was used 
(Downs & Black, 1998), which is suitable for both randomised and non-randomised 
studies. The assessments include quality of reporting, power, internal validity (bias 
and confounding) and external validity (Downs & Black, 1998). The original Downs 
and Black checklist was modified as not all items were relevant to the effectiveness 
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studies in this review. The details of the amended Downs and Black checklist are 
provided in Appendix 4.1. For cost-effectiveness studies, Drummond checklist was 
used (Drummond, 1996).  
 
3.3.6 Data extraction strategy 
 
Data extraction forms were developed as informed by the PRISMA guidelines 
(Moher et al., 2009). The relevant data were extracted from included studies by the 
main reviewer. A second reviewer checked the data extraction result of one included 
study; uncertainty and/or any disagreements were resolved by discussion. The 
extracted data of each study were entered into a summary table (Table 4 and Table 5) 
and a full data extraction table (Appendix 5). The extracted data included the 
following: 
 
 Study characteristics (i.e., author’s name, country and city, study design, 
study setting, sample size, time of study, funding source) 
 Patient baseline characteristics (i.e., inclusion/exclusion criteria, number of 
enrolled/ analysed participants, body mass index, age, race, family history of 
diabetes)  
 Intervention/ comparator characteristics (i.e., selection criteria for high risk 
women, time and method of GDM test) 
 Outcome characteristics (i.e., sensitivity, specificity; cost per GDM 
diagnosed; ICER) 
 
For effectiveness studies where sensitivity and specificity were not directly reported 
but could be calculated from the data, or where sensitivity and specificity were 
calculated using different definitions, the calculations were done by the reviewer 
using the definitions in the review. 
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3.3.7 Data synthesis and interpretation 
 
For effectiveness studies, variables in each study were summarised in text and 
summary tables to observe the similarities and differences. Meta-analysis of 
sensitivity and specificity was conducted in Revman 5; forest plots were produced. 
Pooled estimate of sensitivity and specificity as well as heterogeneity of the included 
studies were analysed by the HSROC (hierarchical summary receiver operating 
characteristic) curve in STATA 12.0. Positive predictive values (PPV) and negative 
predictive values (NPV) according to GDM prevalence were calculated in MS Excel. 
Publication bias of the included studies was evaluated using the Harbords method for 
assessing small study bias using STATA 12.0. 
 
3.4 RESULTS 
 
3.4.1 Included studies 
 
A total of 3577 records were identified, with the removal of duplicates reducing this 
number to 2943 records. Of these, 2837 records were excluded as irrelevant at title 
and abstract stage, leaving behind 97 potentially relevant records. Of the 97 full text 
records screened, 64 records were excluded, and the remaining 33 records were 
included in the review. Amongst the 33 studies selected, there were 28 effectiveness 
studies, one cost-effectiveness study and four cost studies. The PRISMA flow chart 
outlining the process of identifying relevant literature is shown in Figure 3. A list of 
included studies can be found in Appendix 2. The kappa analysis of 20% articles 
(570 articles) at title and abstract stage achieved a k-value of 0.70, whereas the kappa 
analysis of 20% articles (6 articles) at full text stage achieved a k-value of 1.00. 
These outcomes achieved substantial (0.61-0.80) and perfect (0.81-1) agreement 
(Gwet, 2010). 
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A list of records excluded at full text stage with reasons for exclusion is provided in 
Appendix 3. The main reasons for exclusion are broadly outlined herein. Twenty 
studies had only abstracts or access to full text articles was not available. Nineteen 
studies were excluded because of outcome measures, as these studies failed to report 
either sensitivity or specificity according to the definition in the review. Further, the 
same could not be calculated from their data. Fifteen studies were excluded because 
they used study designs that fell under the exclusion criteria. Four studies were 
excluded because of the intervention/comparator, as they did not compare selective 
screening with universal screening. Three studies were excluded because of 
intervention/comparator, as they performed two-step tests for the universal screening 
and one-step test for the selective screening and therefore did not offer comparability. 
Another two studies were excluded as duplicate publications of an already included 
study, and one study was excluded because of intervention/comparator, as the study 
did not include the GDM diagnostic test. 
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Figure 3. PRISMA flow chart of the study selection process 
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3.4.2 Result of the effectiveness studies 
 
3.4.2.1 Quality assessment result of the effectiveness studies 
 
The Downs and Black checklist was used for assessing quality of the effectiveness 
studies. The checklist can be accessed through: http://jech.bmj.com/content/52/6/ 
377.full.pdf+html. The checklist was modified to suit the effectiveness studies in this 
review. The modified version of the checklist consisted of 16 items with a maximum 
score of 16 points.  
The 28 effectiveness studies achieved an average score of 13.4, ranging from 11 to 
15 out of 16 points. The most frequently failed items were due to a number of 
reasons: (1) 27 studies failed to report the sample calculation (item 27); (2) Eight 
studies were unable to guarantee that the participants were representative of the 
entire population because of more than 10% exclusion rate (due to refusal or 
unavailable data) (item 12); (3) Six studies failed to report the outcomes to be 
measured clearly in the Introduction or Methods section (item 2); and (4) Six studies 
failed to take into account the loss to follow-up (if exceeding 10%) in their analysis 
(item 26). The remaining items were generally well fulfilled by the studies. The 
assessment result is illustrated in Appendix 4.2.   
 
3.4.2.2 Characteristics of the effectiveness studies 
 
Data extraction for study characteristics of the 28 effectiveness studies is available in 
Appendix 1. A summary containing the key characteristics of the 15 studies with 
two-step GDM tests (50g GCT followed by OGTT) and 13 studies with a one-step 
GDM test (75g/100g OGTT) is shown in Table 4 and Table 5.  
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(1) 15 studies with two-step GDM tests 
 
The sample size of these studies ranged from 363 (Zoller et al., 1988) to 25118 
(Williams et al., 1999). Seven studies were conducted in the USA (Coustan et al., 
1989; Danilenko-Dixon et al., 1999; Helton et al., 1997; Lavin et al., 1985; Sacks et 
al., 1987; Williams et al., 1999; Zoller et al., 1988). Four studies were conducted in 
European countries, from Spain (Jimenez-Moleon et al., 2002), Italy (Di Cianni et 
al., 2003), Netherlands (Van Leeuwen et al., 2010), and Turkey (Caliskan et al., 
2014), respectively. The remaining four studies were conducted in Australia (Teh et 
al., 2011), Canada (Naylor et al., 1997), Thailand (Arora, et al., 2013), and Iran 
(Hadaegh et al., 2005), respectively. 
 
Excepting one cross-sectional study (Arora et al., 2013), the other 14 studies were 
cohort studies. This involved six prospective studies (Coustan et al., 1989; Hadaegh 
et al., 2005; Lavin et al., 1985; Sacks et al., 1987; Van Leeuwen et al., 2010; Zoller 
et al., 1988), the other eight studies were retrospective studies.  
 
The selection criteria for high risk women they used varied from as few as three risk 
factors of age, obesity, and family history of diabetes (Di Cianni et al., 2003; Moses 
et al., 1995) or age, obesity, and ethnicity (Moses et al., 1998; Naylor et al., 1997) to 
as many as ten risk factors (Jimenez-Moleon et al., 2002). The details of the 
selection criteria risk factors are also available in Table 4.  
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(2) 13 studies with a one-step GDM test 
 
The sample size of these studies ranged from 768 (Shamsuddin et al., 2001) to 
18775 (Cosson et al., 2013). Seven studies were conducted in European countries, 
i.e., three in Italy (Capula et al., 2013; Corrado et al., 2014; Pintaudi et al., 2014), 
one in France (Cosson et al., 2013), one in Sweden (Ostlund & Hanson, 2003), one 
in Denmark (Jensen et al., 2003), and one in eleven Mediterranean countries 
(Savona-Ventura et al., 2013). Two studies were conducted in Australia (Moses et 
al., 1995; Moses et al., 1998). The remaining four studies were conducted in Iran 
(Shirazian et al., 2009), Singapore (Chong et al., 2014), Malaysia (Shamsuddin et al., 
2001), and Sri Lanka (Wagaarachchi et al., 2001), respectively. 
 
The 13 studies involved six prospective cohort studies (Chong et al., 2014; Jensen et 
al., 2003; Moses et al., 1995; Ostlund & Hanson, 2013; Savona-Ventura et al., 2013; 
Wagaarachchi et al., 2001), six retrospective cohort studies (Capula et al., 2013; 
Corrado et al., 2014; Cosson et al., 2013; Moses et al., 1998; Pintaudi et al., 2014; 
Shirazian et al., 2009), and one cross-sectional studies (Shamsuddin et al., 2001). 
The sample size ranged from 768 women (Shamsuddin et al., 2001) to 18775 women 
(Cosson et al., 2013). 
 
The selection criteria for high risk women they used varied, from as few as three risk 
factors of age, obesity, and family history of diabetes (Moses et al., 1995) or age, 
obesity, and ethnicity (Moses et al., 1998), to as many as 9 risk factors (Shamsuddin 
et al., 2001). The details of the selection criteria risk factors are also available in 
Table 5.  
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Table 4. Summary table of key characteristics of the 15 effectiveness studies with two-step GDM tests 
Author/ 
year/ 
Country 
Type of study/ 
Number of 
participants 
Screening 
criteria/ 
Diagnosis 
criteria 
GDM 
prevalence 
by 
universal/ 
selective 
screening 
Selective screening criteria for high risk women Specificity  Sensitivity  Author’s conclusion  
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Arora/ 
2013 
Thailand 
Cross-sectional 
study/ 
593 
50g GCT/ 
100g 
OGTT 
9.3%/ 7.3% ≥30 ≥25 √ √ √ √ — glucosuria, 
hypertension 
47.2% 78.2% Selective screening might 
not be acceptable and 
needs re-evaluation 
Caliskan/ 
2014 
Turkey 
Retrospective 
cohort study/ 
422 
50g GCT/ 
100g 
OGTT 
3.3%/ 3.3% ≥25 ≥25 √ — √ √ — — 30.0% 100.0% Recommend selective 
screening 
Coustan/ 
1989  
USA 
Prospective 
cohort study/ 
6214 
50g GCT/ 
100g 
OGTT 
2.0%/ 1.5% ≥30 ≥85th 
percent
ile for 
height 
√ √ √ √ — — 56.0% 65.0% Do not recommend 
selective screening 
Danilenko-
Dixon/ 
1999 
USA  
Retrospective 
cohort study/ 
18504 
50g GCT/ 
100g 
OGTT 
3.0%/ 3.0%  ≥25 ≥27 √ — — — √ — 9.9% 97.0% Do not recommend 
selective screening 
Di Cianni/ 
2003  
Italy 
Retrospective 
cohort study/ 
3950 
50g GCT/ 
100g 
OGTT 
8.1%/ 8.0% ≥25 ≥25 √ — — — — — 5.6% 98.4% Recommend universal 
screening 
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Hadaegh/ 
2005 
Iran 
Prospective 
cohort study/ 
800 
50g GCT/ 
100g 
OGTT 
8.9%/ 7.9%  ≥25 ≥25 √ — — — — — 31.0% 88.7% Recommend universal 
screening 
Helton/ 
1997 
USA 
Retrospective 
cohort study/ 
3950 
50g GCT/ 
100g 
OGTT 
2.5%/ 1.7%  ≥35 ≥200lb √ √ √ √ — — 74.6% 69.2% Recommend selective 
screening 
Jimenez-
Moleon/ 
2002  
Spain 
Retrospective 
cohort study/ 
2574 
50g GCT/ 
100g 
OGTT 
2.5%/ 2.3%  Age≥3
0 
(ACOG
) or 
≥25 
(ADA) 
≥27 √ √ √ √ — chronic 
hypertension, 
polyhydramnios, 
hpertension induced 
by the pregnancy, 
suspected large 
fetus for gestational 
age 
44.2% 
(ACOG 
critieria); 
15.5% 
(ADA 
criteria)  
89.2% 
(ACOG 
criteria); 
96.9% 
(ADA 
criteria) 
Selective screening is 
desirable only when fairly 
restrictive criteria are 
applied in defining the 
gravidae at risk  
Lavin/ 
1985 
USA 
Prospective 
cohort study/ 
2077 
50g GCT/ 
100g 
OGTT 
1.4%/ 0.7%   √ √ √ √ √ — monilial vaginitis, 
glucosuria, 
polyhydramnios, an 
infant suspected of 
being large for 
gestational age 
53.8% 46.7% Do not recommend 
selective screening 
Naylor/ 
1997  
Canada 
Retrospective 
cohort study/ 
3131 
50g GCT/ 
100g 
OGTT 
2.1%/ 1.9%  ≥30 ≥22 √ — — — — — 34.7% 90.6% Recommend selective 
screening 
Sacks/ 
1987 
USA 
Prospective 
cohort study/ 
4116 
50g GCT/ 
75g OGTT 
3.4%/3.3% ≥25 ≥150po
unds 
√ — √ √ — — 23.0% 97.1% Recommend selective 
screening in early 
pregnancy 
Teh/ 2011 
Australia 
Retrospective 
cohort study/ 
2880 
75g GCT/ 
75g OGTT 
8.7%/8.1% 
(NICE 
criteria); 
8.7% (ADA 
criteria); 
8.6% 
(ADIPS 
criteria) 
NICE criteria 30.1% 
(NICE 
criteria); 
3.5% 
(ADA 
criteria); 
12.6% 
(ADIPS 
criteria) 
92.7% 
(NICE 
criteria); 
100% 
(ADA 
criteria); 
98.6% 
(ADIPS 
criteria) 
Do not recommend 
selective screening 
 ≥30 √ √ √ — √ — 
ADA criteria 
≥25 abnorm
al 
weight 
√ — — √ √ history of abnormal 
glucose metabolism 
ADIPS criteria 
≥30 N/A √ √ — √ √ glycosuria 
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Van 
Leeuwen/ 
2010 
Netherland
s  
Prospective 
cohort study/ 
995 
Random 
plasma 
glucose 
and 50g 
GCT/ 
75g OGTT 
4.6%/ 3.5%   linear 
relation
ship 
betwee
n 22-30 
√ √ — — √ — 57.0% 75.0% Recommend selective 
screening 
Williams/ 
1999 
USA 
Retrospective 
cohort study/ 
25118 
50g GCT/ 
100g 
OGTT 
0.8%/ 0.8%  ≥25 ≥27 √ — — — √ — 11.1% 96.0% No direct conclusion (the 
figures didn't support 
selective screening from 
the reviewer's view) 
Zoller/ 
1988 
USA 
Prospective 
cohort study/ 
363 
50g GCT/ 
100g 
OGTT 
2.8%/ 1.1%  ≥90.72
kg 
√ √ √ √ — glucosuria, 
polyhydramnios, 
intrauterine growth 
consistent with 
large gestational 
aged infant 
61.4% 40.0% Recommend universal 
screening 
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Table 5. Summary table of key characteristics of the 13 effectiveness studies with a one-step GDM test 
Author/ 
year/ 
Country 
Type of study/ 
Number of 
participants 
Screening 
criteria/ 
Diagnosis 
criteria 
GDM 
prevalence 
by 
universal/ 
selective 
screening 
Selective screening criteria for high risk women Specificity  Sensitivity  Author’s conclusion  
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Capula/ 
2013 
Italy 
Retrospective 
cohort study/ 
2448 
75g OGTT 
(IADPSG) 
27.5%/ 
20.5% 
≥35 ≥25 √ √ √ — √ — 22.0% 74.6% Recommend universal 
screening  
Chong/ 
2014 
Singapore 
Prospective 
cohort study/ 
1136 
75g OGTT  
(WHO 
1999) 
18.9%/ 9.8%   >30 √ √ √ — √ — 56.3% 51.6% Recommend universal 
screening  
Corrado/ 
2014 
Italy 
Retrospective 
cohort study/ 
1015 
75g OGTT 
(IADPSG) 
11.3%/ 8.6%  ≥35 ≥25 √ √ √ — — — 41.7% 77.0% Need future study 
Cosson/ 
2013  
France 
Retrospective 
cohort study/ 
18775 
75g OGTT 14.4%/ 9.4% ≥35 ≥25 √ √ √ — — — 41.5% 65.3% Do not recommend 
selective screening 
Jensen/ 
2003 
Denmark 
Prospective 
cohort study/ 
5235 
75g OGTT 2.4%/ 1.9%   ≥27 √ √ √ — — Glucosuria 63.7% 80.6% Recommend selective 
screening 
Moses/ 
1995 
Australia  
Prospective 
cohort study/ 
1185 
75g OGTT 6.7%/ 4.1%  ≥30 ≥30 √ — — — — — 54.2% 60.8% Recommend universal 
screening 
Moses/ 
1998 
Australia  
Retrospective 
cohort study/ 
2907 
75g OGTT 6.3%/ 5.7%  ≥25 ≥25 √ — — — — — 19.7% 91.3% Selective screening needs 
further evaluation in 
different populations  
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Ostlund & 
Hanson/20
03 
Sweden 
Prospective 
cohort study/ 
3616 
75g OGTT 1.7%/ 1.1%   ≥90kg √ √ √ — — — 84.2% 47.5% Do not recommend 
selective screening 
Pintaudi/ 
2014 
Italy 
Retrospective 
cohort study/ 
1015 
75g OGTT 
(IADPSG) 
11.3%/ 
10.0%  
 ≥25 √ — — — — FPG> 4.4mmol/l 36.8% 89.0% Recommend selective 
screening using the 
RECPAM model 
Savona-
Ventura/ 
2013 
Eleven 
Mediterran
ean 
countries 
Prospective 
cohort study/ 
1368 
75g OGTT 8.7%/ 7.0%  ≥25 pre-
pregna
ncy 
BMI 
≥25 or 
a 3rd 
trimest
er BMI 
≥30 
— — — — — FBG >5.0 mmol/L 80.7% 65.9% Recommend selective 
screening for the areas of 
economic restraint 
Shamsuddi
n/ 2001 
Malaysia 
Cross-sectional 
study/ 
768 
75g OGTT 24.9%/ 
10.1%  
≥35 ≥80kg √ √ √ √ — urinary tract 
infection, vaginal 
discharge and 
pruritis vulvae, 
glycosuria 
33.2% 72.2% Recommend universal 
screening  
 Shirazian/ 
2009 
Iran 
Retrospective 
cohort study/ 
924 
75g OGTT 7.4%/ 7.3%  ≥25 ≥25 √ — — — — — 13.6% 98.5% Selective screening do not 
miss substantial number of 
GDM cases 
Wagaarach
chi/ 2001 
Sri Lanka 
Prospective 
cohort study/ 
1004 
75g OGTT 4.1%/ 2.4%  ≥35 ≥30 √ — √ √ — presence of grand 
multiparity 
54.1% 58.5% Recommend universal 
screening  
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3.4.2.3 Data synthesis of the effectiveness studies 
 
The outcomes of GDM incidence, sensitivity, and specificity were summarised for 
the 15 studies with two-step tests and the 13 studies with a one-step test, respectively. 
 
(1) 15 studies with two-step GDM tests 
 
In this category, the GDM incidence under the universal screening approach ranged 
from 0.8% in the US (Williams et al., 1999) to 9.3% in Thailand (Arora et al., 2013). 
Of the 15 studies, five studies recommended selective screening (Caliskan et al., 
2014; Helton et al., 1997; Naylor et al., 1997; Sacks et al., 1987; Van Leeuwen et al., 
2010; Pintaudi et al., 2014), and 8 studies recommended universal screening. Of the 
remaining two studies, one recommended selective screening when fairly restrictive 
selection criteria for risk women were applied (Jimenez-Moleon et al., 2002), and 
one did not make a direct conclusion (Williams et al., 1999). Figures of sensitivity 
and specificity of selective screening compared to universal screening for the 15 
studies are provided in Table 6. Meta-analysis was conducted in Revman 5, and 
forest plot of the sensitivity and specificity was produced (Figure 4). The forest plot 
showed considerable heterogeneity (values) amongst the studies and the trade-off 
between sensitivity and specificity. The sensitivity ranged from 40.0% (with a 
specificity of 61.4%) (Zoller et al., 1988), to 100% (with a specificity of 30%) 
(Caliskan et al., 2014). The specificity ranged from 7.0% (with a sensitivity of 
98.7%) (Corcoy et al., 2004), to 74.6% (with a sensitivity of 69.2%) (Helton et al., 
1997). 
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Figure 4. Forest plot of sensitivity and specificity for the 15 studies                 
with two-step GDM tests 
 
 
There are several reasons for the heterogeneity of sensitivity and specificity between 
studies, including differences in populations and ethnic groups, different selection 
criteria for high risk women as well as GDM prevalence. Different populations have 
different risk profiles for GDM. Table 6 shows that there were three studies which 
developed own risk criteria (Caliskan et al., 2014) or risk score (Naylor et al., 1997; 
Van Leeuwen et al., 2010) based on local population characteristics for selecting 
high risk women for selective screening. All of them found selective screening to be 
effective and recommended the selective approach to screening. The GDM 
incidences of the studies which recommended universal screening (ranged from 1.4% 
to 9.3%; mean 5.5%; median 5.6%) were generally higher than the studies where 
selective screening (ranged from 2.1% to 4.6%, mean 3.2%; median 3.3%) is 
recommended. 
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Table 6. Sensitivity and specificity of selective screening for the 15 studies              
with two-step GDM tests 
 
  
Study Country GDM 
incidence 
(under 
universal 
screening) 
Use of self-
developed 
selection 
criteria 
Sensitivity Specificity Study 
quality 
(max 
score= 
16) 
Five studies recommending selective screening 
Caliskan/ 
2014 
Turkey 3.3% √ (own risk 
criteria) 
100.0% 30.0% 16 
Helton/ 1997 USA 2.5%  69.2% 74.6% 12 
Naylor/ 1997 Canada 2.1% √ (own risk 
score) 
90.6% 34.7% 15 
Sacks/ 1987 USA 3.4%  97.1% 23.0% 12 
Van Leeuwen/ 
2010 
Netherland
s 
4.6% √ (own risk 
score) 
75.0% 57.0% 11 
Eight studies recommending universal screening 
Arora/ 2013 Thailand 9.3% No 78.2% 47.2% 15 
Coustan/ 1989 USA 2.0% No 65.0% 56.0% 13 
Danilenko-
Dixon/ 1999 
USA 3.0% No 97.0% 9.9% 15 
Di Cianni/ 
2003 
Italy 8.1% No 98.4% 5.6% 14 
Hadaegh/ 
2005 
Iran 8.9% No 88.7% 31.0% 15 
Lavin/ 1985 USA 1.4% No 46.7% 53.8% 13 
Teh/ 2011 Australia 8.7% No 92.7% (NICE 
criteria); 
100% (ADA 
criteria); 
98.6% 
(ADIPS 
criteria) 
30.1% 
(NICE 
criteria); 
3.5% 
(ADA 
criteria); 
12.6% 
(ADIPS 
criteria) 
15 
Zoller/ 1988 USA 2.8% No 40.0% 61.4% 12 
Two inconclusive studies 
Jimenez-
Moleon/ 2002 
Spain 2.5% No 89.2% 
(ACOG 
criteria); 
96.9% (ADA 
criteria) 
44.2% 
(ACOG 
critieria); 
15.5% 
(ADA 
criteria)  
13 
Williams/ 
1999 
USA 0.8% No 96.0% 11.1% 12 
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(2) 13 studies with a one-step GDM test 
 
In this category, the GDM incidence under the universal screening approach ranged 
from 1.7% in Sweden (Ostlund & Hanson, 2003) to 27.5% in Italy (Capula et al., 
2013). Of the 13 studies, two studies recommended selective screening (Jensen et al., 
2013; Pintaudi et al., 2014). Seven studies recommended universal screening 
(Capula et al., 2013; Chong et al., 2014; Cosson et al., 2013; Moses et al., 1995; 
Ostlund & Hanson et al., 2003; Shamsuddin et al., 2001; Wagaarachchi et al., 2001). 
Of the remaining four studies, one concluded further study was needed (Corrado et 
al., 2014); one recommended selective screening in economic restraint areas 
(Savona-Ventura et al., 2013); one called for further evaluation (Moses et al., 1988); 
and one did not make a direct recommendation (Shirazian et al., 2009). Figures of 
sensitivity and specificity of selective screening compared to universal screening for 
the 13 studies are provided in Table 7. Meta-analysis was conducted in Revman 5, 
forest plot of the sensitivity and specificity was produced and provided in Figure 5. 
Again, the forest plot showed considerable heterogeneity amongst the studies and the 
trade-off between sensitivity and specificity. The sensitivity ranged from 51.6% 
(with a specificity of 56.3% (Chong et al., 2014), to 98.5% (with a specificity of 
13.6%) (Shirazian et al. ,2009). The specificity ranged from 13.6% (with a 
sensitivity of 98.5%) (Shirazian et al., 2009), to 91.3% (with a sensitivity of 19.7%) 
(Moses et al., 1998). 
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Figure 5. Forest plot of sensitivity and specificity for the 13 studies with a one-
step GDM test 
 
 
Similar to the 15 studies with two-step GDM tests, associations were observed 
between the effectiveness of the selective screening and the selection criteria and 
GDM prevalence. As shown in Table 7, the only one study which developed own 
risk criteria (Pintaudi et al., 2014) for selecting high risk women for selective 
screening found it was very effective and recommended selective screening. The 
GDM incidences of the studies which recommended universal screening (ranged 
from 1.7% to 27.5%; mean 13.6%; median 11.3%) were generally higher than the 
studies which recommended selective screening (ranged from 2.4% to 11.3%; mean 
6.9%; median 6.9%). 
Table 7. Sensitivity and specificity of selective screening for the 13 studies with 
a one-step GDM test 
 
Study Country GDM 
incidence 
(under 
universal 
screening) 
Use of own 
selection 
criteria 
Sensiti-
vity 
Speci-
ficity 
Study 
quality 
Two studies recommending selective screening 
Jensen/ 2003 Denmark 2.4% No 63.7% 80.6% 12 
Pintaudi/ 2014 Italy 11.3% √ 89.0% 36.8% 15 
Seven studies recommending universal screening 
Capula/ 2013 Italy 27.5% No 74.6% 22.0% 15 
Chong/ 2014 Singapore 18.9% No 51.6% 56.3% 15 
Cosson/ 2013 Italy 11.3% No 41.5% 65.3% 11 
Moses/ 1995 Australia 6.7% No 54.2% 60.8% 11 
Ostlund & 
Hanson/2003 
Sweden 1.7% No 47.5% 84.2% 13 
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Shamsuddin/ 
2001 
Malaysia 24.9% No 72.2% 33.2% 14 
Wagaarachchi/ 
2001 
Sri Lanka 4.1% No 58.5% 54.1% 14 
Four inconclusive studies 
Corrado/ 2014 Italy 11.3% No 77.0% 41.7% 14 
Moses/ 1998 Australia 6.3% No 19.7% 91.3% 11 
Savona-Ventura/ 
2013 
Eleven 
Mediterranea
n countries 
8.7% No 65.9% 80.7% 13 
Shirazian/ 2009 Iran 7.4% No 98.5% 13.6% 14 
 
 
(3) Integration of all the 28 effectiveness studies 
 
Combining the two categories, only seven of the 28 effectiveness studies 
recommended selective screening (Caliskan et al., 2014; Helton et al., 1997; Jensen 
et al., 2013; Naylor et al., 1997; Sacks et al., 1987; Van Leeuwen et al., 2010; 
Pintaudi et al., 2014). Fifteen studies recommended universal screening, whereas 
two studies recommended selective screening conditionally, as in when fairly 
restrictive criteria are applied in defining the gravidae at risk (Jimenez-Moleon et al., 
2002) or for the areas of economic restraint (Savona-Ventura et al., 2013). Two 
studies concluded that selective screening needed to be assessed in different 
populations (Moses et al., 1998) or needed further study (Corrado et al., 2014). Two 
studies did not make a recommendation on universal or selective screening 
(Shirazian et al., 2009; William et al., 1999). 
 
(4) The heterogeneity of the included studies 
 
The HSROC (hierarchical summary receiver operating characteristic) curve was 
used to assess the heterogeneity of the studies and pooled estimate of sensitivity and 
specificity. The HSROC curve was generated using the metandi analysis in STATA 
12.0. The results for the 15 studies with two-step tests and 13 studies with a one-step 
test are shown in Figures 6 and 7, respectively. For both groups, high heterogeneity 
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was noted in the results of the studies reviewed. For the 15 studies, the pooled 
estimate of sensitivity and specificity was 0.91 and 0.46, respectively. For the 13 
studies, the pooled estimate of sensitivity and specificity was 0.77 and 0.45, 
respectively.  
 
     
 
 
 
(4) The PPV and NPV of the included studies 
 
Although sensitivity and specificity are used as performance indicators for screening 
or diagnostic test, the positive predictive value (PPV) and negative predictive value 
(NPV) are often reported. The focus of PPV and NPV is on the predictive power of 
the screening or diagnostic test. PPV is the probability of disease given that the test 
is positive. NPV is the probability of no disease given that the test is negative. 
Figures of PPV and NPV are meaningful to and preferred by clinicians who are 
interested in using the test result to predict a patient’s probability of having (or not 
having) a disease. However, it should be noticed that PPV and NPV are not intrinsic 
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Figure 6. HSROC curve for the 15 
studies with two-step GDM test 
 
Figure 7. HSROC curve for the 13 
studies with a one-step GDM test 
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to the test, they depend also on the prevalence of the disease (Altman & Bland, 
1994). Therefore, they are not suitable for the purpose of serving as performance 
indicators for a test. 
 
The PPV and NPV were calculated using the pooled sensitivity, pooled specificity 
and pooled prevalence. The pooled sensitivity and specificity values were generated 
using STATA 12.0, as shown in the HSROC curve section. The pooled prevalence 
was generated using MetaAnalyst software, based on the sample size and prevalence 
of each study. The pooled prevalence of the 15 studies with two-step tests and 13 
studies with a one-step test were 3.9% [2.7%, 5.7%] and 10.0% [6.3%, 15.4%], 
respectively. The PPV and NPV analysis results for the 15 studies with two-step 
tests and 13 studies with a one-step test are shown in Figures 8 and 9, respectively.  
 
Based on the pooled summary ROC model estimates of sensitivity and specificity, 
the figures showed the PPV and NPV values according to the prevalence of GDM. 
As prevalence increases, the PPV increases and NPV decreases. Data points are PPV 
(red point) and NPV (blue point) at sROC point estimates for sensitivity, specificity 
and at pooled prevalence. It is worth noticing that the index test here is not the 
screening test itself (OGTT) but screening women to dichotomise into high or low 
risk of GDM. For the 15 studies, the PPV and NPV was 6.3% and 99.2%, 
respectively. This means that a woman has a 6.3% chance of developing GDM if 
categorised as high risk woman. On the other hand, she has a 99.2% chance of not 
developing GDM if categorised as low risk woman. For the 13 studies, the PPV and 
NPV was 13.3% and 94.5%, respectively. This means that a woman has a 13.3% 
chance of developing GDM if categorised as high risk woman, and a 94.5% chance 
of not developing GDM if categorised as low risk woman. The ellipses provide a 
guide to the likely range in PPV and NPV given the meta-analytic pooled estimates 
for sensitivity and specificity and prevalence; they take into account the 95% 
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confidence intervals (CIs) of PPV and of NPV at the pooled prevalence and the 95% 
CI of the pooled predictive values derived from the 95% Lower CI (LCI) and Upper 
CI (UCL) for the pooled sensitivity and specificity. For the 15 studies and the 13 
studies reviewed, the LCI and UCL for PPV were 13.7% and 36.1%, whereas the 
LCI and UCL for NPV were 91.8% and 95.9%. 
 
 
  
 
 
(5) Publication bias analysis of all the 28 effectiveness studies 
 
Harbords method for small study bias was used for assessing publication bias 
(Category A and B studies together). The results were shown in Figure 10. The 
estimated intercept is 4.520 with a standard error of 1.694, giving a p-value of 0.012. 
The modified test suggests there were small-study effects.  
 
  
Figure 8. PPV and NPV analysis result for 
the 15 studies with two-step GDM tests 
 
Figure 9. PPV and NPV analysis result 
for the 13 studies with a one-step GDM 
test 
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Figure 10. Publication bias analysis for all included studies 
 
 
3.4.3 Result of the cost-effectiveness and cost studies 
 
3.4.3.1 Quality assessment result of the cost-effectiveness and cost studies 
 
The Drummond checklist was used to assess the quality of cost-effectiveness studies. 
(Drummond,1996). Poncet et al. (2002) fulfilled 23 of the 35 assessment criteria, 
failed (or not clear) 8, and the other 4 was not appropriate for the study. The 
assessment result is illustrated in Appendix 4.3.   
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3.4.3.2 Characteristics of the cost-effectiveness and cost studies 
 
Data extraction result for study characteristics of the cost-effectiveness and cost 
studies are provided in Table 8 and Table 9. The cost-effectiveness study (Poncet et 
al., 2002) was conducted in France, and used a health system perspective. Of the 
four cost studies, two were conducted in the USA (Coustan et al., 1989; Reed et al., 
1984), one in Iran (Larijani et al., 2004), and one in Malaysia (Shamsuddin et al., 
2001). All of the included studies used hospital perspective other than the health 
system perspective. The hospital perspective focuses on the immediate direct costs of 
screening and diagnosing patients. 
76 
 
Table 8. Summary table of key characteristics of the cost-effectiveness study 
Author/ year/ 
Country 
Analytical 
framework/ 
Perspective 
Intervention/ 
Comparator 
Selective screening 
criteria for high risk 
women 
Clinical effectiveness 
measures/ 
Resource 
Cost measures/ 
Resource 
Cost-effectiveness 
outcomes 
Author’s 
conclusion  
Poncet/ 2002 
France 
Decision 
analysis and 
cost-
effectiveness 
analysis/ 
Health system 
Screening 1 (S1): 
High risk women 
+50g GCT +100g 
OGTT; 
Screening 2 (S2): 
All pregnant 
women +50g GCT 
+100g OGTT; 
Screening 3 (S3): 
All pregnant 
women +75g 
OGTT/ 
Age≥35, obesity 
(BMI ≥27), family 
history of diabetes, 
personal history of 
GDM, a prior 
macrosomic infant, 
history of adverse 
obstetric outcome 
Macrosomia, prematurity, 
perinatal mortality, and 
hypertensive disorders 
rates/ 
38 published articles 
Costs of screening 
tests, obstetrical 
cares, management 
of GDM, if any, 
delivery cares, and 
sick leave/ 
A prospective study 
of 120 pregnant 
women 
ICERs of S2 were 
1.10-1.11 times of 
S1. 
ICERs of S3 were 
3.27-3.75 times of 
S1. 
Favoured 
selective 
screening 
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Table 9. Summary table of key characteristics of the cost studies 
Author/ 
year/ 
Country 
and city 
Perspect
ive/ 
Price 
year 
Intervention/ 
Comparator 
Selective screening 
criteria for high 
risk women 
Clinical 
effective
ness 
measure
s/ 
Resourc
e 
effectiveness 
outcomes 
Cost 
measures/ 
Resource 
Cost 
referenc
e 
Cost 
outcomes 
Currency Direct or 
indirect 
costs 
Discount Author’s 
conclusion  
Coustan/ 
1989 
USA, 
Rhode 
Island 
Hospital 
perspecti
ve/  
N/A 
(1) Universal 
screening using 50g 
GCT (140 mg/dl) 
+100g OGTT; 
(2) Selective 
screening A 
(Age≥25 et al.) 
using 50g GCT 
(140 mg/dl) +100g 
OGTT; 
(3) Selective 
screening B 
(Age≥30 et al.) 
using 50g GCT 
(140 mg/dl) +100g 
OGTT 
Age≥30, obesity 
(weight ≥85th 
percentile for 
height), family 
history of diabetes, 
personal history of 
GDM, a prior 
macrosomic infant, 
history of adverse 
obstetric outcome 
Sensitivit
y/A 
prospecti
ve cohort 
study of 
6214 
pregnant 
women 
(1) Universal 
screening: 100% 
sensitivity; 
(2) Selective 
screening A 
(Age≥25 et al.): 
85% sensitivity; 
(3) Selective 
screening B 
(Age≥30 et al.): 
65% sensitivity 
Cost per 
GDM case 
detected/A 
prospectiv
e cohort 
study of 
6214 
pregant 
women 
N/A Cost per GDM 
case detected: (1) 
$222; (2) $192; 
(3) $190 
US 
dollars 
Direct 
costs 
(immediate 
direct costs 
incurred by 
the 
hospital 
laboratory 
in the 
screenig 
and 
diagnosis 
of GDM) 
Discount 
was not 
relevant 
and not 
reported 
Do not 
recommend 
selective 
screening 
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Author/ 
year/ 
Country 
and city 
Perspecti
ve/ Price 
year 
Intervention/ 
Comparator 
Selective screening 
criteria for high risk 
women 
Clinical 
effectiven
ess 
measures/ 
Resource 
effectiveness 
outcomes 
Cost 
measures/ 
Resource 
Cost 
reference 
Cost 
outcomes 
Currency Direct or 
indirect 
costs 
Discount 
Larijani/ 
2004 
Iran, 
Tehran 
Hospital 
perspectiv
e/ 2002 
(1) U130 (reference): 
Universal screening 
using 50g GCT (130 
mg/dl) +100g OGTT; 
(2) U140: Universal 
screening using 50g 
GCT (140 mg/dl) 
+100g OGTT; 
(3) S130: Selective 
screening using 50g 
GCT (130 mg/dl) 
+100g OGTT; 
(4) S140: Selective 
screening using 50g 
GCT (140 mg/dl) 
+100g OGTT 
Age≥35, obesity, 
family history of 
diabetes, a prior 
macrosomic infant, 
history of adverse 
obstetric outcome, 
polyhydramnios, 
glycosuria 
GDM 
prevalenc
es, 
sensitiviti
es of 
screening 
strategies/ 
A single 
study of 
2416 
pregnant 
women at 
four 
university 
hospitals 
GDM prevalences: 
4.7% (U130), 4.1% 
(U140), 4.1% (S130), 
3.6 (S140) 
Sensitivities: 100% 
(U130), 88% (U140), 
86% (S130), 77% 
(S140) 
Cost per 
pregnant 
women, 
cost per 
GDM case 
detected/ 
Same single 
study of 
2416 
pregnant 
women at 
four 
university 
hospitals 
Mean 
value of 
the public 
and 
private 
sector 
tariffs, 
assuming 
standard 
material 
and 
services 
Cost per pregnant 
women: IRR 
30,140 ($3.80) for 
U130, IRR 25,641 
($3.20) for U140, 
IRR 21,703 ($2.71) 
for S130, IRR 
19,124 ($2.39) for 
S140; 
Cost per GDM case 
detected: IRR 
644,488 ($80.56) 
for U130, IRR 
619,500 ($77.43) 
for U140, IRR 
535,052 ($66.88) 
for S130, IRR 
525,044 ($65.63) 
for S140 
Iranian 
rials 
(IRR). 
The 
conversi
on rate 
to US 
dollars 
($) was 
$1 = 
IRR 
8,000 
Direct costs 
(immediate 
direct costs 
incurred by 
the hospital 
laboratory 
in the 
screening 
and 
diagnosis of 
GDM) 
Discount 
was not 
relevant 
and not 
reported 
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Author/ 
year/ 
Country 
and city 
Perspecti
ve/ Price 
year 
Intervention/ 
Comparator 
Selective screening 
criteria for high risk 
women 
Clinical 
effectiven
ess 
measures/ 
Resource 
effectiveness 
outcomes 
Cost 
measures/ 
Resource 
Cost 
reference 
Cost 
outcomes 
Currency Direct or 
indirect 
costs 
Discount 
Reed/ 
1984 
USA, Salt 
Lack city 
Hospital 
perspectiv
e/  
N/A 
(1) Universal 
screening using 50g 
GCT (150mg/dl)+ 
100g OGTT; 
(2) Selective 
screening (traditional 
risk factors) using 50g 
GCT (150mg/dl)+ 
100g OGTT; 
(3) Selective 
diagnosis using 100g 
OGTT 
(4) Universal 
diagnosis using 100g 
OGTT 
(5) Selective 
screening (aged over 
25) using 50g GCT 
(150mg/dl)+ 100g 
OGTT. 
Criteria 1:family 
history of diabetes, a 
prior macrosomic 
infant (≥ 9lb), history 
of adverse obstetric 
outcome (two or 
more pregnancies of 
fetal death, neonatal 
death, congenital 
anomly, prematurity, 
excessive wight gain, 
hypertension, or 
proteinuria) 
Criteria 2: age ≥25 
Number 
of cases 
missed/A 
precious 
study of 
O'Sullivan 
et al. 
(1973) 
Number of cases 
missed: (1) 5 (20%), 
(2) 15 (60%), (3) 12 
(48%), (4) 0 (0%), (5) 
6 (24%). 
Cost per 
GDM case 
detected/ A 
precious 
study of 
O'Sullivan 
et al. (1973) 
N/A Cost per GDM case 
detected: (1) 
$684.40, (2) 
$683.18; (3) 
$938.46, (4) 
$976.00; (5) 
$386.11 
US 
dollars 
Direct costs 
(immediate 
direct costs 
incurred by 
the hospital 
laboratory 
in the 
screenig and 
diagnosis of 
GDM) 
Discount 
was not 
relevant 
and not 
reported 
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Author/ 
year/ 
Country 
and city 
Perspecti
ve/ Price 
year 
Intervention/ 
Comparator 
Selective screening 
criteria for high risk 
women 
Clinical 
effectiven
ess 
measures/ 
Resource 
effectiveness 
outcomes 
Cost 
measures/ 
Resource 
Cost 
reference 
Cost 
outcomes 
Currency Direct or 
indirect 
costs 
Discount 
Shamsudd
in/ 2001 
Malaysia 
Hospital 
perspectiv
e/  
N/A 
(1) Universal 
screening using 75g 
OGTT; 
(2) Selective 
screening using 75g 
OGTT. 
Age≥35, obesity 
(weight ≥80kg), 
family history of 
diabetes, personal 
history of GDM, a 
prior macrosomic 
infant, history of 
adverse obstetric 
outcome, urinary 
tract infection, 
vaginal discharge and 
pruritis vulvae, 
glycosuria 
Sensivitity
/A cross-
sectional 
survey of 
768 
pregnant 
women 
(1) Universal 
screening: 100% 
sensitivity; 
(2) Selective 
screening: 72.2% 
sensitivity 
Cost per 
GDM case 
detected/A 
cross-
sectional 
survey of 
768 
pregnant 
women 
N/A Cost per GDM case 
detected: (1) 
Universal 
screening: RM 
12.06; (2) Selective 
screening: RM 
11.15 
Ringgit 
Malaysi
an 
(RM). 
The 
conversi
on rate 
to US 
dollars 
($) was 
$1 = 
RM 
3.80 
Direct costs 
(immediate 
direct costs 
incurred by 
the hospital 
laboratory 
in the 
screenig and 
diagnosis of 
GDM) 
Discount 
was not 
relevant 
and not 
reported 
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3.4.3.3 Data synthesis of the cost-effectiveness and cost studies 
 
The cost-effectiveness study (Poncet et al., 2002) used a health system perspective. 
The cost measures included screening tests, obstetrical cares, management of GDM, 
and if any, delivery cares, and sick leave, starting from the 24
th
 week of gestation till 
discharge from maternity. The outcome measures of effectiveness were macrosomia, 
prematurity, perinatal mortality, and hypertensive disorders rates. Poncet et al. (2002) 
found the cost to obtain one unit of additional effectiveness under universal 
screening was 1.1 times more expensive than selective screening, thus suggested 
selective screening with two-step tests was more cost-effective than universal 
screening. However, this study neither considered the long-term consequences of 
GDM after delivery nor the potential cost of missing a diagnosis of GDM through 
selective screening. Admittedly, these are difficult to measure, nevertheless these 
limitations could potentially affect the ICER of 1.1 reported in this study. 
 
All cost studies used hospital respective considering the direct costs of GDM tests. 
The main outcome of cost per GDM case detected ranged from $2.9 for selective 
screening (while $3.3 for universal screening) in Malaysia (Shamsuddin et al., 2001) 
to $386.11 for selective screening (while $684.40 for universal screening) in the 
USA (Reed et al., 1984). The GDM incidence in the Malaysia study (24.9%) was ten 
times of the GDM incidence in the US study (2.5%), which partly explained the big 
difference in cost per case detected. However, the Malaysia study failed to report the 
detailed cost per unit of GDM screening, which made further comparison of the 
screening cost between the two studies impossible. Reed et al. (1984) found the 
proportions of missed GDM were similar between selective screening (24%) and 
universal screening with two-step tests (20%), when compared with universal 
screening with one-step test, while selective screening for women over 25 years old 
was considerably cheaper in terms of cost per GDM case detected ($386.11 vs. 
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$684.40), thus suggested selective screening for women aged over 25. The other 
three cost studies all recommended universal screening as they found the cost per 
GDM case detected under selective screening approach was just slightly cheaper 
than universal screening, however the selective approach missed a significant 
proportion of GDM cases (Coustan et al., 1989; Larijani et al., 2004; Shamsuddin et 
al., 2001). 
 
 
3.5 DISCUSSION 
 
3.5.1 Statement of principal findings 
 
Only seven out of 28 effectiveness studies recommended selective screening 
(Caliskan et al., 2014; Helton et al., 1997; Naylor et al., 1997; Sacks et al., 1987; 
Van Leeuwen et al., 2010; Jensen et al., 2013; Pintaudi et al., 2014). Fifteen studies 
did not recommend selective screening over universal screening either because of 
low specificity (proportion of women who could be exempted from the screening) or 
low sensitivity (proportion of GDM cases identified) of the selective screening 
approach. Two studies recommended selective screening under certain 
circumstances (Jimenez-Moleon et al., 2002; Savona-Ventura et al., 2013), two 
studies required further research (Moses et al., 1998; Corrado et al., 2014), and the 
remaining two studies did not conclude with a recommendation (Shirazian et al., 
2009; William et al., 1999) 
 
The studies which recommended selective screening had been carried out in areas 
where GDM prevalence was relatively low compared to the contexts of studies 
wherein universal screening was recommended. The studies which recommended 
selective screening involved all four studies that used their own developed selection 
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criteria for identifying women at high risk (Caliskan et al., 2014; Naylor et al., 1997; 
Van Leeuwen et al., 2010; Pintaudi et al., 2014), including the use of a risk scoring 
algorithm (Naylor et al., 1997; Van Leeuwen et al., 2010).  
 
Only one of the four cost studies recommended selective screening for women over 
25 years old (Reed et al., 1984). The other three studies favoured universal screening 
because the cost per GDM case detected was just slightly higher than that for 
selective screening, but this did guarantee that no GDM cases were missed (Coustan 
et al., 1989; Larijani et al., 2004; Shamsuddin et al., 2001). The cost-effectiveness 
study favoured selective screening with two-step tests, since the ICER of universal 
screening was 1.1 times that of the ICER of selective screening (Poncet et al., 2002). 
 
3.5.2 Strengths, limitations, and uncertainties of the review 
 
Four main databases of Medline, EMBASE, Web of Science, and Cochrane 
Database were searched, which covered key resources. A second reviewer conducted 
a kappa analysis of 20% of the studies at title, abstract, and full text stages for the 
screening process. An example data extraction result of an included study was also 
double-checked by the second reviewer. Disagreements were discussed and 
agreements were achieved. This minimised the researcher bias of occasional 
inappropriate performance in the process of selection and data extraction for the 
review.  
 
As mentioned in section 3.4.2.1 earlier, the average quality score of the included 
studies was 13.4 out of 16. The reviewed studies reported excellently on aims and 
objectives, intervention and comparator. However, some of them failed to describe 
the outcome measures clearly in the introduction or methods section. When there 
was more than 10% loss to follow-up, some studies neither described the 
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characteristics of these patients nor took these into account in the final analysis. The 
majority of studies did not report the sample size calculation for their study 
population (please refer to section 3.4.2.1 for more details of the frequently failed 
items). These drawbacks can be seen as having possible implications for their final 
outcomes and conclusion.  
 
Due to the language limit for English written articles only, some potentially valuable 
articles written in other languages could have been missed. One other limitation is 
that the review assessed the efficacy outcomes of sensitivity and specificity, whereas 
the clinical outcomes were not assessed. However, there was a reason for it. The 
outcome measures of the current review changed from clinical outcomes to efficacy 
outcomes (sensitivity and specificity) after conducting a scoping search. Only three 
studies (Griffin et al., 2000; Cosson et al., 2006; Ezimokhai et al., 2006) were 
identified which used the clinical outcome measures. The three studies found the 
clinical outcomes of the GDM women diagnosed by universal screening were better 
than those GDM women diagnosed by selective screening. However, these findings 
could not be used to conclude that universal screening was better as the researchers 
had done because the GDM women diagnosed by selective screening represented 
more severe cases as they had risk factors, thus indicating the potential for worse 
clinical outcomes. The most appropriate study design for a clinical outcome 
comparison should be to compare the clinical outcomes of all women not just GDM 
women under the two screening approaches. No study was found that compared the 
clinical outcomes of all pregnant women under the universal screening versus 
selective screening. Having said so, if we assume that the GDM diagnosis criteria is 
correct (i.e., all the women diagnosed are GDM women, and these GDM women 
need treatment), then exploring the efficacy outcomes is also enough to compare the 
two screening approaches. 
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3.6 CONCLUSION 
 
3.6.1 Implications for service provision 
 
The results of the systematic review showed that only seven of 28 effectiveness 
studies recommended selective screening. These seven studies were conducted in 
areas of relatively low GDM prevalence, and included all four studies which used 
their own selection criteria for selecting high risk women rather than using the 
standard guideline criteria. For areas with high GDM prevalence, universal screening 
for GDM is recommended unless further evidence emerges. For areas with low 
GDM prevalence, it is recommended that on the one hand, they continue their 
current practice (whether it is universal or selective screening) before any robust up-
to-date evidence fight against the current practice (the evidence should share the 
same setting with them including same country, same selection criteria, and same 
OGTT method); on the other hand, they are encouraged to explore the evidence 
themselves regarding the effectiveness of a selective screening approach. There is no 
definitive cut-off for judging whether a country’s GDM incidence is low or high. 
The NICE guideline suggested certain high-risk ethnical groups including South 
Asia (India, Pakistan, Bangladesh), Black Caribbean and Middle Eastern origin 
(Saudi Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon, Egypt) (Webber et al., 2015) for GDM screening. From the current 
systematic review, a cut-off of 3.2% (this is the mean GDM incidence of the five 
studies which recommended selective screening as indicated in page 66) under two-
step GDM screening and a cut-off of 6.9% (this is the mean GDM incidence of the 
two studies which recommended selective screening as indicated in page 69) under 
one-step GDM screening might be considered. 
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From an economic perspective, the cost-effectiveness study and three of the four cost 
studies suggested that universal screening was only slightly more expensive than 
selective screening. Unless further evidence arises, the economics is of less concern 
when deciding which screening approach to use.  
 
3.6.2 Suggested research priorities 
 
Only four studies explored the effectiveness of selective screening using their own 
developed selection criteria, based on the local population (Caliskan et al., 2014; 
Naylor et al., 1997; Van Leeuwen et al., 2010; Pintaudi et al., 2014), all of which 
found selective screening were effective and recommended selective screening. 
Among them, two studies developed and used a risk scoring algorithm (Naylor et al., 
1997; Van Leeuwen et al., 2010). It is recommended that more studies be conducted 
to assess the effectiveness of selective screening using a self developed risk criteria 
which is specific to the local population characteristics, especially for areas with 
relatively low GDM prevalence. Furthermore, more cost-effectiveness studies using 
the perspective of health system are needed, since the evidence of one cost-
effectiveness study is not enough to make a definite conclusion. 
 
The new IADPSG criteria was recommended by the WHO (WHO, 2013) and was 
increasingly adopted by countries worldwide including China, Italy and Australia 
(Chinese Ministry of Health, 2011; Wong, 2014). However, this review found no 
study from these countries comparing universal versus selective screening under the 
new IADPSG OGTT criteria, further studies in this area were therefore suggested. 
Chapter 5 of this PhD research evaluated the effectiveness of a risk score-based 
selective screening approach compared with universal screening under the IADPSG 
criteria in China. Further discussion in the context of the findings from chapter 5 
were made and included in the Overall Discussion chapter at the end of the thesis. 
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When conducting future comparative studies on universal versus selective screening, 
there are several suggestions for a high quality study. Firstly, describe the outcome 
measures clearly in the introduction, method, and result sections; a clear definition 
and presentation of sensitivity and specificity should be reported. Secondly, make 
sure that the study population is representative of the entire pregnant women 
population, justify and clearly describe the inclusion and exclusion criteria. Thirdly, 
report the refusal rate and loss to follow-up rate where applicable, if these rates 
exceed 10%, take them into account in the final analysis. Fourthly, remember to 
report the sample calculation which was frequently ignored by previous studies. 
Finally, if the clinical outcomes are to be assessed, make sure that the clinical 
outcomes of all pregnant women under the universal screening group versus 
selective screening group are compared. Undertaking the above recommended 
research will fill the current evidence gap and generate more useful knowledge, 
contributing to a more robust conclusion about universal versus selective screening. 
 
The findings of the current systematic review help to address the overall thesis aim 
of exploring the most appropriate screening approach for GDM and, in particular,  
comparing the effectiveness and cost-effectiveness of universal versus selective 
screening. Further considerations with reference to the overall thesis aim will be 
presented in Chapter 4 and Chapter 5. 
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Chapter 4: Pregnant women’s attitudes, views, and 
experience of the IADPSG universal screening approach for 
GDM in China: a Q methodology study 
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4.1 BACKGROUND 
 
4.1.1 GDM background 
 
GDM is defined as any degree of glucose intolerance that occurs or is first 
recognised during pregnancy (Turok et al., 2003). Incidence of GDM ranges from 
less than 1% to 28% worldwide (Jiwani et al., 2012). In China, GDM incidence was 
between 8% to 15% under the IADPSG criteria (Shang & Ma, 2011; Wei & Yang, 
2011; Hou et al., 2012; Lu et al., 2012; Jiang et al., 2013). GDM can lead to various 
adverse maternal and fetal outcomes, including spontaneous abortion, caesarean 
section delivery, and pre-eclampsia to the mother; stillbirth, macrosomia, and 
shoulder dystocia to the newborn (Odar et al., 2004). Both mother and newborn are 
at increased risk of developing type 2 diabetes in the future (Damm et al., 2009). 
 
4.1.2 The IADPSG approach for GDM 
 
There is no clear consensus on the best screening approach for GDM. As explained 
in section 1.3.1 in Chapter 1, having all pregnant women (universal screening) or 
only high risk pregnant women (selective screening) to undergo the GDM tests, 
undergoing two-step GDM tests or a one-step GDM test, are all different possible 
options. Before 2011, China was implementing two-step universal screening 
approach for GDM. All pregnant women in China underwent a 50g glucose 
challenge test (GCT) during the 24
th
 to 28
th
 weeks of gestation; those with abnormal 
values then further undergo a 75g or 100g OGTT for diagnosis. Diagnosis was 
confirmed with at least two abnormal values from four measured: blood glucose 
≥5.8mmol/l at fasting, 10.6mmol/l at 1 hour, 9.2mmol/l at 2 hours, and 8.1 mmol/l at 
3 hours (Yang, 2009). With a 50g GCT beforehand, only a small number of women 
need to further undergo the complicated OGTT diagnostic test. 
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In 2010, the IADPSG suggested a one-step universal screening approach for GDM 
(Panel, 2010). All pregnant women, unless already diagnosed with diabetes, undergo 
the OGTT directly during the 24
th
 to 28
th
 weeks of gestation. Diagnosis of GDM is 
made if there is at least one abnormal value from three measured: blood glucose ≥5.1 
mmol/l at fasting, 10mmol/l at 1 hour, and 8.5mmol/l at 2 hours. All diagnosis 
thresholds of OGTT used in this new approach were lower than previous standards. 
 
In July 2011, the Chinese Ministry of Health (MOH) adopted the IADPSG one-step 
universal approach for GDM (Chinese Ministry of Health, 2011), which is expected 
to bring both advantages and disadvantages to pregnant women in China. One 
possible advantage is that women who might have adverse obstetric and perinatal 
outcomes due to higher glycemic levels are less likely to be missed for GDM 
treatment. Another advantage is that GDM women (the minority) are now diagnosed 
with GDM in just one visit, as opposed to two (1-hour 50g GCT screening test 
followed by 3-hour OGTT diagnosis test). The disadvantage of the IADPSG 
approach is that the non-GDM pregnant women (the majority), who previously only 
needed a relatively simple 50g GCT screening test (non-fasting, one hour, one blood 
sample required) now have to undergo the more complicated OGTT test (fasting, 
two hours, three blood samples required). GDM incidence is estimated to increase by 
two to three fold using the IADPSG approach, but it is not completely confirmed that 
these additionally identified women will benefit from treatment, or to what extent 
(Vandorsten et al., 2012).  
 
4.1.3 User perspectives on the IADPSG approach for GDM 
 
As described in section 1.3.5 in Chapter 1, patients are one of the key stakeholders 
whose perspectives and needs should be heard and integrated in any healthcare 
decision making and evaluation. It is important to understand pregnant women’s 
attitudes and views as well as their experiences of the one-step GDM diagnosis 
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approach. Griffiths et al. (1993) explored the attitudes of pregnant women towards 
universal one-step GDM screening with modified OGTT (two blood tests at fasting 
state and after 1 hour; a 75g glucose load is taken either at home or in a collection 
center) in Australia, with generally positive results. The Australian study was 
positive about the convenience of the screening method used, the need for all women 
to be screened in pregnancy, and their desire to be screened in future pregnancies. 
 
However, the study was conducted more than 20 years ago, and no study has been 
conducted recently to understand women’s attitudes or experiences of GDM 
screening, especially in the case of the new IADPSG universal one-step screening 
approach (three blood tests at fasting state, after 1 hour, and 2 hours; a 75g glucose 
load is usually taken at the hospital) for GDM. There is thus a gap in knowledge in 
regards to pregnant women’s views of the GDM test, the GDM information they 
received before and after the test, and their feelings towards the screening process 
and result. To fill the gap, this study used a Q methodology design to explore 
women’s attitudes, views, and experience of the IADPSG universal screening 
approach for GDM in China.    
 
 
4.2 AIM AND OBJECTIVES 
 
The study aimed to investigate pregnant women’s attitudes, views, and experience of 
the IADPSG one-step universal screening approach for GDM in China.  
 
The specific objectives were:  
(1) to develop a list of Q statements for assessing pregnant women’s attitudes, views, 
and experience of the one-step GDM diagnosis approach; 
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(2) to implement the Q methodology study and collect data from pregnant women, 
comprising 15 diagnosed with and 15 without GDM; 
(3) to analyse pregnant women’s responses to provide user perspectives concerning 
the IADPSG recommendations based one-step universal approach for GDM in 
China. 
 
 
4.3 METHODOLOGY 
 
4.3.1 Q methodology 
 
The Q methodology is a systematic study of subjectivity, i.e., a person’s viewpoint, 
opinion, beliefs and attitudes (Brown, 1993). Q methodology was originally invented 
by British psychologist William Stephenson in 1935. The use of Q methodology has 
expanded to other fields outside psychology, most notably in the area of political, 
social, and health sciences (Brown, 1997). In a Q methodology study, participants 
are provided with a set of statements on a certain topic, called the Q-set. 
Respondents, called the P-set, are asked to rank-order the statements into a 
subjectively meaningful pattern (Q-sort) from their individual point of view, 
according to their feelings, preferences, and judgments (Van Exel & de Graaf, 2005). 
Resulting Q-sorts are analysed using correlation and factor analysis (Q-analysis), 
yielding a set of factors whose interpretation reveals a set of points-of-view (the F-
set) (Watts & Stenner, 2005). 
 
The aim of a Q methodology study is to establish the existence of distinct viewpoints 
and thereafter to understand, explicate, and compare findings (Brown, 1980). To 
achieve this, engagement of very few individuals or even a single person could be 
appropriate (Watts & Stenner, 2005). Although 40-60 participants are considered 
suitable in the UK tradition of multiple-participant Q methodology (Stainton Rogers, 
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1995), good analyses might be conducted with considerably less (Stephenson 1953; 
Watts & Stenner, 2005). Q methodology suggests a minimum ratio of two Q-set 
items to every participant, in practice, it is sensible to choose a number of 
participants that is less than the number of Q-set items (Watts & Stenner, 2005). 
 
Q methodology utilises by-person factor analysis, rather than the traditional by-
variable analysis. The Q-set items are treated as sample while the participants are 
variables (Watts & Stenner, 2005). The analysis aims to establish the diversity and 
range of viewpoints expressed by the participants (Cross, 2005). The proportions of 
individuals in a factor are not revealed in the factor analysis, but the distinctive 
points of view in the form of statements that distinguish each other are revealed 
(Ward, 2010). Q sorting uses a quasi-normal distribution (Van Exel & de Graaf, 
2005); an example of Q sorting from ‘agree least’ to ‘agree most’ is shown in 
Appendix 6. Although Q methodology analysis could be achieved using IBM SPSS 
statistics, the ideal analysis software package to use is PQMethod, which has been 
purpose-built to do Q analysis and is free to download (Watts & Stenner, 2005). 
 
4.3.2 Rational of choosing Q methodology 
 
There are both qualitative and quantitative techniques to explore the perceptions, 
attitudes, or viewpoints regarding a research question. Both techniques have 
strengths and weaknesses. Brown (1996) criticised the problems with the 
qualitative/quantitative dichotomy in research, and promoted Q methodology which 
was considered to combine the strengths of both qualitative and quantitative research. 
Wilson (2005) described Q methodology as a technique that has the same level of 
mathematical rigor as quantitative methodology, and meanwhile has an interpretive 
component comparable to that of qualitative methodology. Cross (2005) stated that 
Q methodology allowed for the simultaneous study of objective and subjective issues 
to determine the perceptions.  
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Q methodology is appropriate for the current study, which is about exploring 
pregnant women’s perspectives regarding GDM screening. Use of Q methodology 
overcomes the drawbacks of traditional survey or interview. Traditional survey 
imposes meaning a priori and investigates pre-specified categories. However in Q 
methodology, it allows individuals to determine what is meaningful, valuable, and 
significant from their point of view (Ward, 2010). Interviews can be intrusive, time 
consuming, and sometimes inefficient. The current study involves pregnant women 
who are in vulnerable physical and potentially psychological condition. A Q 
methodology study would be more efficient in keeping the study focused and 
avoiding these risks.  
 
Since Q methodology uses a small sample size to investigate human subjectivity, the 
reliability or generalisability of the study results have often been criticised (Thomas 
& Baas, 1992). According to Brown (1980), an important notion behind Q 
methodology is that only a limited number of distinct viewpoints exist on any topic. 
Any well-developed Q sample, containing the wide range of existing opinions on the 
topic, will reveal these viewpoints (Van Exel & de Graaf, 2005). Thomas and Baas 
(1992) concluded that the reliability and the ability to generalise the sample results 
of Q are of less concern. The Q methodology results are the distinct subjectivities 
about a topic that are operant, not the percentage of the sample (or the general 
population) that adheres to any of them (Van Exel & de Graaf, 2005).   
 
4.3.3 Development of the Q statements 
 
In the current study, a concourse of 90 statements was initially developed regarding 
pregnant women’s attitudes, views, and experience of the GDM diagnosis approach. 
These statements were produced based on literature review, various related websites 
where women express their experience and opinions (e.g., pregnant women’s 
internet forum http://www.netmums.com and Facebook), and by consulting five new 
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mothers in the UK. These five mothers (one was diagnosed with GDM) who 
delivered within the last 6 months at the George Eliot Hospital in Nuneaton in the 
UK were consulted via the PRiDE event ‘Little Elves party’ on 10th December 2013. 
The researcher was assisted by the senior members of the team (PRiDE: 
http://www2.warwick.ac.uk/fac/med/research/mvhealth/patient_care/pride/) during 
the process. Then, a total of 32 Q-set items (i.e., Q statements) were established from 
the concourse by consulting three new mothers in China and three academic staff at 
the Warwick Medical School of the University of Warwick. These three new 
mothers (one was diagnosed with GDM) who delivered within the last year in 
hospitals in Chengdu in China were consulted via telephone from the researcher’s 
personal networks in December 2013. The final 32 statements ask pregnant women’s 
perspectives about the GDM diagnosis test, the GDM information they received and 
would like to receive before and after diagnosis, and their general viewpoints on the 
GDM diagnosis process. A full list of the 32 Q statements is shown in Appendix 7. 
 
4.3.4 FlashQ software for Q methodology study 
 
The use of Q methodology has been facilitated by recent developments in computer 
software. FlashQ is a free Flash application developed by Christian Hackert and 
Gernot Braehler for performing Q-sorts on a computer or online (FlashQ: 
http://www.hackert.biz/flashq/home/). It facilities data collection of the Q 
methodology study and also makes the responses much easier for participants.   
 
The final 32 Q statements were set up using FlashQ. The screenshots illustration of 
how FlashQ programme works on a computer is shown in Appendix 8, including an 
example of the Q-sort results. The FlashQ programme has been translated into 
Chinese, to be conducted among pregnant women in China. The translation was done 
by the researcher whose nationality is Chinese, and was checked by another Chinese 
with a master’s degree in public health.  
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4.3.5 Implementation of the Q methodology study in China 
 
The Q methodology study using FlashQ was conducted with 30 pregnant women at 
the Chengdu First People’s Hospital in China, including 15 diagnosed with and 15 
without GDM.  
 
Pregnant women visit the Department of Obstetrics for their first antenatal care at 
around 12
th
 week of gestation (3 months); a record card and a paper record are 
established for them at this first visit. They visit the hospital every 4 weeks before 
20
th
 week of gestation, every 2 weeks between 20
th
 and 32
rd
 week of gestation, and 
every week after 32
rd
 week of gestation. For antenatal visits before 32
rd
 week of 
gestation, every pregnant woman visits the Registration Room at the first place to 
collect their paper record, and return back the paper record to the Registration Room 
after she visits her doctor.  
 
The recruitment process took place at the Registration Room in the Department of 
Obstetrics. The recruitment was facilitated by the senior staff at the Registration 
Room. The senior staff identified the pregnant women for their gestational week and 
GDM status from their paper records. Pregnant women between 24
th
 to 30
th
 week of 
gestation were considered, which meant they had underwent the OGTT and received 
the GDM diagnosis result. The staff asked the eligible women whether they are 
interested to take part in a small study when they collected from or returned their 
paper records to the senior staff, and referred the women to the researcher who sat 
opposite to the staff at the Registration Room. Interested pregnant women were 
given the ‘Participant Information Leaflet’ by the researcher and were given time to 
read the leaflet in the waiting area beside the Registration Room. Women who 
decided to participate were led to a quiet Outpatient Room 10 metres away from the 
Registration Room by researcher to undertake the study. A ‘Consent Form’ was 
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given to the participant by the researcher to sign, and was collected before the study 
started. All women were given the opportunity to ask the researcher any questions 
about the study before signing the consent forms. The study was undertaken on a 
laptop computer in the Outpatient Room. An instruction sheet of FlashQ was given 
to the participants for guidance (see Appendix 9). The first 15 GDM women and the 
first 15 non-GDM women who consented to take part in the study were recruited. A 
small souvenir from the University of Warwick was given to each woman who 
participated in the study. 
 
4.3.6 Outcome analysis 
 
The analysis of the Q sorts is an objective computerised process, which is one of the 
scientific base of Q methodology (Van Exel & de Graaf, 2005). PQMethod (version 
2.11) was used for Q sorts analysis (PQMethod: http://schmolck.userweb.mwn.de/ 
qmethod/#PQMethod), which is a free statistical programme tailored for Q 
methodology analysis. Its original fortran programme, QMethod, was developed by 
John Atkinson at Kent State University in 1992, and was ported by the maintainer of 
the programme site to the PC and updated with added features to versions later on. 
Brown (1980; 1993) provided a comprehensive overview of the analysis of the Q 
sorts. First, the correlation matrix of all Q sorts is calculated, which reveals the 
degree of (dis)similarity in points of views between the individuals. Second, the 
correlation matrix is subject to factor analysis, which examines how many basically 
different Q sorts are in evidence. Third, the original set of factors is then rotated to 
arrive at a final set of factors. Finally, the calculation of factor scores and difference 
scores are done, which points out the salient statements that deserve special attention 
in describing and interpreting that factor.  Interpretation of the results is based on 
these factor scores and difference scores. The explanations individuals give 
following their ranking are used to interpret the factors and as illustration material. 
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The qualitative comments given by Chinese participants were translated into English 
for interpretation.  
 
4.3.7 Ethical considerations 
 
Pregnant women were fully informed of the study; the ‘Participant Information 
Leaflet’ and ‘Consent Form’ were distributed to pregnant women, and they were free 
to decide whether or not to participate. The information leaflet also clarified their 
right to withdraw from the study freely at any time. If a woman liked to participate, 
her consent form was completed and signed before any data are collected. Any 
woman who withdrew after providing consent to take part in the study were recorded 
and replaced, to ensure 15 GDM and 15 non-GDM participants. 
 
Neither names nor any other identifying information of participants were collected. 
Each woman was anonymised and given a serial number as a unique ID. Collected 
study information, including the Q methodology study results and consent forms, 
could only be accessed by the researcher and the research team from the University 
of Warwick, and the collaborators from the Chengdu First People’s Hospital. After 
the study, the electronic FlashQ results were stored securely in a computer with 
access password in the office at the Warwick Medical School, the University of 
Warwick, while paper records of the consent forms were stored in a locked cabinet 
in the same office.  
 
Ethical consent to conduct this study was sought initially in China, where the 
Hospital Ethics Approval Committee of the Chengdu First People’s Hospital 
scrutinised and approved the research proposal. A further University of Warwick 
Biomedical and Scientific Research Ethics Committee (BSREC) approval to conduct 
this research as part of a Health Sciences PhD programme was sought and granted. 
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The BSREC reference is REGO-2014-704. Please see the full approval letters in 
Appendix 10. 
 
4.4 RESULTS 
 
4.4.1 Data collection results 
 
4.4.1.1 Recruitment and data completion  
 
Please see Appendix 7 for a list of 32 developed Q statements, and Appendix 8 for 
the established FlashQ programme for the Q methodology study. Initially, 17 GDM 
women and 16 non-GDM were recruited to undertake the study. Three were 
excluded since they withdrew in the middle and failed to complete the whole study. 
15 GDM and 15 non-GDM women who fully completed the study were finally 
involved in the study. The FlashQ software automatically generated the result sheets 
in XPS document format after they finished the study. 
 
The participants were required to provide reasons for the two Q statements they most 
agreed with and the two statements they most disagreed with after all the statements 
had been rank ordered. To facilitate this process and to be consistent with all 
participants, the researcher typed their reasons into the FlashQ software. 
 
4.4.1.2 Basic hospital information related to the study 
 
The Chengdu First People’s Hospital is a top-class hospital (tertiary referral hospital) 
in Chengdu, the capital city of Sichuan Province in China. The Department of 
Obstetrics and Gynaecology at the hospital serves more than 3000 deliveries each 
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year. Each pregnant woman registered at the Registration Room in the Department 
of Obstetrics and Gynaecology of the hospital when they first visited the Department 
during 12
th
 to 14
th
 gestational week. The OGTT takes place during the 24
th
 to 28
th
 
gestational week.  
 
At the bottom of the pregnant women’s registration card is brief information about 
the OGTT test. No additional leaflet or material of GDM/OGTT was provided to 
pregnant women. No bulletin was available on GDM/OGTT on the walls in the 
Department of Obstetrics and Gynaecology. There was a “pregnant women’s school” 
at the hospital which provided free weekly courses relevant to pregnancy. However, 
no GDM/OGTT course was provided. The weekly school is non-obligatory, and 
attendance is middling. 
 
There was a scanning machine for report collection, which was located on the same 
floor as the Department of Obstetrics and Gynaecology. Pregnant women wait 
several hours after OGTT to collect their OGTT result from the scanning machine. 
They then give the results sheet to their doctor so that they can receive explanation 
and advice. If a pregnant woman is diagnosed as having GDM, she will then be 
referred to the Department of endocrinology at the hospital for further advice and 
treatment.   
 
4.4.2 Data analysis result 
 
4.4.2.1 The analysis process 
  
The analysis followed the standard procedure using the PQMethod software (Figure 
11), under the instruction of the PQMethod Manual (http://schmolck.org/qmethod/ 
pqmanual.htm). 
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Figure 11. Standard analysis procedure in the PQMethod software 
 
First, ‘1-STATES’ was performed to enter the 32 Q statements. Second, ‘2-
QENTER’ was performed to enter the Q sort of each of the 30 participants. Q sorts 
of the 15 non-GDM women were entered first, followed by Q sorts of the 15 GDM 
women.  
 
‘3-QCENT’ (Centroid analysis) and ‘4-PCA’ (Principal Component analysis)’ were 
two alternative options for extracting (unrotated) factors. The QCENT offers the 
option of choosing between two methods of Centroid extraction, the customary 
method described in Brown (1980) and the Horst’s (1965) method. The Brown 
Centroids, as a default, suggests the ‘magical number’ of seven centroids to extract 
(centroids are factors). ‘5-QROTATE’ and ‘6-QVARIMAX’ are alternative options 
for rotating the factors. ‘5-QROTATE’ allows rotation by hand, whereas ‘6-
QVARIMAX’ is automatic rotation (PQMethod Manual - version 2.35) 
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As pointed out by Watts & Stenner (2005), there was often little reason for 
preferring one method over another for factor extraction and factor rotation. Though 
centroid analysis is generally preferred, the PCA analysis is equally satisfying. For 
factor rotation, in practice many Q methodologists prefer the simplicity and 
reliability of the varimax procedure, which automatically seeks the mathematically 
superior solution (Watts & Stenner, 2005). I chose 3-QCENT and 6-QVARIMAX 
since these two methods were more standardised and automated, and reduced the 
researcher bias of making different selections when using 4-QPCA and 5-
QROTATE. 
 
Finally, ‘7-QANALYZE’ was conducted to perform the final Q analysis of the 
rotated factors. ‘8-VIEWLIST’ was used to view the output file in ‘.lis’ format, 
which could be opened with Notepad. 
 
4.4.2.2 Factor extraction result 
 
Having conducted ‘3-QCENT’ (Centroid analysis) using the ‘Brown Centroids’ 
method, seven factors were extracted. The end product of the factor extraction 
process is a table of factor loadings indicating the initial association, or correlation, 
of each Q sort with each factor (Table 10). The table that is produced is also called 
an unrotated factor matrix. The factor loading (also known as factor saturation) is 
expressed in the form of a correlation coefficient. It tells us the extent to which each 
individual Q sort can be said to exemplify, or is typical of a factor pattern (Watts & 
Stenner, 2012).   
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Table 10. The Un-rotated Factor Matrix Generated by the Centroid Factor 
Analysis 
          Factors       
  Sorts 1 2 3 4 5 6 7 
1 P004 0.6088 -0.2786 -0.2632 -0.0098 -0.4333 0.0412 0.1526 
2 P005 0.7363 0.1622 -0.1214 0.068 0.137 0.0144 0.0106 
3 P006 0.542 -0.3372 0.21 -0.3585 -0.2399 0.0612 0.1254 
4 P007 0.5357 0.396 0.2472 0.0776 0.1194 0.0876 0.0303 
5 P008 0.6216 -0.3305 0.1686 -0.0682 -0.2673 0.0587 0.0634 
6 P013 0.5627 0.4495 -0.2189 -0.1956 -0.2086 0.1145 0.0743 
7 P014 0.6325 0.1883 -0.1458 0.0856 -0.2298 0.0193 0.0511 
8 P015 0.7743 0.3031 0.3454 0.0804 0.1142 0.0506 0.0576 
9 P016 0.5204 0.5202 0.2445 0.2256 -0.297 0.1568 0.1112 
10 P017 0.3189 -0.2663 -0.1286 -0.4792 0.1522 0.0376 0.124 
11 P019 0.8341 0.1064 0.0829 -0.0522 -0.0131 0.0065 0.005 
12 P020 0.1143 -0.5378 0.2914 0.0401 0.0099 0.1659 0.0387 
13 P022 0.3128 -0.6606 -0.407 -0.1481 0.0658 0.2657 0.0905 
14 P023 0.2529 -0.4503 -0.3019 0.4777 0.0699 0.1127 0.1564 
15 P027 0.5429 -0.2722 0.5842 0.0846 0.0785 0.0393 0.169 
16 PG001 0.4242 -0.1486 0.2203 -0.3009 0.2991 0.0114 0.0927 
17 PG009 0.5835 -0.0551 -0.4135 0.3873 -0.0951 0.0015 0.1705 
18 PG010 0.2486 -0.0274 0.1877 -0.0528 -0.1873 0.0003 0.0437 
19 PG011 0.4864 0.4097 -0.2558 0.1322 0.0316 0.0941 0.0382 
20 PG012 0.2495 0.169 -0.0497 -0.3003 0.0419 0.0156 0.0427 
21 PG018 0.4748 -0.3683 -0.1257 0.115 0.2723 0.0736 0.0337 
22 PG021 0.15 -0.1926 -0.3296 -0.1222 0.3412 0.0193 0.098 
23 PG024 0.5231 -0.1518 0.2429 0.324 0.2519 0.0119 0.0934 
24 PG025 0.5925 -0.3197 0.0539 -0.122 0.0242 0.0548 0.0072 
25 PG026 0.6883 0.2395 0.2707 -0.1755 0.1149 0.0313 0.0481 
26 PG028 0.6911 -0.0343 0.0054 0.1779 -0.2189 0.0006 0.0488 
27 PG029 0.3538 0.2027 -0.1965 0.1481 -0.0352 0.0224 0.0311 
28 PG030 0.7141 0.3191 -0.3317 -0.2776 -0.1886 0.0562 0.1207 
29 PG032 0.5907 0.4173 -0.0424 0.0988 0.132 0.0978 0.0063 
30 PG033 0.2997 0.5439 0.1856 0.1445 0.2733 0.173 0.0451 
  Eigenvalues 8.5127 3.3601 1.9397 1.4292 1.1671 0.2335 0.2306 
  
% 
expl.Var. 28 11 6 5 4 1 1 
 
 
The Eignvalue (EV) in the table (Table 10) is indicative of a factor’s statistical 
strength and explanatory power. The absolute and relative sizes of the Eignvalues of 
the factors is a major determinant on how many factors to keep for following 
rotation. One standard requirement is to select only those factors with an eigenvalue 
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greater than 1.00 (Watts & Stenner, 2005), so called Kaiser-Guttman criterion 
(Guttman, 1954; Kaser, 1960, 1970). This cut-off was used because an extracted 
factor with an EV of less than 1.00 actually accounts for less study variance than a 
single Q sort (Watts & Stenner, 2012). Table 10 shows that Factor 1-5 has 
eigenvalues in excess of 1.00. 
 
Furthermore, the Cattell’s (1966) test prevents the arbitrary retention of all factors 
with EVs greater than 1.00 (Watts & Stenner, 2012). This method (Cattell, 1966) is 
more cautious than the Kaiser-Guttman criterion (Guttman, 1954; Kaser, 1960, 
1970). This scree test involves the plotting of these EVs on a line graph, the number 
of factors to extract for rotation is indicated by the point at which the line changes 
slope. A scree test figure was drawn (Figure 12). 
 
 
Figure 12. Scree test of seven principle components 
 
Inspection of Figure 12 shows the slope changes from 114° at factor 1 to 148° at 
factor 2 with 34° increase. The slope then changes from 148° at factor 2 to 165° at 
factor 3 with 17° increase. The point at which the line changes slope is at factor 2. 
1 2 3 4 5 6 7 
Eigenvalue 8.5127 3.3601 1.9397 1.4292 1.1671 0.2335 0.2306 
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This indicates that only two factors should be extracted from the dataset for 
following factor rotation and flagging.  
 
 4.4.2.3 Factor rotation result 
 
 ‘6-QVARIMAX’ was performed for rotation of the factors. Two factors (as 
indicated by the scree test) were automatically rotated. A separate MS-DOS 
programme ‘PQROT.exe’ attached to PQMethod was automatically launched for 
graphical factor rotation and factor flagging (Figure 13).   
 
Flagging factors seeks to associate particular subjects with factors, which is 
necessary for input to the ‘7-QANALYZE’.  
 
Figure 13. Flagging result for rotated factors 
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The factor loadings were flagged with an ‘x’ if they were a significant factor 
defining variants. Stephen's Table ‘quick lookup table - is it significant?’ (Appendix 
11) was used for flagging based on the number of items in the study. According to 
the table, if a study has 32 items (Q statements), then flag anything >0.456 for a p-
value < 0.01 and >0.346 for a p-value <0.05. Factor loadings >0.456 (P<0.001) was 
flagged for this study.   
 
4.4.2.4 Final factor scores result  
 
‘7-QANALYZE’ was conducted to perform the final Q analysis of the rotated 
factors. Only factors that were flagged would be output into the final file (.lis). The 
unflagged Factor 3 was dropped. The ‘8-VIEWLIST’ was used to view the output 
file.lis. 
 
In effect, the Q sorts of all participants that load significantly on a given factor are 
merged together to yield a single (factor exemplifying) Q sort which serves as an 
interpretable ‘best-estimate’ of the pattern or item configuration which characterises 
that factor (Watts & Stenner, 2005). The factor scores (also known as factor arrays) 
which exemplify the best-estimate Q sorts of the two flagged factors (the factor 1 
pattern and the factor 2 pattern) were displayed in Table 11 and subject to 
interpretation.  
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Table 11. Factor scores table for Factor 1 and Factor 2 
Statement factors 1 2 
  1  The OGTT is convenient 1 -3 
  2  Having blood drawn three times within 2 hours OGTT is too much -1 3 
  3  The duration of 2 hours for the OGTT test is too long -1 3 
  4  The time from having the OGTT test to collecting the result was satisfactory 1 -2 
  5  I feel it is more convenient to collect my GDM diagnosis result during my next visit to 
the hospital, rather than waiting for several hours to collect it on that day -1 1 
  6  I prefer face-to-face notification of the GDM diagnosis result when I come to the 
hospital rather than being telephoned when the result comes out 0 -1 
  7  It was easy to find the scan machine for collecting my GDM diagnosis result 2 2 
  8  The GDM diagnosis result sheet was NOT understandable -2 -1 
  9  I was satisfied with the doctor's explanation when I gave my GDM diagnosis result 
sheet to him/her to review 1 0 
 10  I wish I had been given more information about GDM and GDM diagnosis before I 
had the OGTT 2 2 
 11  I wish I had been given more information about GDM and GDM diagnosis after I had 
the OGTT 2 2 
 12  I am NOT satisfied with the GDM information I received from the doctors/nurses at 
the hospital -1 -2 
 13  I am satisfied with the GDM information I received from the weekly lectures for 
pregnant women at the hospital 0 -1 
 14  I am NOT satisfied with the GDM information I received from the leaflet/bulletin 
board at the hospital 0 0 
 15  I would prefer to receive GDM information from weekly lectures for pregnant women 
at the hospital 0 -1 
 16  I would prefer to receive GDM information from an education leaflet provided by the 
hospital 0 0 
 17  I would NOT prefer to receive GDM information from the hospital bulletin board -1 -2 
 18  I would NOT prefer to search for GDM information (from internet, TV, magazines, 
books, etc.) by myself -2 0 
 19  I would prefer my family (parents, husband/partner) or my friends to search for GDM 
information for me -1 0 
 20  I would prefer to learn about GDM from talking to women who have or had GDM 0 0 
 21  Testing for GDM is very important and necessary 3 1 
 22  The OGTT should be conducted for all pregnant women 3 2 
 23  I feel it is a burden to undergo the OGTT -3 -1 
 24  I was confused about the OGTT -2 -2 
 25  I was unhappy with the OGTT -3 -1 
 26  I am satisfied with the whole process of being tested for GDM 1 0 
 27  I am satisfied with the support I received throughout the OGTT procedure 2 1 
 28  I was treated with dignity and respect by staff in the hospital throughout the whole 
OGTT procedure 1 1 
 29  The doctor who gave the OGTT to me was NOT knowledgeable and informative 0 0 
 30  The doctor who did the OGTT listened to my concerns and listened to what I needed 0 1 
 31  Sometimes I felt afraid to ask the hospital staff relevant advice about OGTT and 
GDM -2 -3 
 32  All necessary explanations and advice about OGTT were given by hospital staff 1 1 
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4.4.3 Interpretation of the results 
 
4.4.3.1 Basic characteristics of participants  
 
Thirty patients (15 non-GDM and 15 GDM women) participated in the Q 
methodology study. The mean age was 28.6 years old. The participants underwent 
the OGTT at around 25
th
 week of gestation (ranged from 23
rd
 to 29
th
 week). They 
were interviewed about four weeks after their OGTT, which was at 29
th
 week of 
gestation (ranged from 25
th
 to 32
nd
 week). 26.7% of the participants had not received 
any information about GDM before their OGTT, the number reduced to 6.6% after 
OGTT and before referral to the endocrinology department. 83.3% of the 
participants felt the Q methodology study was easy to complete (Table 12). 
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                  Table 12. Basic characteristics of participants 
         
# ID 
GDM 
status Age 
Current 
gestatio
nal week 
Gestatio
nal week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether 
Q study is 
easy to 
complete 
1 P004 
Non-
GDM 27 27 23 No N/A Yes Friend Yes 
2 P005 
Non-
GDM 33 26 25 Yes Friend Yes hospital Yes 
3 P006 
Non-
GDM 26 28 24 Yes Media, friend Yes 
Media, 
hospital, 
friend Yes 
4 P007 
Non-
GDM 24 28 27 Yes Hospital Yes 
Other 
pregnant 
women at 
hospital Yes 
5 P008 
Non-
GDM 25 30 24 Yes 
Media, 
hospital Yes hospital Yes 
6 P013 
Non-
GDM 28 28 24 Yes 
Hospital, 
friend Yes 
Hospital, 
friend, other 
pregant 
women at 
hospital Yes 
7 P014 
Non-
GDM 27 27 24 Yes Media Yes 
Media, 
hospital Yes 
8 P015 
Non-
GDM 22 29 25 Yes 
Media, other 
pregnant 
women at 
hospital Yes 
Hospital, 
husband Yes 
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# ID 
GDM 
status Age 
Current 
gestatio
nal week 
Gestatio
nal week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether 
Q study is 
easy to 
complete 
9 P016 
Non-
GDM 32 30 23 Yes 
Media, 
hospital, 
friend Yes 
Media, 
hospital Yes 
10 P017 
Non-
GDM 28 30 26 Yes Media Yes Media Yes 
11 P019 
Non-
GDM 32 28 24 Yes 
Media, 
hospital, 
parents Yes 
Media,hospita
l, parents Yes 
12 P020 
Non-
GDM 31 30 27 Yes Friend Yes Hospital Yes 
13 P022 
Non-
GDM 28 28 24 No N/A No N/A Yes 
14 P023 
Non-
GDM 29 29 24 No N/A Yes Hospital Yes 
15 P027 
Non-
GDM 29 27 24 Yes 
Media, other 
pregnant 
women at 
hospital Yes 
Media, 
hospital Yes 
16 PG001 GDM 29 29 26 Yes Media Yes 
Media, 
hospital No 
17 PG009 GDM 26 28 24 Yes 
Hospital, 
husband, 
friend Yes 
Hospital, 
husband, 
friend No 
18 PG010 GDM 21 32 26 No N/A Yes Hospital No 
19 PG011 GDM 25 29 24 Yes Friend Yes Media, friend Yes 
20 PG012 GDM 30 32 24 No N/A Yes Media Yes 
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# ID 
GDM 
status Age 
Current 
gestatio
nal week 
Gestatio
nal week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether 
Q study is 
easy to 
complete 
21 PG018 GDM 29 28 24 No N/A Yes 
Media, 
hospital No 
22 PG021 GDM 28 28 24 No N/A No N/A Yes 
23 PG024 GDM 33 30 26 Yes Hospital Yes 
Media, 
hospital Yes 
24 PG025 GDM 23 25 25 Yes Hospital Yes Hospital Yes 
25 PG026 GDM 40 26 25 No N/A Yes 
Media, 
hospital, 
friend Yes 
26 PG028 GDM 26 28 25 Yes Friend Yes Hospital No 
27 PG029 GDM 32 32 24 Yes 
Media, 
hospital Yes 
Media, 
hospital Yes 
28 PG030 GDM 35 32 29 Yes Hospital Yes Hospital Yes 
29 PG032 GDM 28 32 24 Yes Media, friend Yes 
Media, 
hospital, 
friend Yes 
30 PG033 GDM 32 31 24 Yes 
Hospital, 
other 
pregnant 
women at 
hospital Yes 
Media, 
hospital, other 
pregnant 
women at 
hospital Yes 
 
Mean  
50% 
GDM 28.6 29 25 26.7% No   6.6% No   83.3% Yes 
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4.4.3.2 Interpretation of the Q analysis results 
 
Seven factors were extracted, two were rotated, two were flagged, explaining 39% of 
the variance and accounting for 22 of the 30 participants. Participant loading 
of  ≥0.456 reached significance at p <0.01, indicating that each loading participant 
closely exemplifies the factor they load onto. 
 
The factor scores (or factor arrays) for the two flagged factors were the most 
important aspect of the study result (Table 11). For ease of interpretation it is 
standard Q-methodological practice to generate a single exemplary Q-sort by 
merging (according to a procedure of weighted averaging) the Q-sorts of all 
significantly loading participants: factor array.  
 
The two flagged factors (factor 1 and factor 2) were two significant shared 
viewpoints on GDM screening among these pregnant women. Each factor pattern 
(viewpoint) can be exemplified by a best-estimate Q sort (factor scores) in the table. 
The exemplary Q sort was then interpreted and supplemented by the qualitative 
comments gathered from participants who had loaded significantly on the factor 
being interpreted. The interpretative task in Q methodology involves the production 
of a series of summarising accounts, each of which explicates the viewpoint being 
expressed by a particular factor (Watts & Stenner, 2005). A clear interpretation of 
the factor emerges when the various item rankings (scores) and participants 
comments are effectively combined. The rankings which informed the interpretation 
at each stage are also included in the interpretation text (as a point of reference for 
the reader) (Watts & Stenner, 2005). 
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Factor 1: GDM diagnosis is very important and the OGTT should be conducted 
for all pregnant women. 
 
Demographic information: Factor 1 has 13 significantly loading participants 
(participant loading ≥0.456) and it explains 28% of the study variance. It has an 
eigenvalue of 8.51. There are almost equal number of non-GDM (7) and GDM (6) 
women in this group. They have an average age of 29.5 years old (Table 13). 
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                 Table 13. Basic characteristics of significantly loading participants for factor 1 
# ID 
GDM 
status Age 
Current 
gestation
al week 
Gestation
al week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether Q 
study is easy 
to complete 
2 P005 
Non-
GDM 33 26 25 Yes Friend Yes hospital Yes 
4 P007 
Non-
GDM 24 28 27 Yes Hospital Yes 
Other pregnant 
women at hospital Yes 
6 P013 
Non-
GDM 28 28 24 Yes Hospital, friend Yes 
Hospital, friend, 
other pregant 
women at hospital Yes 
7 P014 
Non-
GDM 27 27 24 Yes Media Yes Media, hospital Yes 
8 P015 
Non-
GDM 22 29 25 Yes 
Media, other 
pregnant women 
at hospital Yes Hospital, husband Yes 
9 P016 
Non-
GDM 32 30 23 Yes 
Media, hospital, 
friend Yes Media, hospital Yes 
11 P019 
Non-
GDM 32 28 24 Yes 
Media, hospital, 
parents Yes 
Media,hospital, 
parents Yes 
19 PG011 GDM 25 29 24 Yes Friend Yes Media, friend Yes 
25 PG026 GDM 40 26 25 No N/A Yes 
Media, hospital, 
friend Yes 
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# ID 
GDM 
status Age 
Current 
gestation
al week 
Gestation
al week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether Q 
study is easy 
to complete 
           26 PG028 GDM 26 28 25 Yes Friend Yes Hospital No 
28 PG030 GDM 35 32 29 Yes Hospital Yes Hospital Yes 
29 PG032 GDM 28 32 24 Yes Media, friend Yes 
Media, hospital, 
friend Yes 
30 PG033 GDM 32 31 24 Yes 
Hospital, other 
pregnant women 
at hospital Yes 
Media, hospital, 
other pregnant 
women at hospital Yes 
 
Mean  
46.2% 
GDM 29.5 29 25 7.7% No 
 
0% No 
 
92.3% Yes 
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Factor interpretation: This group of women shared a strong viewpoint that testing 
for GDM is very important and necessary (17: +3) and the OGTT should be 
conducted for all pregnant women (18: +3). There is neither a burden to undergo the 
OGTT (23: -3) nor any unhappiness for OGTT (25: -3). OGTT is convenient (1: +1). 
Having blood drawn three times within 2 hours OGTT is not deemed too much (2: -
1), nor is the duration of 2 hours for the OGTT deemed too long (3: -1). 
 
It is very easy to find the scan machine for collecting the GDM diagnosis result (7: 
+2) and the diagnosis result is understandable (8: -2). Waiting for several hours to 
collect the OGTT result on that day is better than collecting the OGTT result during 
the next visit to the hospital (5: -1), since they were eager to know their OGTT 
results rather than waiting for another 1-2 weeks. Pregnant women did not complain 
much about the several hours waiting time. It was potentially because in China due 
to both the massive number of patient visits and concerns over cost savings, the 
hospitals usually run a large biochemical analyzer to test a batch of hundreds of 
sample together after these all being collected, it was normal to wait a few hours to 
collect the result of a test conducted by a large biochemical analyzer (including 
OGTT). 
 
The whole process of being test for GDM is satisfactory (26: +1), including the 
support received throughout the OGTT procedure (27: +2). All necessary 
explanations and advice about OGTT were given by hospital staff (32: +1), and there 
was no confusion about the OGTT (24: -2). The GDM information received from the 
doctors/nurses at the hospital was satisfactory (12: -1), including doctor's explanation 
when giving the GDM diagnosis result sheet to him/her to review (9: +1). Pregnant 
women are treated with dignity and respect (28: +1). There is no fear of asking the 
hospital staff relevant advice about OGTT and GDM (31: -2).  
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The findings suggest that the participants, nevertheless, wished strongly to be given 
more information about GDM and GDM diagnosis both before (10: +2) and after (11: 
+2) the OGTT. They also prefer to search GDM information (from internet, TV, 
magazines, books, etc.) by themselves (18: -2) and to receive GDM information 
from the hospital bulletin board if available (17: -1). Interestingly, they do not prefer 
their family (parents, husband/partner) or friends to search for GDM information for 
them (19: -1).  
 
Factor 2: GDM diagnosis (OGTT) is inconvenient and a burden for pregnant 
women to some extent.   
 
Demographic information: Factor 2 has 11 significantly loading participants 
(participant loading ≥0.456) and it explains 11% of the study variance. It has an 
eigenvalue of 3.36. There are more non-GDM (8) and GDM (3) women in this group. 
They have an average age of 27.7 years old (Table 14). 
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                   Table 14. Basic characteristics of significantly loading participants for factor 2 
# ID 
GDM 
status Age 
Current 
gestation
al week 
Gestation
al week 
for 
OGTT 
Received 
GDM 
information 
before OGTT 
Information 
Source 
Received 
GDM 
information 
after OGTT 
Information 
Source 
Whether Q 
study is 
easy to 
complete 
1 P004 Non-GDM 27 27 23 No N/A Yes Friend Yes 
3 P006 Non-GDM 26 28 24 Yes Media, friend Yes 
Media, 
hospital, 
friend Yes 
5 P008 Non-GDM 25 30 24 Yes 
Media, 
hospital Yes hospital Yes 
11 P019 Non-GDM 32 28 24 Yes 
Media, 
hospital, 
parents Yes 
Media, 
hospital, 
parents Yes 
12 P020 Non-GDM 31 30 27 Yes Friend Yes Hospital Yes 
13 P022 Non-GDM 28 28 24 No N/A No N/A Yes 
14 P023 Non-GDM 29 29 24 No N/A Yes Hospital Yes 
15 P027 Non-GDM 29 27 24 Yes 
Media, other 
pregnant 
women at 
hospital Yes 
Media, 
hospital Yes 
21 PG018 GDM 29 28 24 No N/A Yes 
Media, 
hospital No 
24 PG025 GDM 23 25 25 Yes Hospital Yes Hospital Yes 
26 PG028 GDM 26 28 25 Yes Friend Yes Hospital No 
  Mean 
27.2% 
GDM 27.7 28 24 36.4% No   0.9% No   81.8% Yes 
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Factor interpretation: This group of women shared a strong viewpoint that OGTT 
is not convenient at all (1: -3). Having blood drawn three times is too much (2: +3), 
and the duration of 2 hours for the OGTT is too long (3: +3). However, GDM testing 
is still important and necessary (21: +1), and OGTT should be conducted for all 
pregnant women (22: +2). The OGTT does not bring unhappiness (25: -1). 
 
The time between having the OGTT test and collecting the OGTT result is not 
satisfactory (4: -2). It would be more convenient to collect the diagnosis result at the 
next hospital visit rather than waiting for several hours to collect it on that day (5: 
+1). Moreover, compared to collecting the result in person, it is preferable to be 
informed about the result by telephone when comes out (6: -1). Nonetheless, the 
scanning machine for result collection is easy to find (7: +2). 
 
The GDM diagnosis results sheet is understandable (8: -1). The GDM information 
received from the weekly courses for pregnant women at the hospital is not 
satisfactory (13: -1).  Actually, the GDM/OGTT topic was not covered by the 
weekly courses, though it covered a series of other subjects relevant to pregnancy.  
The weekly courses were neither a preferred delivery resource for them (15: -1), due 
to the inflexibility of the timescale of the courses. It is deemed preferable to receive 
the GDM information from the hospital bulletin board (17: -2). 
 
Throughout the OGTT procedure, the support is satisfactory (27: +1) and pregnant 
women are respected (28: +1). The doctor who carried out the OGTT listened to 
pregnant women’s concerns and needs (30: +1). Necessary explanations and advice 
about OGTT are offered (32: +1) and there is no fear at all for asking questions 
regarding to OGTT and GDM (31: -3). Though satisfied with the GDM information 
received from the doctors/nurses at the hospital (12: -2) and feels no confusion about 
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the OGTT (24: -2), it is regarded as strongly desirable to receive more information 
about GDM and GDM diagnosis both before (10: +2) and after (11: +2) the OGTT. 
 
Comparing factor 1 and factor 2: Viewpoints and participant characteristics 
 
Viewpoints: Both shared viewpoints suggest an equally strong need for more 
information about GDM and GDM diagnosis both before (10: +2) and after (11: +2) 
the OGTT.  
 
Factor 1 viewpoint feels OGTT is convenient (1: +1) and not at all a burden (23: -3). 
However, factor 2 viewpoint feels strongly that OGTT is inconvenient (1: -3) and 
potentially causes some burden (23: -1). Compared to factor 2 viewpoint, factor 1 
believes much more strongly in the importance/ necessity of conducting OGTT (21: 
+3 for factor 1 and +1 for factor 2), and agree more firmly that OGTT should be 
undertaken for all pregnant women (22: +3 for factor 1 and +2 for factor 2). 
 
Participant characteristics: When comparing the participants for factor 1 and 
factor 2, participants for factor 2 had higher proportion of non-GDM women (72.8% 
versus 53.8%). The factor 2 participants also tended to know less about GDM before 
OGTT (63.6% versus 92.3% received GDM information).  More non-GDM women 
in factor 2 participants and ignorance of OGTT before undergoing the test might 
both have contributed to the factor 2 viewpoint that OGTT was inconvenient. Both 
groups found the Q methodology study easy to complete (81.8% for factor 2 and 
92.3% for factor 1). 
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4.5 DISCUSSION 
 
4.5.1 Statement of principal findings 
 
Two distinctive viewpoints emerged as to whether or not OGTT was convenient. 
The mainstream viewpoint advanced by the pregnant women was that OGTT was 
acceptable and not a burden for them (factor 1). However, non-GDM women tended 
to feel that OGTT was not convenient at all and relatively burdensome (factor 2). 
More specifically, they felt that having blood drawn three times within 2 hours 
OGTT was too much, and that the duration of 2 hours was also too long. Although 
both groups, representing different viewpoints, felt that conducting OGTT was 
important and necessary for all pregnant women, factor 2 participants ranked this 
opinion as less important. Overall, non-GDM women tended to feel that OGTT was 
less important or necessary and reported that OGTT was very inconvenient and 
relatively burdensome. 
 
Both participant groups ranked highly the statements that they would like to be 
provided with more information about GDM and OGTT both before and after 
undertaking the OGTT. Whilst they felt no confusion about the OGTT and agreed 
that the explanations and advice about OGTT were offered. However, this was only 
a brief explanation of GDM and their test results when they gave their OGTT result 
sheet to their doctor for consultation. The pregnant women strongly wished to be 
provided more information about GDM and OGTT. Regarding the delivery of 
information, both participant groups preferred to receive information from the 
hospital bulletin board. Education leaflet were also considered to be an option. 
Factor 2 participants did not prefer to receive the information from the weekly 
courses of the “pregnant women’s school” at the hospital, due to the inflexibility of 
timing. 
122 
 
4.5.2 Strengths and limitations of the study 
 
The representativeness of the study was achieved by involving an equal number of 
GDM and non-GDM women. The process of conducting the Q methodology study 
was highly standardised, which avoided potential bias due to different practices. In 
particular, the study recruited participant who had undertaken their OGTT 2-4 weeks 
prior to the study. An instruction sheet was provided to each participant to read 
before they fulfill the FlashQ on the computer. The researcher was in the study room 
so that the participant could ask any question or help when needed. This also ensured 
that the FlashQ was accurately completed.  
 
One difficulty of the Q methodology study was the use of exhaustive sources to 
create a conclusive Q-set of statements. Although this study has developed the Q 
statements based on various sources including literature reviews, various related 
websites, five new mothers in the UK, three new mothers in China, and three 
academic staff at the Warwick Medical School of the University of Warwick, it 
could still be limited and the Q-set may not be as broad and inclusive of all opinions 
as ideal. One other weakness of the Q methodology study is that some participants 
may have found the Q sorting process slightly tiring because of the number of Q 
statements to sort. The researcher had encouraged their patience for completion 
before the sorting process started.  
 
4.5.3 Implications for practice 
 
One essential implication of the research results was the need to provide more GDM 
and OGTT information to pregnant women both before and after OGTT to meet their 
needs. Both factor 1 and 2 participants indicated a strong need for more information. 
At the time of the study, only a very brief introduction of OGTT inscribed on the 
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bottom two lines on the registration card was provided to pregnant women. They 
either ignored it or felt that the information was insufficient. In line with participant 
preferences in both groups, the hospital could develop a bulletin board showcasing 
the information of GDM and OGTT installed on the wall of the waiting area in the 
Department of Obstetrics and Gynaecology. Another option would be to develop a 
GDM leaflet to be offered to pregnant women at their first registration or any time 
before their OGTT. It might not be a priority to include a GDM/OGTT course in the 
“pregnant women’s school” at the hospital, as factor 2 participants in particular 
pointed out to the inflexibility of the course timing in terms of attendance.  
 
Although both points of view indicated that instructions conveyed by doctor/nurse 
about OGTT and explanation of GDM were satisfactory, the participants 
nevertheless wished for further explanation. Based on the findings, doctors are 
encouraged to give GDM women more information when explaining their OGTT 
result before referring them to the endocrinology department. 
 
 
4.5.4 Implications for future research 
 
The non-GDM women tended to rank very highly that the OGTT was not convenient 
at all, they also felt it was a relative burden for them to some extent. Especially, they 
felt strongly that having blood drawn three times is too much, and the duration of 2 
hours for the OGTT is too long. It is worthwhile considering and exploring ways to 
reduce the burden of OGTT. As indicated by the current systematic review of the 
PhD, selective screening might be as effective as universal screening if a risk scoring 
algorithm was developed and used based on the local population for selecting high 
risk pregnant women. The burden of non-GDM women could be significantly 
relieved if a selective screening approach was efficient. However, thus far there was 
no study assessing the selective screening approach under the IADPSG criteria, thus 
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the applicability is unknown. It is recommended that such a study be conducted to 
explore whether a selective screening approach using a risk scoring algorithm will be 
effective in the Chinese population under the new IADPSG recommendation.   
  
Regarding the Q methodology itself, this is a convenient tool for participants to 
perform. In the current study, more than 80% participants felt it was easy to 
complete the Q methodology study. Among the reasons why Q methodology was not 
convenient, repetitive comments suggested the three boxes for Disagree, Neutral, 
and Agree were too small when there was a need to drag the Q statements to the Q 
pyramid. They could not see all the Q statements in the box at a glance but had to 
scroll the scrolling bar, which was neither convenient or pleasant (Appendix 12). It 
would be easier for the participants if the three boxes could be enlarged in future 
FlashQ versions.    
 
4.6 CONCLUSION 
 
Overall, pregnant women agree in different levels that the OGTT for GDM diagnosis 
is important and needs to be conducted for all pregnant women. Non-GDM women 
tended to feel strongly that OGTT was inconvenient at all in terms of three blood 
samples being taken and the 2 hours duration time, and felt that it was a burden 
relatively speaking to undertake the OGTT. Whist being satisfied with the whole 
OGTT service and the information received, both GDM and non-GDM women 
strongly wished to be provided with more information on GDM and OGTT both 
before and after the OGTT. In practice, hospitals were encouraged to provide more 
information on GDM and OGTT to pregnant women both before and after OGTT, 
using hospital bulletin board or by delivering education leaflet. The Q methodology 
study is a smart and convenient tool to use for investigating perspectives and 
attitudes. 
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The findings of the Q methodology study filled the existing gap in knowledge and 
addressed the research objective of exploring user perspectives on the new IADPSG 
universal screening approach. This helped to address the overall thesis aim of 
evaluating and identifying the best screening approach. The Q methodology study 
results implied the need for future research to explore the possibility of reducing the 
OGTT burden for non-GDM women, possibly by investigating the effectiveness of a 
selective screening approach under the IADPSG criteria. In the next chapter, a risk 
score-based selective screening approach for GDM under the IADPSG will be 
explored further. 
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Chapter 5: The effectiveness of a risk score-based selective 
screening approach for GDM under the IADPSG criteria in 
China: a case-control study 
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5.1 BACKGROUND  
 
5.1.1 The IADPSG approach for GDM diagnosis 
 
As stated in Chapter 1, there is no consensus on the best screening and diagnosis 
approaches for GDM (Tieu et al., 2010; Waugh et al., 2010), whether it should be 
universal screening or selective screening? Or whether two-step GDM tests or a one-
step GDM test should be used? Globally, different countries are implementing 
different screening approaches for GDM. In 2010, the IADPSG recommended a 
major change in GDM diagnosis, promoting a one-step 75g OGTT for GDM 
diagnosis for all pregnant women during 24
th
 to 28
th
 week of gestation with lower 
threshold values than used previously (Panel, 2010). The new IADPSG approach 
was expected to substantially increase the GDM incidence, potentially double or 
triple the incidence (Panel, 2010). 
 
Worldwide controversy continues on whether or not to adopt the IADPSG approach 
for GDM. China adopted the IADPSG one-step universal approach in July 2011 
(Chinese Ministry of Health, 2011), which is the first country applying the IADPSG 
recommendation. Prior to this time, China implemented a two-step universal 
approach for GDM, pregnant women underwent a 50g GCT for GDM screening 
followed by either a 75g or 100g OGTT for confirmation of GDM diagnosis. 
Diagnosis was made with at least two abnormal values from four measured: fasting 
glucose ≥5.8 mmol/l, 10.6 mmol/l at 1 hour, 9.2 mmol/l at 2 hours, and 8.1 mmol/l at 
3 hours. 
 
Concerns over the costs and cost-effectiveness are among the key reasons that 
countries hesitate adopting the IADPSG approach. The increased costs are 
comprised of the increased diagnosis costs by conducting OGTT among all pregnant 
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women, and the increased healthcare costs by treating the additional women 
diagnosed as GDM. If, as concluded by all the observational studies, the IADPSG 
approach is more clinically effective, it will be necessary to spend the additional 
treatment expenditure on these GDMs. However, there is still a need to explore 
whether the diagnosis costs of conducting the OGTT could be reduced without 
comprising the clinical effectiveness, which will improve the cost-effectiveness of 
the IADPSG approach.  
 
5.1.2 Users perspectives of the IADPSG diagnosis approach 
 
Under the new IADPSG approach, the GDM incidence in China was reported to be 
from 8% to 15% (Shang & Ma, 2011; Wei & Yang, 2011; Hou et al., 2012; Lu et al., 
2012; Jiang et al., 2013). The OGTT diagnostic test has to be performed on 100 
pregnant women in order to diagnose 8 to 15 GDM women. Non-GDM women who 
would have only received a simple 50g GCT test (non-fasting, one hour, one blood 
sample required) under the two-step approach now have to undertake the more 
complicated OGTT test (fasting, two hours, three blood samples required). 
Additional burden has been created on the non-GDM pregnant women by the 
IADPSG approach.  
 
A Q methodology study of ‘Pregnant women’s attitudes, views, and experience of 
the IADPSG approach for GDM in China’ was conducted as part of the PhD 
research (Chapter 4). The result suggested that pregnant women tended to feel a 
burden to undertake the fasting and 2-hour oral Glucose Tolerance Test (OGTT) for 
GDM under the IADPSG approach, and they wish more information be given before 
the test. This result also implied a need to explore the possibility of reducing the 
OGTTs without comprising the clinical effectiveness, to reduce the burden for 
pregnant women.  
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5.1.3 The risk scoring algorithm for selecting high risk pregnant women 
for GDM diagnosis 
 
Many studies were conducted which compared selective screening versus universal 
screening approach for GDM. A systematic review of ‘The effectiveness and cost-
effectiveness of screening for GDM: universal or selective screening?’ was 
conducted as part of the PhD research. The result suggested that although universal 
screening was recommended for general settings, selective screening could 
potentially be effective when used self-developed criteria specific for local 
population for selecting high risk women. In the review, four studies used a self-
developed selection criteria based on local population for the selective screening 
approach (Caliskan et al., 2014; Naylor et al., 1997; Pintaudi et al., 2014; Van 
Leeuwen et al., 2010). All achieved satisfactory sensitivity and specificity, and 
recommended selective screening. Among them, two studies (Naylor et al., 1997; 
Van Leeuwen et al., 2010) used a risk scoring algorithm for selecting women at high 
risk, which were more specific. These findings implied the possibility that applying a 
risk scoring algorithm to select high risk women for the IADPSG approach might 
work.   
 
Whether a selective approach (either by risk factors or by a risk scoring algorithm) is 
effective or not depends on its sensitivity and specificity. Sensitivity is the 
proportion of GDM who are diagnosed out by selective approach, while specificity is 
the proportion of non-GDM who are classified as low risk women and avoid the 
GDM test. The higher the sensitivity and specificity, the better the selective approach 
performs. However, the question is, what are our acceptable value of sensitivity and 
specificity, especially the sensitivity. A sensitivity of 100% by missing no GDM 
cases is ideal; how about a sensitivity of 90% by missing 10% GDM cases and a 
sensitivity of 80% by missing 20% of GDM cases? No study capable of answering 
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this question directly has been found. Some studies investigated the prognosis of 
missed cases of GDM in selective screening, who were GDM cases with low risk 
factors. Langer et al. (2005) suggested unrecognised GDM in women of normal 
weight (BMI<25 kg/m
2
) was not associated with an increase in the incidence of 
macrosomia or shoulder dystocia. Cosson et al. (2006) found the foetal and maternal 
prognosis for women with GDM with no risk factor was similar to that of women 
without GDM. To the contrast, others studies (Moses et al., 1998; Capula et al., 
2013) found the pregnancy outcomes of women with GDM from a low-risk group 
are similar to the outcomes of other women with GDM. There is controversy about 
whether the prognosis of missed GDM cases is similar to non-GDMs or to other 
GDM women. A sensitivity of 100% is definitively valuable; however, whether a 
sensitivity of 90%, 80% or even less is acceptable really depends on each country. 
 
5.1.4 Potential GDM risk factors for establishing the risk scoring 
algorithm under the IADPSG approach in China 
 
Advanced maternal age, overweight (high BMI), family history of diabetes (among 
first-degree family member), history of GDM, history of macrosomia, and certain 
ethnic/racial group including South Asia (especially India, Pakistan or Bangladesh) 
are commonly recognised risk factors for GDM, as informed by the worldwide 
guidelines on the risk factors used for GDM selective screening criteria (Association, 
1997; Force, 2008; Walker, 2008; NICE 2015) and the risk scoring algorithm studies 
(Naylor et al., 1997; Phaloprakarn et al., 2009; Van Leeuwen et al., 2010). Other 
risk factors including gestational weight gain, polycystic ovary syndrome (PCOS), 
waist circumference, thigh circumference, leg length, mother’s birth weight, height, 
high blood pressure during first trimester, family history of hypertension, irregular 
menstruation, vulvovaginal candidiasis, triglycerides, total cholesterol, α-
Thalassaemia, hemoglobin, maternal smoking, occupation, educational attainment, 
socio-economic status, carrying Hepatitis B virus are also found to be significantly 
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associated with developing GDM by previous Chinese studies under the previous 
two-step approach for GDM diagnosis (Lao & Ho, 2001; Lao et al., 2001; Lao et al., 
2002; Lao & Ho, 2003; Yang et al., 2002; Jiao, 2003; Yang et al., 2005; Chen et al., 
2006; Qiang et al., 2006; Lao et al., 2007; Ma et al., 2007; Ren et al. 2008; Yuan, 
2008; Yang et al. 2009; Qian, 2012; Du, 2013). In addition, elevated serum ferritin 
level was found to be a GDM risk factor among the Americans (Chen et al., 2006). 
 
The GDM risk factors are expected to change under the new IADPSG diagnosis 
approach. With reduced OGTT thresholds, the new IADPSG criteria diagnoses much 
more women with mild to moderate glucose intolerance (who would not be 
diagnosed as GDM under the old diagnosis criteria) (Test, 2008).The differences 
between the GDM and non-GDM women are less distinctive using the IADPSG 
criteria. As a result, the risk factors might be different or be less than before (odds 
ratios might decrease and some risk factors might disappear). Only one study 
investigated the GDM risk factors under the new IADSPG approach in China (Hou 
et al., 2012). Their study used a retrospective cohort of 1136 pregnant women and 
explored 14 potential GDM risk factors. The GDM incidence was found be to 
10.39%; advanced maternal age, high BMI, family history of diabetes, and 
polycystic ovary syndrome (PCOS) were identified to be significantly associated 
with developing GDM (Hou et al., 2012). 
 
5.1.5 The rationale of a risk scoring algorithm study for improving the 
IADPSG approach in China 
 
The new IADPSG approach for GDM diagnosis was demonstrated to be more 
clinically effective by all the observational studies (Test, 2008; Lapolla et al., 2011; 
Benhalima et al., 2013; Shang & Ma, 2011; Wei & Yang, 2011; Lu et al., 2012; 
Jiang et al., 2013), that the additionally women diagnosed as GDM by the IADPSG 
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approach had significantly higher incidences of adverse outcomes; diagnosing and 
treating these women would improve the outcomes. However, concerns exist about 
the increased costs and the cost-effectiveness of the IADPSG approach (Association, 
2010; NIH, 2013). China adopted the IADPSG approach in 2011 (Chinese Ministry 
of Health, 2011). The intervention and relevant costs for additionally diagnosed 
GDM women are necessary provided the IADPSG approach is more clinically 
effective; then exploring the ways to reduce unnecessary diagnosis tests becomes an 
option.  
 
As implied by the conducted systematic review, the use of a risk scoring algorithm 
might significantly reduce the screening tests performed without missing much 
GDM cases (Naylor et al., 1997; Van Leeuwen et al., 2010). However, no study has 
been conducted to explore the effectiveness of a risk scoring algorithm using the 
GDM risk factors under the IADPSG approach. The conducted Q methodology 
study also suggested the need of exploring a selective screening approach to reduce 
the burden of undergoing OGTT for pregnant women. The current study was 
conducted to fill the gap and explore whether applying a risk scoring algorithm to 
select the high risk women for the IADPSG one-step approach would work. A risk 
scoring algorithm works if it can significantly reduce the OGTT tests performed 
while still diagnose the same level of GDM cases. By performing less OGTT tests, it 
might potentially not only reduce the diagnosis costs, but also reduce the burden of 
non-GDM women for undertaking unnecessary OGTT test. 
 
The specificity of the risk scoring algorithm (i.e., proportion of non-GDM women 
who exempt from the OGTT tests) were identified at a sensitivity (i.e., proportion of 
GDM correctly diagnosed) of 100%, 90%, and 80%, respectively. A sensitivity of 
100% was ideal, however, the specificity at 90% and 80% sensitivity were also 
provided for policy making. 
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5.2. AIM AND OBJECTIVES 
 
The study aimed to investigate the feasibility of using known and novel risk factors 
for GDM to establish a risk scoring algorithm to identify pregnant women at high 
risk of developing GDM for the IADPSG approach in China. 
 
The specific objectives were:  
(1) to explore the risk factors for GDM under the new IADPSG approach; 
(2) to develop and assess a risk scoring algorithm for selecting the high risk pregnant 
women for IADPSG approach for GDM in China. 
 
5.3. METHODOLOGY 
 
The study included two stages. First, a nested case-control study was conducted to 
explore risk factors significantly associated with GDM under the IADPSG approach. 
Second, a risk scoring algorithm (i.e., an equation using adjusted odds ratios of the 
GDM risk factors to predict the possibility of developing GDM) was developed and 
assessed for selecting high risk women for the IADPSG approach. 
 
5.3.1 A nested case-control study for investigating the GDM risk factors 
under the IADPSG approach 
 
5.3.1.1 Nested case-control study design 
 
A nested case-control study was conducted to investigate GDM risk factors and their 
adjusted odds ratios, in order to formulate the equation of the risk scoring algorithm. 
A nested case-control study is a type of case-control study conducted within a cohort. 
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In a nested case-control study, one begins with a defined cohort and identifies cases 
that have already occurred (retrospective nested case-control study) or as they occur 
(prospective nested case-control study). Then, for each case, a specified number of 
controls who have not developed the disease by the time of disease occurrence in the 
case is selected from the cohort (Ernster, 1994). Similar to a case-control study, the 
nested case-control study observes from effect to cause. The effect can be a 
particular condition or disease, while the causes are existing or past attributes or 
exposures thought to be relevant to the development of the condition or disease 
under study (Schlesselman & Schneiderman, 1982). The current study used a 
retrospective nested case-control study design to investigate the GDM risk factors 
within an existing cohort. 
 
5.3.1.2 Data source 
 
The study used the records of a cohort of pregnant women who delivered in year 
2013 at the Chengdu First People’s Hospital. The IADPSG one-step universal 
approach for GDM was implemented by the hospital since the beginning of 2012. 
The hospital has approximately 3000 birth deliveries per year. Since the GDM 
incidence was estimated at 8%-15% in China under the new IADPSG approach 
(Shang & Ma, 2011; Wei & Yang, 2011; Hou et al., 2012; Lu et al., 2012; Jiang et 
al., 2013), it was estimated that about 300 GDM cases would be identified in year 
2013.  
 
5.3.1.3 Potential GDM risk factors to be investigated 
 
Due to the possible dilution or change in GDM risk factors under the IADPSG 
approach as described in the Introduction section, all risk factors that are potentially 
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associated with GDM as informed by the previous guidelines and studies were 
investigated. However, the risk factor of ethnics was not included since the pregnant 
women would be presumably all Chinese; the thigh circumference and leg length 
was not investigated as they were not measured at the hospital. A full list of potential 
GDM risk factors planned for investigation for formulating the risk scores algorithm 
is shown in Appendix 13. The researcher consulted the Chengdu First People’s 
Hospital and confirmed that data on these variables in Appendix 1 were recorded. 
The list was further confirmed after the researcher arrived at the hospital and began 
the process of checking pregnant women’s records.  
 
5.3.1.4 Sample size calculation and selection of control group 
 
The number of participants selected to study specific disease-exposure relationships 
is a fundamental consideration in planning a case-control study (Schlesselman & 
Schneiderman, 1982). Sample size calculation is based on the anticipated effect size 
(anticipated differences in risk factors between GDM group and non-GDM group), 
80% power and 0.05 significance level (Campbell et al., 1995). Ideally, each risk 
factor could give an estimate of sample size; the largest sample size should be 
chosen. In this study, the cohort of about 3000 pregnant women in 2013 was 
estimated to give about 300 cases. The estimated 300 cases was considered 
appropriate in sample size, compared to other identified case-control studies on 
GDM risk factors in China (Lao & Ho, 2003; Chen et al., 2006; Yuan, 2008; Qian, 
2012; Hou et al., 201; Du, 2013), which used from 21 to 90 cases; and compared to 
the case-control studies within the two risk scoring systems studies (Naylor et al., 
1997; Van Leeuwen et al., 2010), which used 156 and 24 cases, respectively. The 
other risk scoring algorithm study (Phaloprakarn et al., 2009) investigated the risk 
factors for a positive 50g GCT screening test, not for a positive OGTT diagnosis test 
(positive GDM), thus was not considered.  
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In a nested case-control study, time matching is an essential feature of this design, 
that one or more controls are matched to cases on date of entry into the cohort, or 
length of time in the cohort, or a combination of these measures (Wacholder, 1991). 
The aim of time matching is to avoid the situation that a cohort member who serves 
as a control at one point in time may later become a case; and that a cohort member 
may be selected as a control for more than one case (Ernster, 1994). In the current 
study, since the one-step OGTT took place at the 24th week of gestation at the 
hospital for diagnosing GDM, all GDM cases and non-GDM controls were 
automatically matched on the length of time in the cohort. Matching on potential 
confounding variables is an important consideration of a case-control study design. 
The primary objective of matching is to eliminate biased comparisons between cases 
and controls (Schlesselman & Schneiderman, 1982). One advantage of nested case-
control study is that cases and controls are automatically matched on factors 
common to all cohort members (Bailey et al., 2005), which are year of admission 
and hospital of admission in this study. Age, sex, race, weight, occupation, parity, 
personal or family history of disease are usually served as matching factors. 
However, in the current study, participants were Chinese females, and the other 
commonly used matching factors were all potential risk factors for developing GDM 
under investigation, thus matching on these variables was not considered suitable in 
the study. Thereby a random selection of non-GDM women with an equal number to 
the cases (about 300) from the 2013 cohort will be selected as the control group, 
using randomisation feature in MS Excel. 
 
5.3.1.5 Data collection 
 
The cohort of pregnant women who delivered in 2013 at the hospital was identified 
from the Electronic Medical Record System (EMRS) at the hospital. This was done 
by filtering the patients with a hospitalisation date to the Department of Obstetrics 
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between 1 January 2013 and 31 December 2013 from the EMRS. Their patient IDs 
were retrieved into a MS Excel sheet. The following records were removed at a later 
stage: (1) repetitive records of patients who had more than one hospitalisation to the 
department during the period; (2) patients who were hospitalised but did not deliver 
at the department (left the hospital before delivery). 
 
GDM cases in 2013 were identified by filtering the International Classification of 
Diseases (ICD) code of GDM (O24.401) in 2013 in the EMRS. Non-GDM controls 
were randomly selected in two steps. First, a sub-cohort of pregnant women, with a 
number that was slightly more than the GDM cases, was randomly selected using the 
randomisation feature in MS Excel. Second, GDM cases were excluded from the 
sub-cohort, the remaining ones were served as controls. 
 
The paper version of the patient medical records had all available information of the 
GDM risk factors. Some of the risk factors were also available in electronic version 
from the EMRS at the hospital. Data collection was conducted by the researcher in 
two steps. First, data of risk factors in electronic records were collected. This was 
done by assessing to the EMRS through an internal computer at the hospital, and 
browsing the electronic record of each patient. Second, data of the risk factors which 
were only available in paper records were collected. The patient IDs were used to 
locate the paper version of their medical records at the Medical Records Room of the 
hospital. The research was based at the Records Room, took down and browsed the 
paper record of each patient. Any missing, insufficient, or incorrect data identified 
from the electronic records were also checked and supplemented by the original 
paper records.  
 
The list of investigated GDM risk factors and their availability from electronic and 
paper records is shown in Appendix 13. The whole process was supervised and 
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facilitated by senior hospital staff in the Department of Gynaecology and Obstetrics, 
and staff in the Medical Records Room.  
 
5.3.1.6 Data analysis 
 
All the data collected on the MS Excel datasheet were imported into a SPSS 
datasheet for analysis. IBM SPSS Statistics 21 software was used. The risk factors 
were independent variables, the GDM diagnosis results was dependant variable. First, 
univariable analysis was used to identify the risk factors associated with GDM. For 
each of the GDM and non-GDM group, continuous variables (e.g., age, height, BMI, 
gestational weight gain, waist circumference) were summaried in terms of means and 
standard errors (SE); their significances (odds ratio with 95% confidence interval 
and p-value) were tested using t-test. Categorical variables (e.g., family history of 
diabetes, history of macrosomia, polycystic ovary syndrome, irregular menstruation) 
were summarised in terms of numbers and proportions; their significances (odds 
ratio with 96% confidence interval and p-value) were tested using Chi-squared test.  
 
The risk factors which are found to be significantly associate with GDM (P<0.05) 
from the univariable analysis were further analysed by the multivariable analysis 
(multiple logistic regression analysis) to adjust for interaction and confounding 
between these risk factors, to identify their independent effect on predicting GDM 
(i.e., adjusted odds ratio). The multiple logistic regression analysis is used for studies 
where the dependant variable is categorical variable, thus is appropriate for the study 
where the GDM diagnosis result (dependant variable) is binary variable (categorical 
variable). The independent variables (i.e., the risk factors in this study) for multiple 
logistic regression analysis can be either categorical or continuous variable. 
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To determine whether continuous variables (i.e., age, height BMI, gestational weight 
gain, waist circumference) had a linear or categorical (e.g., age≥ 25 years, BMI≥30 
kg/m
2
) relationship with GDM, the assumption of linearity was evaluated using 
piecewise polynomials (splines) and visual inspection (Harreet al., 1988). If the 
relationship was linear, these continuous variables were used directly in the logistical 
regression analysis. If the relationship was not linear, then thresholds of the variable 
were identified to approach linearity, transforming the continuous variable into 
categorical variable (Harreet al., 1988). Finally, all the risk factors data were 
analysed by the multiple logistic regression to give the adjusted odds ratios (equals 
to exp(bj) in the logistic model) with 95% confidence intervals and p-values.  
 
5.3.2 Formulation and assessment of the risk scoring algorithm 
 
5.3.2.1 Formulation of the risk scoring algorithm 
 
From the nested case-control study, a list of risk factors which were significantly 
associated with GDM was identified. The multiple logistic regression result provided 
their individual effect (adjusted odds ratios) for predicting GDM. The risk scoring 
algorithm was formulated using the adjusted odds ratios of these risk factors. For 
example, if six risk factors were found to be significantly associated with GDM from 
the multiple logistic regression analysis, including age, BMI, gestational weight gain, 
family history of diabetes, history of macrosomia, and polycystic ovary syndrome 
(PCOS). The risk score, which is the possibility of developing GDM, equals to 
exp(A)/[1 + exp(A)]. A=Constant + Log(OR1)×age +Log(OR2)×BMI + 
Log(OR3)×gestational weight gain + Log(OR4)×family history of diabetes + 
Log(OR5)×history of macrosomia + Log(OR6) ×PCOS. 
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5.3.2.2 A ROC curve analysis to assess the risk scoring algorithm 
 
The established risk scoring algorithm gave every pregnant woman a risk score. The 
higher the risk score was, the bigger chance to develop GDM during pregnancy. To 
identify an appropriate cut-off score to select high risk pregnant women for IADPSG 
was essential, which should maximise the sensitivity and specificity of the risk 
scoring algorithm. The gold standard is usually defined as the “test or criterion” that 
determines the true presence or absence of the condition (here GDM) in the index-
tested population. In this study, the gold standard was a 75g OGTT on all pregnant 
women (universal approach) in which the high risk population was screened 
according to a screening criterion. The test being evaluated is usually called the 
index test. In this study, the index test was screening women to dichotomise into 
high or low risk of GDM according to the risk scoring algorithm. So a positive index 
test result was returned if a woman was at high risk, and a negative index test was 
when the risk scoring algorithm said she was at low risk. 
 
In a standard definition, sensitivity is the proportion of people who have the disease 
that the test correctly detects. Specificity is the proportion of people who do not have 
the disease that the test correctly identifies as not having the disease (Bailey et al., 
2005). In this study, sensitivity was the proportion of GDM who were correctly 
screened as high risk women by the risk scoring algorithm. Specificity was the 
proportion non-GDM women who were correctly classified as low risk women and 
avoided the OGTT under the IADPSG approach.  
 
Different cut-off scores would offer different sensitivity and specificity. A Receiver 
Operating Characteristic (ROC) curve was used to identify a cut-off score which 
maximised the sensitivity and specificity of the risk scoring algorithm (i.e., a cut-off 
score which missed minimal GDM women while exempted a significant proportion 
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of low risk women from OGTT). A ROC curve is a graphical plot which assesses the 
overall value of a test if a test is based on an observed variable that lies on a 
continuous or graded scale (Hanley & McNeil, 1983). The ROC curve is widely used 
in medical research for assessing the value of a clinical test against the gold standard 
test, in terms of sensitivity and specificity. In this study, the ROC curve was used to 
assess the index test of a risk scoring algorithm with the IADPSG approach against 
the IADPSG universal approach.  
 
IBM SPSS Statistics 21 software was used to draw the ROC curve. Normally, the 
new test is considered fair if the area under the curve (AUC) is more than 0.7; and 
the best cut-off score is the most upper-left point. In this study, more weight was 
given to sensitivity in order to miss as less GDM women as possible. A sensitivity of 
100% by missing no GDM was ideal. However, the cut-off score and the 
corresponding specificity at a sensitivity of 90% and 80% were also acceptable. A 
specificity higher than 30% was considered effective, which meant the risk scoring 
algorithm could exempt more than 30% of the non-GDM women from the OGTT 
test. All the figures at 100%, 90% and 80% sensitivity will be calculated and 
presented for the study. 
 
5.3.3 Ethical considerations 
 
Pregnant women’s records were used to investigate GDM risk factors in this study. 
However, only their patient IDs were retrieved from the electronic records for 
identification. Their names, contact information, or any other identifying data were 
not collected. All women were anonymised and were not identifiable. 
 
All data analysed were collected in a confidential way and anonymity were 
preserved. Individual women whose records were used in this study were not asked 
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to provide consent, since there was no requirement for any contact between the 
women and the researcher; only anonymised data were collected from routinely 
maintained hospital records. 
 
Ethical consent to conduct this study was sought initially in China, where the 
Hospital Ethics Approval Committee of the Chengdu First People’s Hospital 
scrutinised and approved the research proposal. A further University of Warwick 
Biomedical and Scientific Research Ethics Committee (BSREC) approval to conduct 
this research as part of a Health Sciences PhD programme was sought and granted. 
The BSREC reference is REGO-2014-705. Please see the full approval letters in 
Appendix 14. 
 
5.4 RESULTS 
 
5.4.1 Data collection results 
 
5.4.1.1 Records of participants 
 
Ethical approvals from the Chengdu First People’s Hospital and the University of 
Warwick were received in May 2014. Data were collected by the researcher from 1 
June to 31 December 2014 at the Chengdu Hospital. A cohort of 2897 pregnant 
women who delivered at the Department of Obstetrics at the hospital in 2013 was 
identified from the EMRS at the hospital; their patient IDs were extracted and 
recorded. 
 
Among the cohort of 2897 women, there were 272 GDM cases. The GDM incidence 
was 9.4%. A sub-cohort of 310 women was randomly selected using the 
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randomisation feature in MS Excel. After excluding the GDM women in the sub-
cohort, 278 non-GDM women formed the control group. 
 
5.4.1.2 Records of potential GDM risk factors availability of records 
 
Electronic and paper records of these 550 women were retrieved according to the list 
of 26 potential GDM risk factors under investigation. Details of historical risk 
factors were supplied by the pregnant women and recorded by the clinicians at the 
Department. All the current risk factors were tested or measured either by the 
Chengdu Hospital or occasionally by another hospital if the women were transferred 
to the Chengdu Hospital from another hospital during her pregnancy.  
 
The availability of the records is shown in Appendix 13. Gestational weight gain 
before 24
th
 gestational week, PCOS, waist circumference at first antenatal visit, and 
blood pressure during first trimester were only available through paper records. For 
risk factors which were available through electronic records, some had missing data 
and were supplemented by paper records. These involved family history of diabetes, 
history of macrosomia, family history of hypertension, vulvovaginal candidiasis, 
hemoglobin during first trimester, serum ferritin level during the first trimester, and 
HBV. Personal history of GDM, mother’s birth weight, triglycerides, total 
cholesterol, α-thalassaemia, education level, and family income were not available 
from the records. Maternal smoking was recorded as ‘No’ for all the 550 women. 
After the first round of data collection, missing data and outliers were checked and 
were supplemented or corrected by browsing the relevant records for a second time.   
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5.4.2 GDM incidence and basic characteristics of participants 
 
272 GDM cases were identified from the cohort of 2897 pregnant women of in 2013. 
GDM incidence was 9.4%. The basic characteristics of participants are shown in 
Table 15. The mean age of GDM women and non-GDM women was 30 and 28 years 
old, respectively. The average height of GDM women and non-GDM women was 
158.5 cm and 159.8 cm. The GDM group had higher BMI (22.5 versus 21.2) and 
larger waist circumference (85.1cm versus 82.6cm) on average as compared to non-
GDM women. The unemployment rate was equally low in the two groups, which 
was 3.4% for GDM women and 3.3% for non-GDM women. About 34.7% of the 
GDM women and 20.5% of non-GDM women had previous deliveries. Also, 8.1% 
of the GDM women and 9.4% of the non-GDM women had a previous adverse 
history of pregnancy. Within the GDM group, 11.4% women had a family history of 
diabetes and 21.7% women had a family history of hypertension, whereas within the 
non-GDM group, it was 4.0% and 23.4% respectively.  
Table 15. Basic Characteristics of participants 
  GDM (n=272) Non-GDM (n=278) 
Age 29.8 ± 5.1 27.6 ±3.9 
Height (cm) 158.5 ± 5.2 159.8 ± 4.4 
BMI (kg/m2) 22.5 ± 3.4 21.2 ± 3.0 
Waist circumference (cm) 85.1 ± 8.6 82.6 ± 7.9 
Occupation (unemployed) 3.4% 3.3% 
Previous deliveries 34.7% 20.5% 
Adverse pregnancy history 8.1% 9.4% 
Family history of diabetes 11.4% 4.0% 
Family history of hypertension 21.7% 23.4% 
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5.4.3 Formulation of the risk scoring algorithm 
 
5.4.3.1 GDM risk factors identified from univariable logistic regression 
 
Univariable logistic regression was performed to test the association between each 
risk factor and GDM, using the binary logistic regression feature in IBM SPSS 
Statistics 21. Table 16 shows the result of the univariable logistic regression. Factors 
with a P-value of less than 0.05 were potential risk factors associated with GDM, and 
have been indicated in bold letters in Table 16. Age, height, BMI, previous deliveries, 
family history of diabetes, systolic and diastolic blood pressure during first trimester, 
and waist circumference were identified as potential GDM risk factors.  
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Table 16. Univariable logistic regression result for identifying potential GDM 
risk factors 
  
GDM 
(n=272) 
Non-GDM 
(n=278) 
P-
value Odds Ratio 
Age 29.8 ± 5.1 27.6 ±3.9 0.000 1.116 
Height (cm) 158.5 ± 5.2 159.8 ± 4.4 0.002 0.945 
BMI (kg/m2) 22.5 ± 3.4 21.2 ± 3.0 0.000 1.120 
Waist circumference (cm) 85.1 ± 8.6 82.6 ± 7.9 0.000 1.040 
Gestational weight gain at 24th week (kg) 6.5 ± 4.5 6.3 ± 5.2 0.510 1.012 
Occupation (unemployed) 3.4% 3.3% 0.942 1.035 
Previous deliveries 34.7% 20.5% 0.000 2.243 
Adverse pregnancy history 8.1% 9.4% 0.600 0.853 
History of macrosomia 4.2% 3.7% 0.736 1.162 
Irregular menstruation 3.7% 5.8% 0.156 0.573 
Vulvovaginal candidiasis (VC) 10.4% 9.3% 0.684 1.130 
Hepatitis B virus carrier (HBV) 8.9% 6.2% 0.233 1.480 
Family history of diabetes 11.4% 4.0% 0.002 3.122 
Family history of hypertension 21.7% 23.4% 0.635 0.908 
Polycystic ovary syndrome (PCOS) 0.7% 0.0% 0.999 1657357548 
Hemoglobin (>130g/L) 21.7% 20.8% 0.806 1.071 
Serum ferritin level (≥upper quartile of 
123.5ng/ml) 26.2% 24.1% 0.916 1.038 
Systolic blood pressure (≥120mmHg) 29.7% 19.4% 0.017 1.900 
Diastolic blood pressure (≥80mmHg) 33.8% 14.9% 0.002 3.429 
 
 
5.4.3.2 The risk scoring algorithm established from the multiple logistic 
regression 
 
Before performing multiple logistic regression, the correlations between each of the 
potential risk factors were tested using SPSS. Co-linearity between two continuous 
variables was tested by scatter plot. Correlation between a categorical and a 
continuous variable was tested by means of a chi-square test. Correlation between 
two categorical variables was not applicable in this study; if applicable, it would be 
tested by box plot. The overview of the correlation result is illustrated in Table 17. 
The detailed correlation results are shown in Figure 14, 15, 16.  
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Table 17. Overview of co-linearity between each of the potential risk factors 
Risk factor Co-linearity/correlation 
1. Age and height Not applicable 
2. Age and BMI No 
3. Age and waist circumference  No 
4. Age and previous deliveries No 
5. Age and family history of diabetes Not applicable 
6. Age and systolic blood pressure No 
7. Age and diastolic blood pressure No 
8. Height and BMI No 
9. Height and waist circumference No 
10. Height and previous deliveries Not applicable 
11. Height and family history of diabetes No 
12. Height and systolic blood pressure No 
13. Height and diastolic blood pressure No 
14. BMI and waist circumference Yes  
15. BMI and previous deliveries No 
16. BMI and family history of diabetes No 
17. BMI and systolic blood pressure No 
18. BMI and diastolic blood pressure No 
19. Waist circumference and previous deliveries No 
20. Waist circumference and family history of diabetes No 
21. Waist circumference and systolic blood pressure No 
22. Waist circumference and diastolic blood pressure No 
23. Previous deliveries and family history of diabetes No 
24. Previous deliveries and systolic blood pressure Not applicable 
25. Previous deliveries and diastolic blood pressure Not applicable 
26. Family history of diabetes and systolic blood pressure Not applicable 
27. Family history of diabetes and diastolic blood pressure Not applicable 
28. Systolic blood pressure and diastolic blood pressure Yes 
 
 
     
       2. Age and BMI                               3. Age and waist circumference           4. Age and previous deliveries 
      
6. Age and systolic blood pressure          7. Age and diastolic blood pressure     8. Height and BMI 
Figure 14. Scatter plot result for the co-linearity/correlation                               
between two continuous variables 
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9.Height and waist circumference     11.Height and family history of diabetes        
      
13. Height and diastolic blood pressure    14. BMI and waist circumference       15. BMI and previous deliveries 
 
      
16. BMI and family history of diabetes   17. BMI and systolic blood pressure   
 
       
 
 
 
    
 
 
Figure 14 (continued). Scatter plot result for the co-linearity/correlation 
between two continuous variables 
19. Waist circumference and 
previous deliveries 
20. Waist circumference and 
family history of diabetes 
21. Waist circumference and 
systolic blood pressure 
22. Waist circumference and 
diastolic blood pressure   
23. Previous deliveries and 
family history of diabetes 
12. Height and systolic blood pressure 
18. BMI and diastolic blood pressure 
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Correlations 
 MBMI WC (pre-
pregnancy or 
during first 
trimester) 
MBMI 
Pearson Correlation 1 .625** 
Sig. (2-tailed)  .000 
N 550 530 
WC (pre-pregnancy or during 
first trimester) 
Pearson Correlation .625** 1 
Sig. (2-tailed) .000  
N 530 530 
**. Correlation is significant at the 0.01 level (2-tailed). 
Figure 15. Correlation between BMI and waist circumference as identified from 
the scatter plot 
 
 
SBP(if>120) * DBP (if>80) Crosstabulation 
Count   
 DBP (if>80) Total 
0 1 
SBP(if>120) 
0 448 15 463 
1 46 22 68 
Total 494 37 531 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 77.524a 1 .000   
Continuity Correctionb 73.098 1 .000   
Likelihood Ratio 50.473 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 77.378 1 .000   
N of Valid Cases 531     
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.74. 
b. Computed only for a 2x2 table 
Figure 16. Chi-square test result for the correlation between two categorical 
variables (between systolic blood pressure and diastolic blood pressure) 
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As illustrated in Table 17 as an overview, BMI and waist circumference were 
correlated, as well as systolic and diastolic blood pressure. For correlation between 
BMI and waist circumference (Figure 15), the p-value for the Pearson correlation 
test was less than 0.01, which suggested that they were significantly associated with 
each other. The correlation between systolic and diastolic blood pressure was shown 
in Figure 16. Again, the p-value for the Pearson correlation test was less than 0.01, 
indicating that systolic and diastolic blood pressure was correlated with each other.   
 
Although the correlation analysis showed two of the eight GDM risk factors were 
not independent risk factors for GDM, to maximise the accuracy of the predication, 
all the eight risk factors needed to be added to the multiple logistic regression model 
to establish the risk scoring algorithm. To predict the possibility of developing GDM, 
it is not necessary to know the individual independent effect of each risk factor, but 
to have the overall effect of these risk factors for prediction. 
 
Several performances were also made to compare the ROC curves using all eight 
risk factors and all non-correlated factors (six risk factors). The ROC curve using all 
eight risk factors achieved much better sensitivity, specificity, and area under the 
curve. This also supported the rationale of entering all risk factors into the multiple 
logistic regression model for prediction. 
 
Table 18. Multiple logistic regression result for formulating the risk scoring 
algorithm 
  B P-value Odds ratio 
Age 0.069 0.007 1.072 
Height -0.058 0.006 0.944 
BMI 0.06 0.11 1.061 
Waist circumference (WC)  0.009 0.557 1.009 
Previous deliveries (PD)  0.38 0.117 1.462 
Family history of diabetes (FHD)  1.163 0.003 3.198 
Systolic blood pressure (SBP) (≥120mmHg)  0.308 0.326 1.361 
Diastolic blood pressure (DBP) (≥80mmHg)  0.952 0.031 2.592 
Constant 4.87 0.152 130.376 
151 
 
The risk score, which is the probability of developing GDM is formulated as： Risk 
score =probability =exp (A)/ [1 + exp (A)]; while A =4.87 + 0.069*Age - 
0.058*Height + 0.06*BMI + 0.009*WC + 0.38*PD + 1.163*FHD + 0.308*SBP + 
0.958*DBP (see Table 18 for abbreviations). Although BMI, waist circumference, 
previous deliveries, and systolic blood pressure became insignificant in the multiple 
logistic regression, they were still predicators for developing GDM. To make the risk 
scoring algorithm simpler, the last decimal in the formula was rounded up and it was 
tested that there was no difference. The final risk score was calculated as: Risk score 
=probability =exp (A)/ [1 + exp (A)]; while A =4.87 + 0.07*Age - 0.06*Height + 
0.06*BMI + 0.009*WC + 0.38*PD + 1.16*FHD + 0.31*SBP + 0.96*DBP (see 
Table 18 for abbreviations). 
 
Linearity analysis of the continuous variables (age, height, BMI, waist circumference) 
was conducted using visual inspection (Harreet al., 1988). The relationships between 
these continuous variables and GDM were linear, which suggested that these 
continuous variables could be used directly in logistical regression analysis. For the 
same reason, the continuous variables (age, height, BMI, waist circumference) were 
not transformed into categorical variables using cut-off thresholds, which could 
significantly reduce the accuracy and effectiveness of the risk scoring algorithm.     
 
5.4.4 Assessment of the risk scoring algorithm 
 
Using the established risk scoring algorithm, each woman’s risk score (0~1) was 
calculated based on her risk profile. A ROC curve as drawn using SPSS (Figure 17). 
The vertical axis is sensitivity, which is the proportion of GDM women who are 
correctly being categorised as high-risk by the risk scoring algorithm and are 
diagnosed. The lateral axis is 1-specificity, that specificity is the proportion of non-
GDM women who are correctly categorised as low-risk by the risk scoring algorithm 
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and avoid OGTT. The curve is the risk score, by which different cut-off scores give 
different combinations of sensitivity and specificity. 
 
 
 
 
 
 
Figure 17. ROC curve with cut-off scores for assessing the risk scoring 
algorithm 
 
The Area under curve (AUC) is 0.7, which is fair for an index test (the risk scoring 
algorithm). A full list of cut-off scores and corresponding sensitivities and 
specificities of the ROC curve was illustrated in Appendix 15. Table 19 shows the 
two cut-off scores identified at 80% and 90% sensitivity of the risk scoring algorithm. 
A cut-off score of 0.37 (the red point in Figure 17) was identified at a sensitivity of 
80%, and the corresponding specificity is 45%. This means using a cut-off score of 
0.37 for selecting high risk women can exempt nearly half (45%) of non-GDM 
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women from the OGTT, and still diagnose 80% of GDM. A cut-off score of 0.32 
(the green point in Figure 17) was identified at a sensitivity of 90%, with the 
corresponding specificity being 24%. This indicates that using a cut-off score of 0.32 
could miss less GDM women (only 10%), but could only exempt 24% of the non-
GDM women from test. A more detailed 2x2 table showing the figures behind the 
two cut-off scores was illustrated in Appendix 16.  
Table 19. Cut-off scores for 80% and 90% sensitivity of the risk scoring 
algorithm 
Risk score  Specificity Sensitivity  
0.37  45%  80%  
0.32  24%  90%  
 
There are no definitive cut-off points or standards for determining what level of 
sensitivity and specificity that can indicate effective and suitable screening, 
especially in view of the trade-off between sensitivity and specificity. However, a 
number of factors can be considered to determine the levels of sensitivity or 
specificity that are acceptable. First of all, the context in which screening has to take 
place plays an important role in decision making. For GDM screening, as in this 
study, we are more interested in sensitivity with the aim of missing as few GDM 
women as possible than specificity due to the potential for adverse events in GDM 
women and newborns. Second, the suitability of a screening test also takes into 
consideration the simplicity and costs. The risk scoring algorithm as an index test in 
this context is quick, cheap and easy, enabling doctors to calculate the risk scores of 
pregnant women based on their existing medical records. On the other hand, OGTT 
as the actual test, is relatively complicated in terms of the fasting state required and 
the need for two hourly tests as well as three blood samples. Thus, a high specificity 
to avoid unnecessary OGTT would be important and favorable. Third, whether or not 
a type of screening should be adopted also depends on the size and the condition of 
the population. Pregnant women make up a large group of the population, and they 
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are in a vulnerable condition. Therefore, high specificity to exempt mass non-GDM 
women from the screening would be advantageous. Based on the reasons outlined 
above, a sensitivity of 80% was deemed to be acceptable with a specificity of 45%. 
A selective IADPSG approach using a risk scoring algorithm based on local 
population profile was potentially effective in China. 
 
 
5.5 DISCUSSION 
 
5.5.1 Statement of principal findings 
 
The incidence of GDM in China was 9.4% under the new IADPSG screening criteria. 
A selective screening approach to screening for GDM was developed using a risk 
score. The strategy hinged on a clinical scoring algorithm that grouped pregnant 
women according to their risk of developing GDM. Its efficiency was achieved by 
not screening pregnant women in the low risk group, thus significantly reducing the 
number of unnecessary OGTT. The risk scoring algorithm was able to spare nearly 
half (45%) of the non-GDM women the need to undergo a screening blood test 
(OGTT), which composed 41% of the whole pregnant population. Use of the risk 
score-based selective screening approach could save numerous monetary costs and 
distress for individual pregnant women in China. However, on the other hand, 20% 
of GDM women (that is 2% of the whole pregnant population), would be missed if a 
selective screening approach is used, who might develop adverse clinical outcomes. 
 
 
5.5.2 Strengths and limitations of the study 
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The nested case-control study design has several strengths. It allows the study of 
multiple potential causes of a disease (e.g., multiple risk factors for developing 
GDM); it is useful for the study of rare cases (e.g., GDM with an incidence of 9.4% 
in China under the IADPSG approach). The retrospective nested case-control study 
uses existing data and avoids effort devoted to the follow-up of individuals. It is free 
from selection bias (unable to refuse for participation) or differential recall bias (all 
data were examined and recorded rather than self-reported). Compared to case-
control study, the advantage of nested case-control study is that the cases and 
controls are from the same cohort, thereby automatically matched on factors 
common to all cohort members and reduces bias (Bailey et al., 2005). 
 
The study was advantageous in exploring a full range of potential GDM risk factors 
(more than 20 risk factors) which were more extensive than the previously conducted 
two risk score studies (Naylor et al., 1997; Van Leeuwen et al., 2010). Naylor et al. 
(1997) explored six risk factors involving age, race, BMI, parity, family history of 
diabetes, adverse obstetrical history. Van Leeuwen et al. (2010) explored eight risk 
factors which were age, BMI, ethnicity, family history of diabetes, smoking, 
previous miscarriage, history of GDM, history of perinatal death. 
 
The disadvantage might be that the case-control study design relies on existing 
patient records, which sometimes can be insufficient, inaccurate, or impossible for 
validation. In the present study, all participants answered ‘No’ for smoking during 
pregnancy, and one might question the reliability o this. Another limitation is that 
there were no data on the GDM history of patients which was thought to be a 
significant risk factor for developing GDM. The lack of data was due to China’s one-
child policy from 1979 to 2013, whereby couples in China could only have one child. 
Ethnic minorities are exceptions, and also in some rural areas, families were allowed 
to have two children if the first was a girl. Since 2013, the policy changed, in that 
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couples where at least one was a single child could have two children. Since 2015, 
China has completely ended the one-child policy and couples are now allowed to 
have two children. In this study, the collected data showed that 20.5% non-GDM 
women and 34.7% GDM women had previous deliveries. A certain proportion of 
these women could have a history of GDM which were not recorded. The risk 
scoring algorithm could be more accurate and effective if the GDM history data of 
these women were recorded.  
 
In addition, the setting of the retrospective case-control study was potentially 
different when applying the risk score for selective screening in a prospective setting. 
Furthermore, the risk score algorithm was established and assessed using the 
retrospective cohort of 2897 pregnant women who delivered at the hospital in 2013 
(derivation cohort). The effectiveness of the risk scoring algorithm might need 
further validation especially using a prospective cohort (validation cohort) from 
another district in China. 
 
5.5.3 Implication for practice and further research 
 
By way of implications for practice, a selective screening approach using a risk score 
might be considered an alternative option to the IADPSG universal screening under 
implementation in China. The decision to choose the selective approach is subject to 
consideration of the tradeoff between saved costs (monetary costs, time cost, distress 
for individuals) for nearly half of the non-GDM women (about 41% of pregnant 
women) and the potentially adverse outcomes of overlooking 20% GDM women 
(about 2% of pregnant women). Although not all missing GDM women will develop 
adverse clinical events, if this happens, the outcome will be unequivocally adverse 
for any woman who does develop GDM. 
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Clinicians will not find it difficult to use the scoring algorithm. All eight risk factors 
can be found easily on the patient records. If applied in real practice, a simple 
computer or web-based calculation tool similar to QRISK2 tool for cardiovascular 
risk calculation (https://www.qrisk.org/2016/) might need to be developed to 
enhance the ease of application.   
 
In terms of the research implications, a further validation cohort is needed to validate 
the effectiveness of this risk scoring algorithm. More specifically, a prospective 
cohort from other areas of China would be preferable. It is recommended that the 
effectiveness of such a risk scoring algorithm should be assessed by other countries 
who currently using a selective screening approach based on standard risk factor 
guidelines as well as countries, which while implementing universal screening are 
considering the possibility of a selective screening approach. For countries that have 
already adopted the IADPSG universal screening approach, an effective risk scoring 
algorithm for selective screening might potentially save considerable costs and 
distress for pregnant women. 
 
 
5.6 CONCLUSION 
 
A risk scoring algorithm for selective screening based on the local Chinese 
population was established and assessed. It was able to exempt 45% of non-GDM 
pregnant women from undergoing OGTT, but it overlooked 20% of the GDM 
women. Whether or not to implement a universal or selective screening approach 
depends on consideration of the tradeoff between burdening exemptible non-GDM 
women (41% of whole pregnant population) and the possible adverse clinical events 
of the overlooked GDM women (2% of whole pregnant population). A validation 
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study using another cohort will be needed to further affirm the effectiveness of the 
risk scoring algorithm.  
 
The findings of the study addressed the research objective of establishing and 
evaluating the effectiveness of a risk score-based selective screening approach under 
the IADPSG criteria. The results suggested that it could be considered as an 
alternative screening approach with the added benefit of significant monetary 
savings and burden exemptions. This was due to the fact that it would spare nearly 
half of the pregnant women from undergoing unnecessary OGTT, but the cost of 
overlooking 20% GDM women (2% pregnant women) would still exist. The findings 
supported the overall thesis aim with reference to exploring the optimal screening 
approach for GDM. 
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Chapter 6: Overall Discussion 
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6.1 AN OVERVIEW OF MAIN FINDINGS 
 
GDM prevalence has increased with the increasing global epidemic of obesity and 
type 2 diabetes, as well as other factors, including increased maternal age. The GDM 
prevalence varies significantly among countries because of different population 
characteristics and risks, screening approaches, screening tests, and adopted criteria.  
 
The evaluation and development of an effective and cost-effective screening 
approach for GDM is invaluable for pregnant women, their offspring, and the whole 
society. This research evaluated the current evidence on universal versus selective 
screening, investigated pregnant women’s perspective for GDM screening, and 
explored the effectiveness of a selective screening approach for GDM based on risk 
scores in Chinese population under the new IADPSG criteria. Several important 
inconsistencies in evidence and research gaps have been answered and fulfilled, 
thereby providing several implications of the current practice in GDM screening. 
However, certain challenges are still encountered. Future studies are recommended 
on risk score-based selective screening and qualitative perspective research under 
other local screening settings other than China to facilitate more sophisticated and 
well-informed decision making in a particular country. 
 
6.1.1 Universal versus selective screening for GDM 
 
The systematic review included 33 studies, involving 28 effectiveness studies, four 
cost studies and one cost-effectiveness study. A trade-off was observed between 
sensitivity and specificity for the effectiveness of selective screening. Only seven of 
the 28 effectiveness studies recommended selective screening for pregnant women 
(Caliskan et al., 2014; Helton et al., 1997; Jensen et al., 2013; Naylor et al., 1997; 
Sacks et al., 1987; Van Leeuwen et al., 2010; Pintaudi et al., 2014). Compared with 
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studies which recommended universal screening, these seven studies had been 
conducted in areas of relatively low GDM prevalence. The seven studies included all 
the four studies that had developed their own selection criteria for identifying high 
risk women based on local population risk profiles rather than on standard guidelines 
(Caliskan et al., 2014; Naylor et al., 1997; Van Leeuwen et al., 2010; Pintaudi et al., 
2014). Two of the four studies used a risk scoring algorithm (Naylor et al., 1997; 
Van Leeuwen et al., 2010). This suggested that selective screening with self-
developed selection criteria for high risk women could potentially be effective. 
 
Limited evidence exists on the cost-effectiveness of selective screening compared to 
universal screening. The cost-effectiveness study (Poncet et al., 2002) and three of 
the four cost studies (Coustan et al., 1989; Larijani et al., 2004; Shamsuddin et al., 
2001) showed that universal screening was slightly more expensive and less cost-
effective in comparison with selective screening.  
 
6.1.2 Pregnant women’s perspectives of GDM screening 
 
China is currently implementing the new IADPSG one-step universal screening 
approach for GDM. Q methodology was used to investigate the perspectives of 
Chinese women on GDM screening under this approach. Thirty pregnant women (15 
GDM and 15 non-GDM women) were involved in ranking the pre-developed 32 Q 
statements. Two distinctive points of view shared by the respondents emerged from 
the Q analysis results. In general, the pregnant women agreed that GDM screening 
was important and necessary to be conducted for all pregnant women. However, 
non-GDM women felt strongly that GDM screening test (OGTT) was inconvenient 
in terms of the three blood samples needed and the duration of two hours, thereby 
experiencing a relative burden in undergoing the OGTT. Both GDM and non-GDM 
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women keenly desired to be provided with more information on GDM and OGTT 
both before and after undergoing the GDM screening.  
 
Although it is useful to learn that universal screening is generally accepted by 
pregnant women, the result also illustrates the importance of exploring an effective 
selective screening approach that might exempt non-GDM pregnant women without 
affecting GDM women. In addition, since this has been identified as a strong need, 
more information on GDM and OGTT should be offered to pregnant women. 
 
6.1.3 The effectiveness of risk score-based selective screening under 
IADPSG    
 
A risk score-based selective screening approach for GDM was developed and 
assessed under new IADPSG criteria in China. A risk scoring algorithm for 
identifying high risk pregnant women was established, using existing and novel risk 
factors identified from the nested case-control study. By using a cut-off score of 0.37, 
the risk score-based selective screening approach yielded a sensitivity of 80% and a 
specificity of 45%. . Using this approach, on one hand, 45% of the non-GDM, which 
is 41% of the whole pregnant population were correctly identified as low-risk 
women and thereby spared from the unnecessary OGTT screening test. While this 
indicates potential for significant monetary savings for the country and prevention of 
unnecessary burden for pregnant women, this approach carries possible risks. The 
advantages were available at the cost of missing 20% of the GDM women, which 
percentage represented 2% of the pregnant population, thereby highlighting concerns 
when making a decision as to the adoption of the optimal screening approach. 
 
 
6.2. COMPARISON WITH PREVIOUS STUDIES 
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6.2.1 Universal versus selective screening for GDM 
 
Two systematic reviews (Hieronimus & Le Meaux, 2010; Tieu et al., 2010) and two 
health technology assessment (HTA) reports (Scott et al., 2002; Waugh et al., 2010) 
have been conducted previously, involving a comparison of universal versus 
selective screening. They were limited due to either the databases searched 
(Hieronimus & Le Meaux, 2010), the types of study included (Tieu et al., 2010), or 
the focus and number of the effectiveness studies included (Scott et al., 2002; 
Waugh et al., 2010).  
 
Hieronimus and Le Meaux (2010) used efficacy outcome measures of sensitivity and 
specificity for effectiveness studies. However, they searched only two databases of 
Medline and Cochrane database from 1990 to 2010, and did not assess the quality of 
the included studies. A total of 14 effectiveness studies were included in the review, 
which concluded that the benefit of GDM screening and treatment were only proven 
in women presenting GDM risk factors, while the relevance of screening for women 
with no risk factors remained controversial. Tieu et al. (2010) evaluated the 
screening, diagnosis and treatment of GDM, and included only randomised and 
quasi-randomised trials. Only one quasi-experimental study (Griffin et al., 2000) was 
identified comparing the clinical outcome measures of the two screening approaches, 
which in itself reflects bias and limitations. Tieu et al. (2010) did not make a definite 
conclusion about which screening approach should be recommended. Scott et al., 
(2002) and Waugh et al. (2010) evaluated the treatment and screening for GDM. 
Each of these reviews involved a short sub-section discussing risk factor screening 
compared to universal screening. Only nine effectiveness studies were described in 
the review by Scott et al., indicating that selective screening on the basis of risk 
factors would miss about half of the women with GDM. Waugh et al. (2010) 
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included an additional study by Cosson et al. (2006) with regards to the effectiveness 
of selective screening versus universal screening to the review by Scott et al. 
 
The current systematic review extended and updated the previous reviews by using 
broader types of study designs, including the recent studies published after 2010 as 
well as fully analysing the efficacy outcome measures of sensitivity and specificity 
of selective screening in comparison with universal screening. This is the most 
comprehensive and up-to-date systematic review on universal versus selective 
screening up till this point, and a number of informative conclusions as to the two 
approaches have been drawn in comparison with those of the four preceding reviews. 
 
6.2.2 Pregnant women’s perspectives of GDM screening 
 
In line with the participant views expressed in the single study done by Griffiths et 
al. (1993) in Australia which explored the attitudes of pregnant women toward 
universal one-step GDM screening with modified OGTT, the participants of this 
current study also generally felt it was important and necessary to conduct a 
screening test for all pregnant women. However, unlike positive attitudes towards 
the convenience of the screening method used in Australia, non-GDM pregnant 
women in China tended to feel that the OGTT test was not convenient at all, and that 
it was potentially burdensome. This may be attributable to the difference in the GDM 
screening tests administered in the Australian study and those administered in the 
current study in China. In the Australian study, a 75g OGTT involved one blood 
sample taken in a fasting state either at home or in a collection center, followed by a 
further blood sample taken after 2 hours. Whereas in China, a 75g OGTT involved 
one blood sample taken in a fasting state at the hospital, followed by two blood 
samples taken after 1 hour and 2 hours. The 75g OGTT was more complicated in the 
current study in China. Apart from the differences in OGTT itself, there might be 
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other contributors to their attitudes including cultural issues and knowledge about 
OGTT before undergoing the test. The Q methodology study showed that 63.6% of 
factor 2 participants and 92.3% of factor 1 participants received GDM information 
before undergoing OGTT. Health education about GDM and OGTT before the test 
would make the OGTT process more acceptable. 
 
6.2.3 The effectiveness of risk score-based selective screening under 
IADPSG    
 
Four previous studies developed and used their own developed selection criteria for 
identifying high risk women for GDM screening (Caliskan et al., 2014; Naylor et al., 
1997; Van Leeuwen et al., 2010; Pintaudi et al., 2014). Two of these used a risk 
scoring algorithm and were conducted in Canada (Naylor et al., 1997) and the 
Netherlands (Van Leeuwen et al., 2010) respectively. Naylor et al. (1997) found that 
risk score-based selective screening achieved a sensitive of 90.6% and specificity of 
34.7%, while Van Leeuwen et al. (2010)’s risk scoring algorithm reached a 
sensitivity of 75.0% and a specificity of 57.0%. Both studies recommended selective 
screening over universal screening as a conclusion. 
 
The findings of the current risk scoring study in China were consistent with and 
supported the two previous risk scoring studies. It found that the risk scoring 
algorithm yielded a sensitive of 80% and a specificity of 45%. It may be noticed that 
there were differences in setting among the three studies. The Canadian study used 
two-step GDM tests and had a GDM prevalence of 2.1% in 1997 (Naylor et al., 
1997). The Netherlands study used two-step GDM tests and had a GDM prevalence 
of 4.6% in 2010 (Van Leeuwen et al., 2010). For the current study in China, the one-
step GDM test using IADPSG criteria was used and the incidence of GDM was 9.4%. 
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Despite the differences in settings, selective screening using a risk scoring algorithm 
nonetheless seemed to be effective.  
 
6.3 STUDY STRENGTHS AND LIMITATIONS  
 
6.3.1 Strengths of study 
 
Firstly, all three studies of this PhD research addressed research questions that have 
not been completely answered before. The previous systematic reviews on universal 
versus selective screening were limited in terms of the databases searched 
(Hieronimus & Le Meaux, 2010), the types of studies included (Tieu et al., 2010), or 
the scope of the effectiveness of the studies (Scott et al., 2002; Waugh et al., 2010). 
The systematic review in this research provided a comprehensive synthesis of 
current evidence on the effectiveness and cost-effectiveness of universal versus 
selective screening for GDM. Griffiths et al. (2013) investigated the attitudes of 
pregnant women towards two-step GDM screening in Australia, while the present Q 
methodology study is a unique study that explores user perspectives towards the 
IADPSG one-step screening for GDM. Two studies carried out previously (Naylor et 
al., 1997; Van Leeuwen et al., 2010) assessed a risk score-based selective screening 
approach for two-step GDM screening, while this risk score study is distinct because 
it is the first study exploring the selective approach under the new IADPSG one-step 
GDM screening. Hence, the findings of this PhD research will make new 
contributions to the current knowledge.  
 
Secondly, this PhD research used a mixed-method study design, involving a 
systematic review, a qualitative as well as a quantitative study. The Q methodology 
provided user perspectives that are considered to be essential to patient-centred 
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healthcare. The risk score quantitative study used robust research design and 
investigated a full list of potential risk factors for developing a risk scoring algorithm. 
 
6.3.2 Limitations of study 
 
The current review has followed the standard process of conducting a systematic 
review. Four main databases of Medline, EMBASE, Web of Science and Cochrane 
Database were used, and research literature in the English language was searched. 
One of the limitations was that some potentially relevant studies, which were not 
reported in English may have been left out.  
 
The findings of the Q methodology study and the risk score study are limited in 
terms of generalisability. The two studies were conducted in a Chinese context, 
wherein the IADPSG one-step universal screening for GDM was adopted. Due to the 
physical and cultural differences in population characteristics and differences in 
methods of screening tests, the conclusions of the two studies can be claimed to be 
applicable only to the Chinese population. However, the methods are generalisable, 
and they provide an important reference for other countries, especially those 
countries which are also implementing the IADPSG one-step screening approach.   
 
The risk scoring algorithm was established and assessed using a retrospective cohort 
of 2897 pregnant women who gave birth to their babies at the hospital in 2013 
(derivation cohort). A further validation cohort to validate the effectiveness of the 
risk scoring algorithm is needed, preferably a cohort from other areas of China. A 
user-friendly computer or web-based tool, similar to the QRISK2 tool for 
cardiovascular risk calculation (https://www.qrisk.org/2016/) might be needed in the 
future to facilitate calculation and enhance ease of application.   
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6.4 STUDY IMPLICATIONS 
 
6.4.1 Implications for practice 
 
The systematic review has analysed and drawn conclusions based on existing 
evidence in the field. Universal screening is recommended for countries or areas 
wherein GDM prevalence is relatively high and economic constraints are not 
experienced. For areas where GDM prevalence is low, it is recommended that they 
retain their current practice (whether it is universal or selective screening) before 
more robust evidence emerges. For countries which are implementing selective 
screening, a risk score-based selective screening approach could be explored. For the 
risk score calculation in real practice during future implementation, it is easy for 
practitioners to make calculations when they are facilitated by a simple web- or 
computer-based calculation tool. A similar tool is the QRISK2 tool for 
cardiovascular risk calculation (https://www.qrisk.org/2016/).  
 
Pregnant women generally believe that the IADPSG one-step screening approach is 
important and necessary to be carried out on all expectant mothers. However, the 
non-GDM women feel strongly that the OGTT test is inconvenient and a burden. 
Also both the GDM and non-GDM participants felt that they would like more 
information both before and after the OGTT. In GDM screening services, it is 
recommended that a detailed GDM and OGTT information leaflet should be offered 
to pregnant women both before and after the OGTT to meet their health needs. 
 
Translating the research evidence to real-world guidelines, policymaking and 
implementation can be challenging and time-consuming. While a great deal of 
research evidence exists, relatively little has been disseminated, taken up or applied 
in practice. Currently, as described in the Chapter 1, substantial inconsistencies and 
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controversies exist between research evidence, guidelines and different field 
practices for gestational diabetes screening. The research evidence is of little 
relevance if it remains unused by health clinicians and policymakers. 
 
However, policymaking or guideline setting is a process of deliberation. Apart from 
scientific evidence, other factors such as values and the culture of each country can 
be influential. Countries have different values in relation to effectiveness and cost-
effectiveness, which are sometimes associated with, but not always relevant to, the 
economic level of the country. For example, cost-effectiveness of heath care is 
emphasised in the UK (Raspe, 2016), which might be one of the reasons for 
implementation of selective screening in the UK as suggested by NICE (2015). 
Secondly, different countries have different normative cultures in healthcare. For 
example, Sweden and Norway have person-centred solidarity, whereas the UK has 
community-centred solidarity (Raspe, 2016). The UK tends to care more about 
health maximisation as a whole, compared to the person-centred solidarity, which 
tends to prioritise the worst off or sickest. Under such cultural imperatives, the UK 
presents a large chance to balance the benefit of avoiding unnecessary OGTT/burden 
for non-GDM women (over 90% of all pregnant women) and the cost of missing a 
small proportion of GDM women. Thirdly, understanding patient needs and 
promoting patient involvement in healthcare decision making is being increasingly 
emphasised and implemented. Therefore, it is considered of value to provide space 
for the projection of patients’ voices when making any healthcare decision including 
GDM screening. 
 
6.4.2 Recommendations for future research 
 
The systematic review identified only one cost-effectiveness study on universal 
versus selective screening for GDM (Poncet et al., 2002). This showed a slight 
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difference between, indicating that the cost to obtain one unit of additional 
effectiveness under universal screening was 1.1 times more expensive than that for 
selective screening. More cost-effectiveness studies will be needed to advance more 
robust conclusions.  
 
There are only three existing studies on a risk score-based selective screening 
approach for GDM, each demonstrating that developing a risk-scoring algorithm 
based on the local population profile made selective screening an effective screening 
approach. However, more risk score studies are recommended for each country. The 
effectiveness of the risk score-based selective screening approach is high dependent 
on the local setting of each country. When conducting future risk-score studies, it is 
essential that the researchers should investigate a full range of potential GDM risk 
factors to maximise the accuracy and effectiveness of the prediction model, since it 
is uncertain whether any other simple biomarkers can improve upon this prediction. 
A recent study (Meek et al., 2016) showed how even random glucose is a better 
predictor of GDM than BMI or maternal age during the first trimester. Some recent 
studies showed that the homeostatic model assessment for insulin resistance index 
(HOMA IR) level was associated with GDM and could be used as a predictor 
(Mohamed et al., 2013; Alptekin et al., 2016). Whether these hold true in Chinese 
population is a matter of research in the future. Additionally, it also remains to be 
established whether the random glucose indicator could be improved by using 
HbA1c as a predictor, either on its own or as a composite risk marker. Whether any 
urinary metabolomics during 1
st
 trimester could be used as predictor for GDM worth 
further investigation. In the study of Sachse et al. (2012), an increase of excreted 
urinary citrate correlated with the severity of GDM was observed. Meta-analysis of 
candidate gene studies and genome-wide association analysis (GWAS) have 
identified a number of genes which were reproducibly associated with GDM, 
including TCF7L2, GCK, KCNJ11, KCNQ1, CDKAL1, IGF2BP2, MTNR1B, and 
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IRS1 (Lowe et al., 2016). These genes are also associated with T2DM. Genetics of 
T2DM and GDM as predictive markers of GDM are also worth exploring in the 
future. 
 
Since only two studies on pregnant women’s perspectives on GDM screening have 
been conducted in Australia (Griffiths et al., 1993) and China, with the Australian 
study being conducted early in 1993, future qualitative perspective studies are 
needed under other local screening settings other than China. This is to ensure that 
patient needs and viewpoints are understood fully so as to facilitate decisionmaking 
for each country. 
 
There is trend to transfer the outcome measure of test accuracy to clinical outcomes 
for screening studies. The systematic review synthesised the test accuracy of 
selective screening in comparison with universal screening. As explained in the 
Discussion section in Chapter 3, the present systematic review did not synthesise 
clinical outcomes is because there were only three studies (Griffin et al., 2000; 
Cosson et al., 2006; Ezimokhai et al., 2006) using the clinical outcome measures but 
each had the same bias in study design. The most appropriate study design compares 
the clinical outcomes of all pregnant women not just GDM women under the two 
screening approaches. Therefore, it is recommended that future studies are designed 
in line with this consideration. Moreover, future studies can also examine the clinical 
outcomes of the GDM women with lowest risk. These are the GDM women who 
would be missed during the application of selective screening as having none or low 
risks; whether or not these lowest risk GDM women develop adverse outcomes has 
important implications for assessing the selective screening approach. As a further 
step beyond using clinical outcome measures, future studies could consider using a 
decision tree to illustrate the two choices of universal screening and selective 
screening approaches.  A decision tree is a decision support tool that uses a tree-like 
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graph or model of decisions and their possible consequences, including chance event 
outcomes, resource costs, and utility. Use of this technique can further facilitate the 
judgment and decision making in clinical medicine. 
 
 
6.5 CONCLUSIONS 
 
The optimal GDM screening approach is ‘setting dependent’. It is influenced by the 
population characteristics and risks, the different screening tests and criteria used, 
and the patients’ perspectives, as well as wider context of healthcare value and 
culture. This PhD research has provided scientific evidence on the effectiveness and 
cost-effectiveness of universal versus selective screening and patient perspectives, 
and it has also explored a risk score-based selective screening approach under the 
new IADPSG criteria. 
 
Although it appears that universal screening is the best approach, there are a number 
of associated issues pertaining to the cost of resources, patient burden and lack of 
cost-effectiveness. This means that using the universal approach to identify and 
manage all pregnant women may not really be worth it, especially for those at the 
lower end of the risk. Selective screening is therefore believed to be the better 
approach, but how this can be conducted is the most pertinent question. Ideally each 
population should have its own high risk screening criterion. Potentially, selective 
screening with criteria that is appropriate for the population can be efficient; by not 
employing universal screening can save numerous costs and the anxiety of 
undergoing OGTT. Nevertheless, the cost of the missing GDM and their long-term 
consequences after delivery through selective screening needs to be further explored 
by future studies. 
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The Q methodology study highlights the burden and inconvenience around OGTT 
and the diagnosis of GDM. There needs to be further work to minimise this by better 
education as well as selective screening of individuals with varying risks. The case-
control study has shown weighting of simple risk factors can be a better predictor of 
risk. Using the risk score algorithm could spare 41% of pregnant women from 
screening, while accurately identifying 80% GDM cases. Whether one hundred 
percent of the cases can be picked up is the debate. However, even if 20% GDM 
cases are missed (as in this study), these are the GDM women with the lowest 
preexisting risk factor profile. Further prospective study is ideally needed to examine 
the clinical outcomes of these lowest risk GDM women, so as to justify the adoption 
of the selective screening approach. 
 
In terms of real-world implementation, aside from the scientific evidence on 
effectiveness, cost-effectiveness and patient perspectives investigated by this 
research, it needs to be borne in mind that the country’s value and culture in 
healthcare policy can also contribute to final healthcare decision making. It needs to 
be noted that such decision making is a deliberate and time-consuming process. 
 
This thesis has successfully addressed the research aims and the stated research 
objectives. With regard to further investigation into the optimal screening approach 
for GDM, several other important areas for future research have been identified. 
More cost-effectiveness studies on selective versus universal screening are needed. 
Testing the effectiveness of risk score-based selective screening is highly 
recommended for other countries. This is especially true for countries that have not 
assessed the effectiveness of a selective screening approach and for countries 
wishing to explore the possibility of improving their selective screening approach. A 
full range of traditional and novel biomarkers should be investigated when 
developing the selection criteria for identifying high risk women. Within literature, 
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there is a clear gap for more country-specific research on understanding pregnant 
women’s perspectives on GDM screening in their own setting. Furthermore, more 
screening studies using clinical outcome measures with the correct study design and 
more prognostic studies are needed. It is believed that the findings of future research 
in light of the recommendations in this study will offer stronger and more specific 
evidence for making a robust evaluation of the best screening approach for each 
country.   
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APPENDICES 
 
Appendix 1. Search strategy in Medline, EMBASE, Cochrane Database, 
and Web of Science. 
 
Appendix 1.1 Search strategy in Medline (searched on 1April 2013 and updated 
on 14 November 2014) 
 
Searches Results Search Type 
1 exp Mass Screening/ 105316 Advanced 
2 "screen*".m_titl. 115146 Advanced 
3 exp Diabetes, Gestational/ 7494 Advanced 
4 (diabet* adj3 gestation*).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, 
rare disease supplementary concept, unique identifier] 
8855 Advanced 
5 gdm.mp. 2876 Advanced 
6 1 or 2 170957 Advanced 
7 3 or 4 or 5 10221 Advanced 
8 6 and 7 894 Advanced 
9 limit 8 to (English language and yr="1980 -Current") 767 Advanced 
 
 
Appendix 1.2 Search strategy in Embase (searched on 1 April 2013 and updated 
on 14 November 2014) 
 
Searches Results Search Type 
1 exp mass screening/ or exp screening/ 485964 Advanced 
2 "screen*".m_titl. 152843 Advanced 
3 exp pregnancy diabetes mellitus/ 21701 Advanced 
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4 (diabet* adj3 gestation*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword] 
13846 Advanced 
5 gdm.mp. 5168 Advanced 
6 1 or 2 529667 Advanced 
7 3 or 4 or 5 24866 Advanced 
8 6 and 7 2444 Advanced 
9 limit 8 to (English language and yr="1980 -Current") 2154 Advanced 
 
Appendix 1.3 Search strategy in SCI and SSCI (Web of Science) (searched on 1 
April 2013 and updated on 14 November 2014) 
 
Searched on Web of Science on (gestation* same diabet*) and screen* in ‘TITLE’ 
from 1980 onwards. 
Results 
568 articles 
 
Appendix 1.4 Search strategy in Cochrane Database (searched on 1 April 2013 
and updated on 14 November 2014) 
 
Searched on (gestation* near diabet*) and screen*. 
All Results (81) 
Cochrane Reviews (3) 
Other Reviews (8) 
Trials (55) 
Methods Studies (0) 
Technology Assessments (9) 
Economic Evaluations (13 
Cochrane Groups (0) 
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Appendix 2. Table of included studies for systematic review 
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Appendix 2.2 Cost-effectiveness and cost studies 
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Appendix 3. Table of excluded studies and reasons for exclusion 
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1 Agarwal, M. M. & Punnose, J. (2001) Screening for gestational diabetes 
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Universal or selective screening? Journal of Maternal-Fetal and 
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specificity 
4 Arcidiacono, B, Capula, C, Chiefari, E, Ventura, V, Iiritano, S, Vero, A, 
Puccio, L, Pullano, V, Foti, D, Brunetti, A, & Vero, R n.d., (2013). 
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abstract only 
181 
 
11 Berger, H., Crane, J., Farine, D., Armson, A., De La Ronde, S., Keenan-
Lindsay, L., Leduc, L., Reid, G. & Van Aerde, J. (2002) Screening for 
gestational diabetes mellitus. Journal of obstetrics and gynaecology 
Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : 
JOGC, 24 (11): 894-912. 
Literature review 
12 Brody, S. C., Harris, R. & Lohr, K. (2003) Screening for gestational 
diabetes: A summary of the evidence for the U.S. Preventive Services 
Task Force. Obstetrics and Gynecology, 101 (2): 380-392. 
Systematic review 
(and didn’t include 
universal versus 
selective screening) 
13 Calonge, N., Petitti, D. B., DeWitt, T. G., Gordis, L., Gregory, K. D., 
Harris, R., Isham, G., LeFevre, M. L., Loveland-Cherry, C., Marion, L. 
N., Moyer, V. A., Ockene, J. K., Sawaya, G. F., Siu, A. L., Teutsch, S. 
M. & Yawn, B. P. (2008) Screening for gestational diabetes mellitus: 
U.S. preventive services task force recommendation statement. Annals 
of Internal Medicine, 148 (10): 759-765. 
Systematic review 
(and didn’t include 
universal versus 
selective screening) 
14 Cao, X. P., Chen, S. J., Wang, Z. L., Chen, S., Li, Y. B. & Xiao, H. P. 
(2009) The Value of Screening Based on Traditional Risk Factors Is 
Low in Identifying Gestational Diabetes and High in Predicting 
Postpartum Diabetes. Diabetes, 58 A470-A470. 
Outcome measures 
didn’t include 
sensitivity and 
specificity of 
screening; conference 
publication with 
abstract only 
15 Chen, P. Y., E. A. Finkelstein, et al. (2014). "Cost-effectiveness analysis 
on gestational diabetes mellitus screening strategies." Journal of 
Maternal-Fetal and Neonatal Medicine 27: 69-70. 
Abstract only. Full 
text not available. 
16 Chevalier, N., Hieronimus, S., Giaume, V., Brucker-Davis, F., Bongain, 
A. & Fenichel, P. (2009) Obstetrical outcomes in pregnancies with 
gestational diabetes: what benefits? Which patients? Diabetologia, 52 
(S1) S458. 
Abstract only 
17 Chevalier, N., Fenichel, P., Giaume, V., Loizeau, S., Bongain, A., 
Daideri, G., Brucker-Davis, F. & Hieronimus, S. (2011) Universal two-
step screening strategy for gestational diabetes has weak relevance in 
French Mediterranean women: Should we simplify the screening 
strategy for gestational diabetes in France? Diabetes & Metabolism, 37 
(5): 419-425. 
Outcome measures 
only included 
sensitivity, but no 
specificity 
18 Corcoy, R., Garcia-Patterson, A., Pau, E., Pascual, E., Altirriba, O., 
Adelantado, J. M. & de Leiva, A. (2004) Is selective screening for 
gestational diabetes mellitus worthwhile everywhere? Acta 
Diabetologica, 41 (4): 154-157. 
The specificity 
couldn’t be calculated 
using the definition in 
the review 
19 Cosson, E., Benchimol, M., Carbillon, L., Pharisien, I., Paries, J., 
Valensi, P., Lormeau, B., Bolie, S., Uzan, M. & Attali, J. R. (2006) 
Universal rather than selective screening for gestational diabetes 
mellitus may improve fetal outcomes. Diabetes & Metabolism, 32 (2): 
140-146. 
Outcome measures 
only included 
sensitivity, but no 
specificity 
182 
 
20 Cosson, E., C. Cussac-Pillegand, et al. (2014). "The diagnostic and 
prognostic performance of a selective screening strategy for gestational 
diabetes mellitus according to ethnicity in Europe." Journal of Clinical 
Endocrinology & Metabolism 99(3): 996-1005. 
Duplicate with an 
included study 
(Cosson et al., 2013) 
21 Davey, R. X. & Hamblin, P. S. (2001) Selective versus universal 
screening for gestational diabetes mellitus: an evaluation of predictive 
risk factors. Medical Journal of Australia, 174 (3): 118-121. 
Outcome measures 
included sensitivity 
and specificity. 
However, sensivitity 
was calulated based 
on all risk factors, 
while specificity was 
calculated only based 
on age. 
22 Di Cianni, G., Volpe, L., Casadidio, I., Bottone, P., Marselli, L., 
Lencioni, C., Boldrini, A., Teti, G., Del Prato, S. & Benzi, L. (2002) 
Universal screening and intensive metabolic management of gestational 
diabetes: cost-effectiveness in Italy. Acta Diabetologica, 39 (2): 69-73. 
Universal screening 
approah included 
screening and 
diagnosis test, 
however, selective 
screening approach 
only included 
diagnosis test. Not 
comparatable.  
23 Dietrich, M. L., Dolnicek, T. F. & Rayburn, W. F. (1987) 
GESTATIONAL DIABETES SCREENING IN A PRIVATE, 
MIDWESTERN AMERICAN POPULATION. American Journal of 
Obstetrics and Gynecology, 156 (6): 1403-1408. 
The specificity 
couldn’t be calculated 
using the definition in 
the review 
24 Donovan, L., Hartling, L., Muise, M., Guthrie, A., Vandermeer, B. & 
Dryden, D. M. (2013) Screening Tests for Gestational Diabetes: A 
Systematic Review for the US Preventive Services Task Force. Annals 
of internal medicine,  
Systematic review 
(and didn’t include 
universal versus 
selective screening) 
25 Ezimokhai, M., Joseph, A. & Bradley-Watson, P. (2006) Audit of 
pregnancies complicated by diabetes from one center five years apart 
with selective versus universal screening. Annals of the New York 
Academy of Sciences, 1084 132-140. 
Outcome measures 
didn’t include 
sensitivity and 
specificity of 
screening 
26 Farrar, D., Wright, J., Whitelaw, D. & Tuffnell, D. (2011) Evaluation of 
the impact of universal screening for gestational diabetes mellitus on 
maternal and neonatal health outcomes. Archives of Disease in 
Childhood: Fetal and Neonatal Edition, 96 Fa126. 
Outcome measures 
didn’t include 
sensitivity and 
specificity of 
screening; conference 
publication with 
abstract only 
183 
 
27 Griffin, M. E., Coffey, M., Johnson, H., Scanlon, P., Foley, M., Stronge, 
J., O'Meara, N. M. & Firth, R. G. (2000) Universal vs. risk factor-based 
screening for gestational diabetes mellitus: detection rates, gestation at 
diagnosis and outcome. Diabetic Medicine, 17 (1): 26-32. 
Outcome measures 
didn’t include 
sensitivity and 
specificity of 
screening 
28 Hall, C., Going, A., Moutter, S., Thynne, A. D., Salloum, M., Sengupta, 
S. & Cummings, M. H. (2009) Highlighting the dilemmas of GTTs 
performed during pregnancy: Are we screening appropriately? Diabetic 
Medicine, 26 178. 
Conference 
publication with 
abstract only 
29 Hapuarachi, S., N. Rahman, et al. (2014). "Is national targeted screening 
for gestational diabetes fit for purpose? Experience from East of 
England hospital." BJOG: An International Journal of Obstetrics and 
Gynaecology 121: 161. 
Abstract only 
30 Healy, G. M., Vellinga, A., Carmody, L., Avalos, G., Mustafa, E., 
Khalil, S., Noctor, E., Kirwan, B. & Dunne, F. P. (2012a) Atlantic DIP: 
Universal vs. Selective Screening for Gestational Diabetes (GDM). 
Diabetes, 61 A641. 
Outcome measures 
didn’t include 
sensitivity and 
specificity of 
screening 
31 Healy, G. M., Vellinga, A., Carmody, L., Avalos, G., Mustafa, E., 
Khalil, S., Noctor, E., Kirwan, B. & Dunne, F. P. (2012b) Atlantic DIP: 
What does selective screening for gestational diabetes miss? 
Diabetologia, 55 S38. 
Conference 
publication with 
abstract only 
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Universal screening 
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screening and 
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however, selective 
screening approach 
only included 
186 
 
diagnosis test. Not 
comparatable. 
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A322-A322. 
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Abstract/full text not 
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62 Wilson, N., Ashawesh, K., Smith, S. & Anwar, A. (2008) The cost of 
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Only a summary of 
GDM screenig cost 
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NICE 63. Diabetic Medicine, 26 31. 
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Abstract only 
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Appendix 4 Quality assessment results 
 
Appendix 4.1 Amended Downs and Black Checklist for assessing the effectiveness 
studies 
 
The original Downs and Black checklist has 27 items with a maximum score of 32 
points. The checklist was modified as not all items were relevant to the effectiveness 
studies in this review. All the 37 effectiveness studies were cohort studies/cross-
sectional studies, no randomised controlled study was included. Item 23 and 24 
about randomisation were removed. For all the cohort studies, selective screening 
and universal screening were from the same cohort, and the screening and diagnosis 
were conducted at the same time period. Item 21 and 22 about whether intervention 
and comparison group were from the same population and whether were recruited 
over the same period of time were removed. Since universal and selective screening 
group were form the same cohort, they were free from potential confounding factors. 
Item 5 and 25 about confounders were deleted. Sensitivity and specificity of 
selective screening compared to universal screening are main outcome measures. 
The two figures are fixed and invariable for each cohort. Item 7 about the estimate of 
variability for main outcomes and item 10 about the report of P-values were not 
applicable. The main adverse event of selective screening is missing GDM women, 
which was measured in terms of sensitivity. Item 8 about if all adverse events of 
intervention were reported will always be answered with Yes, thus was deleted. The 
screening and diagnosis of GDM are biomedical tests, which should not be affected 
by the blinding status of participants or the clinicians. Item 14 about blinding of 
study subjects and item 15 of blinding those measuring the outcomes was removed. 
Also, the biomedical tests results are automatically In addition, item 27 about power 
was revised from a scale of 0 to 5 to a scale of 0 to 1. It will be scored as 1 if there 
was power calculation in the study; and scored as 0 if there was no power calculation 
or explanation whether the number of participants was appropriate. The modified 
version of the checklist consists 16 items with a maximum score of 16 points. The 
checklist was employed for each of the effectiveness study of a cohort design. 
Higher scores reflected a superior quality of investigation. 
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Appendix 4.2 Quality assessment results of the effectiveness studies  
Down & Black Checklist Arora 
et al. 
(2013) 
Caliskan 
et al. 
(2004) 
Capula 
et al. 
(2013) 
Chong 
et al. 
(2014) 
Corrado 
et al. 
(2014) 
Cosson 
et al. 
(2013) 
Coustan 
et al. 
(1989) 
Danilenko-
Dixon et al. 
(1999) 
Di Cianni 
et al. 
(2003) 
1. Is the hypothesis/ aim/ objective of the study 
clearly described? 
1 1 1 1 1 1 1 1 1 
2.Are the main outcomes to be measured clearly 
described in the Introduction or Methods section? 
1 1 1 1 0 0 0 1 0 
3.Are the characteristics of the patients included 
in the study clearly described ? 
1 1 1 1 1 1 0 1 1 
4. Are the interventions of interest clearly 
described? 
1 1 1 1 1 1 1 1 1 
6.Are the main findings of the study clearly 
described? 
1 1 1 1 1 1 1 1 1 
9.Have the characteristics of patients lost to 
follow-up been described? 
1 1 1 1 1 0 1 1 1 
11. Were the subjects asked to participate in the 
study representative of the entire population from 
which they were recruited? 
1 1 1 1 1 1 1 1 1 
12. Were those subjects who were prepared to 
participate representative of the entire population 
from which they were recruited? 
1 1 1 1 1 0 1 1 1 
13. Were the staff, places, and facilities where the 
patients were treated, representative of the 
treatment the majority of patients receive? 
1 1 1 1 1 1 1 1 1 
16.If any of the results of the study were based 
on“data dredging”, was this made clear? 
1 1 1 1 1 1 1 1 1 
17. In trials and cohort studies, do the analyses 
adjust for different lengths of follow-up of 
patients, or in case-control studies, is the time 
period between the intervention and outcome the 
same for cases and controls? 
1 1 1 1 1 1 1 1 1 
18. Were the statistical tests used to assess the 1 1 1 1 1 1 1 1 1 
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main outcomes appropriate? 
19.Was compliance with the intervention/s 
reliable? 
1 1 1 1 1 1 1 1 1 
20. Were the main outcome measures used 
accurate (valid and reliable)? 
1 1 1 1 1 1 1 1 1 
26.Were losses of patients to follow-up taken into 
account? 
1 1 1 1 1 0 1 1 1 
27.Did the study have sufficient power to detect a 
clinically important effect where the probability 
value for a difference being due to chance is less 
than 5%? 
0 0 0 0 0 0 0 0 0 
Total score 15 16 15 15 14 11 13 15 14 
NB: (1) 1-Yes; 0-No or unable to determine; (2) For the detailed description of how to judge each item, please see the original Downs and Black checklist 
(Downs & Black, 1998). 
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Down & Black Checklist Hadaegh 
et al. 
(2005) 
Helton 
et al. 
(1997) 
Jensen 
et al. 
(2003) 
Jimenez-
Moleon 
et al. 
(2002) 
Lavin 
(1985) 
Moses 
et al. 
(1995) 
Moses 
et al. 
(1998) 
Naylor 
et al. 
(1997) 
Pintaudi 
et al. 
(2014) 
1. Is the hypothesis/ aim/ objective of the study clearly 
described? 
1 1 1 1 1 1 1 1 1 
2.Are the main outcomes to be measured clearly 
described in the Introduction or Methods section? 
1 1 1 1 0 1 1 1 1 
3.Are the characteristics of the patients included in the 
study clearly described ? 
1 0 1 1 0 1 1 1 1 
4. Are the interventions of interest clearly described? 1 1 1 1 1 1 1 1 1 
6.Are the main findings of the study clearly described? 1 1 1 1 1 1 1 1 1 
9.Have the characteristics of patients lost to follow-up 
been described? 
1 1 0 1 1 0 0 1 1 
11. Were the subjects asked to participate in the study 
representative of the entire population from which they 
were recruited? 
1 1 1 1 1 1 1 1 1 
12. Were those subjects who were prepared to 
participate representative of the entire population from 
which they were recruited? 
1 0 0 0 1 0 0 1 1 
13. Were the staff, places, and facilities where the 
patients were treated, representative of the treatment the 
majority of patients receive? 
1 1 1 1 1 1 1 1 1 
16.If any of the results of the study were based on“data 
dredging”, was this made clear? 
1 1 1 1 1 1 1 1 1 
17. In trials and cohort studies, do the analyses adjust 
for different lengths of follow-up of patients, or in case-
control studies, is the time period between the 
intervention and outcome the same for cases and 
controls? 
1 1 1 1 1 1 1 1 1 
18. Were the statistical tests used to assess the main 
outcomes appropriate? 
1 1 1 1 1 1 1 1 1 
19.Was compliance with the intervention/s reliable? 0 0 0 0 1 0 0 1 1 
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20. Were the main outcome measures used accurate 
(valid and reliable)? 
1 1 1 1 1 1 1 1 1 
26.Were losses of patients to follow-up taken into 
account? 
1 1 1 1 1 0 0 1 1 
27.Did the study have sufficient power to detect a 
clinically important effect where the probability value for 
a difference being due to chance is less than 5%? 
1 0 0 0 0 0 0 0 0 
Total score 15 12 12 13 13 11 11 15 15 
NB: (1) 1-Yes; 0-No or unable to determine; (2) For the detailed description of how to judge each item, please see the original Downs and Black checklist 
(Downs & Black, 1998). 
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Down & Black Checklist Sacks 
et al. 
(1987) 
Teh et 
al. 
(2011) 
Van 
Leeuw
en et 
al. 
(2010) 
Willia
ms et 
al. 
(1999) 
Zoller 
et al. 
(1988) 
Ostlun
d & 
Hanson 
(2003) 
Savona-
Ventur
a et al. 
(2013) 
Shams
uddin 
et al. 
(2001) 
Shiraz
ian et 
al. 
(2009) 
Waga
arach
chi et 
al. 
(2001) 
1. Is the hypothesis/ aim/ objective of the study clearly 
described? 
1 1 1 1 1 1 1 1 1 1 
2.Are the main outcomes to be measured clearly described 
in the Introduction or Methods section? 
1 1 1 1 0 1 1 1 1 1 
3.Are the characteristics of the patients included in the 
study clearly described ? 
0 1 0 0 0 1 1 1 0 0 
4. Are the interventions of interest clearly described? 1 1 1 1 1 1 1 1 1 1 
6.Are the main findings of the study clearly described? 1 1 1 1 1 1 1 1 1 1 
9.Have the characteristics of patients lost to follow-up 
been described? 
1 1 0 0 1 1 1 0 1 1 
11. Were the subjects asked to participate in the study 
representative of the entire population from which they 
were recruited? 
1 1 1 1 1 1 0 1 1 1 
12. Were those subjects who were prepared to participate 
representative of the entire population from which they 
were recruited? 
1 1 1 1 1 0 0 1 1 1 
13. Were the staff, places, and facilities where the patients 
were treated, representative of the treatment the majority 
of patients receive? 
1 1 1 1 1 1 1 1 1 1 
16.If any of the results of the study were based on“data 
dredging”, was this made clear? 
1 1 1 1 1 1 1 1 1 1 
17. In trials and cohort studies, do the analyses adjust for 
different lengths of follow-up of patients, or in case-
control studies, is the time period between the intervention 
and outcome the same for cases and controls? 
0 1 1 1 1 1 1 1 1 1 
18. Were the statistical tests used to assess the main 
outcomes appropriate? 
1 1 1 1 1 1 1 1 1 1 
19.Was compliance with the intervention/s reliable? 1 1 0 1 1 1 1 1 1 1 
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20. Were the main outcome measures used accurate (valid 
and reliable)? 
1 1 1 0 0 1 1 1 1 1 
26.Were losses of patients to follow-up taken into 
account? 
0 1 0 1 1 0 1 1 1 1 
27.Did the study have sufficient power to detect a 
clinically important effect where the probability value for 
a difference being due to chance is less than 5%? 
0 0 0 0 0 0 0 0 0 0 
Total score 12 15 11 12 12 13 13 14 14 14 
NB: (1) 1-Yes; 0-No or unable to determine; (2) For the detailed description of how to judge each item, please see the original Downs and Black checklist 
(Downs & Black, 1998). 
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Appendix 4.3 Quality assessment results of the cost-effectiveness studies 
Assessment result of Poncet et al., (2002) 
Item Yes No Not clear Not appropriate 
Study design         
1. The research question is stated. √  ¨  ¨   
2. The economic importance of the research question is stated. √  ¨  ¨   
3. The viewpoint(s) of the analysis are clearly stated and justified. √  ¨  ¨   
4. The rationale for choosing alternative programmes or interventions compared is stated.  ¨  ¨ √   
5. The alternatives being compared are clearly described. √  ¨  ¨   
6. The form of economic evaluation used is stated. √  ¨  ¨   
7. The choice of form of economic evaluation is justified in relation to the questions addressed.  ¨  ¨ √   
Data collection         
8. The source(s) of effectiveness estimates used are stated. √  ¨  ¨   
9. Details of the design and results of effectiveness study are given (if based on a single study).  ¨  ¨  ¨ √ 
10. Details of the methods of synthesis or meta-analysis of estimates are given (if based on a synthesis of 
a number of effectiveness studies). 
 ¨ √  ¨  ¨
11. The primary outcome measure(s) for the economic evaluation are clearly stated. √  ¨  ¨   
12. Methods to value benefits are stated. √  ¨  ¨  ¨
13. Details of the subjects from whom valuations were obtained were given. √  ¨  ¨  ¨
14. Productivity changes (if included) are reported separately.  ¨  ¨  ¨ √ 
15. The relevance of productivity changes to the study question is discussed.  ¨  ¨  ¨ √ 
16. Quantities of resource use are reported separately from their unit costs.  ¨ √  ¨   
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17. Methods for the estimation of quantities and unit costs are described.  ¨ √  ¨   
18. Currency and price data are recorded.  ¨ √  ¨   
19. Details of currency of price adjustments for inflation or currency conversion are given. √  ¨  ¨   
20. Details of any model used are given. √  ¨  ¨  ¨
21. The choice of model used and the key parameters on which it is based are justified. √  ¨  ¨  ¨
Analysis and interpretation of results         
22. Time horizon of costs and benefits is stated. √  ¨  ¨  ¨
23. The discount rate(s) is stated. √  ¨  ¨  ¨
24. The choice of discount rate(s) is justified.  ¨  ¨  ¨ √ 
25. An explanation is given if costs and benefits are not discounted. √  ¨  ¨  ¨
26. Details of statistical tests and confidence intervals are given for stochastic data.  ¨  ¨ √  ¨
27. The approach to sensitivity analysis is given. √  ¨  ¨  ¨
28. The choice of variables for sensitivity analysis is justified. √  ¨  ¨  ¨
29. The ranges over which the variables are varied are justified. √  ¨  ¨  ¨
30. Relevant alternatives are compared. √  ¨  ¨  ¨
31. Incremental analysis is reported. √  ¨  ¨  ¨
32. Major outcomes are presented in a disaggregated as well as aggregated form.  ¨ √  ¨   
33. The answer to the study question is given. √  ¨  ¨   
34. Conclusions follow from the data reported. √  ¨  ¨   
35. Conclusions are accompanied by the appropriate caveats. √  ¨  ¨   
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Appendix 5 Data extraction results  
 
Appendix 5.1 Study characteristics of the 15 effectiveness studies with two-step tests 
(1) Data extraction result for Arora et al. (2013)  
1. Study details 
Study ID: 01 
First author surname: Arora 
Year of publication: 2013 
Country and city: Thailand, Lampang 
Study design: Cross-sectional study 
Study setting: the antenatal care clinic of Lampang Regional Hospital 
Number of centres: 1 
Inclusion and exclusion criteria: All pregnant women of appropriate gestational age for screening during the study period were included. 
Time of study: Between 4 January to 30 September 2010 
Funding: Information not available 
2. Aim of the study 
 This study aims to assess the GDM prevalence by using universal screening, and to show the diagnostic value of selective screening at Lampang Hospital. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 613 
Number of participants consented/included 613 
Number of participants in the end after those missed/excluded/lost to 593 (18 were exclude either because they were lost to follow-up or could not 
197 
 
follow-up at a later stage complete the screening protocol)  
Characteristics of participants 
Mean age (years) N/A (29.7% ≥30 years old) 
Mean BMI (kg/m
2
) N/A (21.9% ≥25) 
Ethnicity 95.1% Thai/ Chinese Thai, 2.0% Hill tribe, 2.9% others 
Participants with a family history of diabetes among first-degree relatives  13.3% 
4. Selection criteria for high-risk women 
Reference of criteria N/A 
Type of criteria Risk factor ≥1  
Number of risk factors used 8 
Maternal age Yes (≥30) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (≥4000g) 
History of adverse obstetric outcome Yes (history of dead fetus in utero, fetal anomaly) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Glucosuria 
Hypertension 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  593 593 (same cohort) 
Selection   
Number of high risk women  313 
Number of low risk women  280 
Screening   
Number of women undertook screening 593 313 
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Time of screening Women at risk: at first prenatal visits, and again at 
24 weeks or more of gestation if the test was 
negative 
Other women: 24 weeks or more of gestation 
Women at risk: at first prenatal visits, and again at 
24 weeks or more of gestation if the test was 
negative 
 
Screening test 50g GCT: ≥ 140 mg/dl at 1 hour Same as universal group 
Screening criteria reference N/A N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 95 mg/dl, 1-hour 180 mg/dl, 
2-hour 155 mg/dl and 3-hour 140 mg/dl) 
Same as universal group 
Diagnosis criteria reference ACOG criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) (GDM prevalence) 
55/593 (9.3%) 43/593 (7.3%) 
Sensitivity 100% (reference) 78.2%=43/55 
Specificity 0% (reference)  49.8%=(280-12)/(593-55) 
5.3 Other information 
None. 
6. Authors conclusion 
21.8% GDM cases might be missed if using risk-based screening, this might not be acceptable. The risk-based screening policy adopted throughout the 
country needs to be re-evaluated.  
7. Reviewer’s conclusion 
Though selective screening based on risk factors could exempt 49.8% non-GDM women from screening, 21.8% GDM cases would be missed by the 
selective approach. The conclusion of ‘risk-based screening might not be acceptable and needs to be re-evaluated’ is an accurate reflection of the results 
presented.  
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(2) Data extraction result for Caliskan et al. (2004)  
1. Study details 
Study ID: 02 
First author surname: Caliskan 
Year of publication: 2004 
Country and city: Turkey, Ankara 
Study design: Retrospective cohort study 
Study setting: Antenatal policlinics of the Social Security Council Maternity and Women’s Health Teaching Hospital 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women having singleton pregnancies between 24 and 28 weeks of gestation without a previous diagnosis of 
diabetes mellitus 
Time of study: Between May to July 2000 
Funding: Information not available 
2. Aim of the study 
 This study aims to test whether a prospective application of a risk factor scoring can be an alternative screening strategy for diagnosing GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 425 
Number of participants consented/included 425 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
422 (3 women could not tolerate a 100g OGTT, they all had a 50g 
GCT<7.2mmol/l) 
Characteristics of participants 
Mean age (years) 24.9±4.9 (16-40) (48% ≥ 25 years old) 
Mean BMI (kg/m
2
) 23.9±3.5 (16.9-39.1) (31.55% ≥ 25) 
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Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  24.6% 
4. Selection criteria for high-risk women 
Reference of criteria From a retrospective study they performed (unpublished data) 
Type of criteria Risk factor ≥1 or ≥2 
Number of risk factors used 5 
Maternal age Yes (≥25) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM None 
A prior macrosomic infant Yes (>4000g) 
History of adverse obstetric outcome Yes (recurrent spontaneous abortions, fetal anomaly despite a normal 
karyotype and prior unexplained in utero fetal death at a gestational age ≥20 
weeks) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
5. Comparison of universal versus selective screening 
5.1 Selection criteria: risk factor ≥ 1 
 Universal screening Selective screening 
Number of participants  422 422 (same cohort) 
Selection   
Number of high risk women  297 
Number of low risk women  125 
Screening   
Number of women undertook screening 422 297 
Time of screening 24-28 weeks of gestation Same as universal group 
Screening test 50g GCT: ≥ 7.2 mmol/l (130 mg/dl) at 1 hour Same as universal group 
Screening criteria reference N/A N/A 
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Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis 1 week after screening Same as universal group 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 5.8 mmol/l (105 mg/dl), 1-
hour 10.6 mmol/l (190 mg/dl), 2-hour 9.2 mmol/l 
(165 mg/dl) and 3-hour 8.1 mmol/l (145 mg/dl) 
Same as universal group 
Diagnosis criteria reference National Diabetes Data Group Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
14 (3.3%) 14 (3.3%) 
Sensitivity 100% (reference) 100%=14/14 
Specificity 0% (reference) 30.6%=(125-0)/(422-14) 
5.2 Selection criteria: risk factor ≥ 2 
 Universal screening Selective screening 
Number of participants 422 422 (same cohort) 
Selection 
Number of high risk women  157 
Number of low risk women  265 
Screening   
Number of women undertook screening 422 422 
Time of screening 24-28 weeks of gestation Same as universal group 
Screening test 50g GCT: ≥ 7.2 mmol/l (130 mg/dl) at 1 hour Same as universal group 
Screening criteria reference N/A N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis 
Number of women undertook diagnosis N/A N/A 
Time of diagnosis 1 week after screening Same as universal group 
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Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 5.8 mmol/l (105 mg/dl), 1-
hour 10.6 mmol/l (190 mg/dl), 2-hour 9.2 mmol/l 
(165 mg/dl) and 3-hour 8.1 mmol/l (145 mg/dl) 
Same as universal group 
Diagnosis criteria reference National Diabetes Data Group Same as universal group 
Number of women diagnosed positive-GDM 
women (%) (GDM prevalence) 
14/422 (3.3%) 12/422 (2.8%) 
Sensitivity 100% (reference) 85.7%=12/14 
Specificity 0% (reference)  64.5%=(265-2)/(422-14) 
5.3 Other information 
Logistic regression analysis revealed that an increase in the score by one caused a three times increase in GDM risk (OR=3, CI=1.9–5). 
6. Authors conclusion 
A well integrated, population-based scoring will decrease the number of unnecessary testing but still diagnose 85–100% of GDM cases. 
7. Reviewer’s conclusion 
This is a well-designed and clearly reported study. Using the risk scores ≥1 or ≥ 2, the sensitivity ranged from 100% to 85.7%, while the specificity ranged 
from 30.6% to 64.5%. It is rationale for the authors to conclude a well integrated risk scoring system based on the evidence of the population could reach a 
satisfying result. However, it is worth noticing that the selective criteria of risk scoring system are actually risk factors (women presenting ≥1 or ≥ 2 risk 
factors were deemed as high risk women).  
  
 
(3) Data extraction result for Coustan et al. (1989)  
1. Study details 
Study ID: 05 
First author surname: Coustan 
Year of publication: 1989 
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Country and city: USA, Rhode Island 
Study design: Prospective cohort study 
Study setting: Four large obstetric practices in the region, and the obstetric clinic service 
Number of centres: 5 
Inclusion and exclusion criteria: Pregnant women (details not available) 
Time of study: Between July 1 1984 to December 30 1986 
Funding: Supported in part by the Centres for Disease Control (Atlanta, Georgia), the Rhode Island Department of Health, and the National Institutes of 
Health 
2. Aim of the study 
 This study aims to evaluate the sensitivity and cost-effectiveness of various screening schemes. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 6214 
Number of participants consented/included 6106 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
5379 (108 women’s questionnaires of risk factors were not available) 
Characteristics of participants 
Mean age (years) N/A (27%≥30 years old)  
Mean BMI (kg/m
2
) N/A 
Ethnicity 87.9% white, 8.1% black, 1.2% Asian, 0.5% Indian, 0.1% Chinese, 2.0% 
unkown 
Participants with a family history of diabetes among first-degree relatives N/A 
4. Selection criteria for high-risk women 
Reference of criteria The American College of Obstetricians and Gynecologists (ACOG) 
Type of criteria Risk factor ≥1 
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Number of risk factors used 6 
Maternal age Yes (≥30) 
Obesity Yes (weight ≥85th percentile for height) 
Family history of diabetes among first-degree relatives Yes (among first- or second-degree relatives) 
Personal history of GDM Yes 
A prior macrosomic infant Yes (≥ 9 lb) 
History of adverse obstetric outcome Yes (previous stillborn, neonatal death, or preterm delivery) 
Member of an ethnic or racial group with a high prevalence of GDM   None 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  6106 6106 (same cohort) 
Selection   
Number of high risk women   2680 
Number of low risk women  3426 
Screening   
Number of women undertook screening 6106 2680 
Time of screening 24-28 weeks of gestation Same as universal group 
Screening test 50g GCT: ≥130 mg/dl at 1 hour Same as universal group 
Screening criteria reference N/A Same as universal group 
Number of women screened positive (%) N/A Same as universal group 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis N/A Same as universal group 
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Diagnosis test 100g OGTT Same as universal group 
Diagnosis criteria reference The ACOG and the National Diabetes Data Group Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
125/6106 (2.0%) 81/6106 (1.1%) 
Sensitivity 100% (reference) 64.8%=81/125 
Specificity 0% (reference) 56.5%=(3426-44)/(6106-125) 
5.3 Other information 
None. 
6. Authors conclusion 
If the ACOG recommendation of selective screening was used, 35% GDM women would be missed, with little cost savings. 
7. Reviewer’s conclusion 
The sensitivity of 65% (35% GDM would be missed) was estimated from the general population of pregnant women, not calculated from the GDM 
population. The figure of 108 (1.8%) women whose risk factors were not available was very small to affect the accuracy of study results of specificity and 
sensitivity. 
 
 
 
(4) Data extraction result for Danilenko-Dixon et al. (1999)  
1. Study details 
Study ID: 06 
First author surname: Danilenko-Dixon  
Year of publication: 1999 
Country and city: USA, Rochester 
Study design: Retrospective cohort study 
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Study setting: Mayo Clinic in Rochester 
Number of centres: 1 
Inclusion and exclusion criteria: All women receiving obstetric care at the Mayo Clinic (Rochester, Minnesota) 
Time of study: Between 1 January 1986 to 31 December 1997 
Funding: Information not available 
2. Aim of the study 
 This study aims to evaluate the impact of the 1997 American Diabetes Association selective screening guidelines for GDM applied to a universally 
screened population. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 18834 
Number of participants consented/included 18504 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
18174 (330 women had one or more of the risk factors data according to the 
ADA low-risk criteria missed) 
Characteristics of participants 
Mean age (years) 28.8±5.3 (82.2%≥ 30 years old; 51.2%≥ 25 years old)  
Mean BMI (kg/m
2
) 24.3±5.1 (33%≥ 25; 22%≥ 27) 
Ethnicity 92.6% white, 0.7% African American, 4.9% Asian, 1.7% Hispanic, 0.1% Other 
Participants with a family history of diabetes among first-degree relatives  7.7% 
4. Selection criteria for high-risk women 
Reference of criteria 1997 American Diabetes Association GDM screening guidelines (same with 
the Fourth International Workshop-Conference on GDM) 
Type of criteria Risk factor ≥1 
Number of risk factors used 4 
Maternal age Yes (≥25) 
Obesity Yes (BMI ≥27) 
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Family history of diabetes among first-degree relatives Yes (among first degree relatives) 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  18504 18504 (same cohort) 
Selection   
Number of high risk women   16672 
Number of low risk women  1832 
Screening   
Number of women undertook screening 18504 16672 
Time of screening 24-30 weeks of gestation Same as universal group 
Screening test 50g GCT: ≥140 mg/dl at 1 hour Same as universal group 
Screening criteria reference N/A Same as universal group 
Number of women screened positive (%) 3683 (20%) N/A 
Diagnosis   
Number of women undertook diagnosis 3683 N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT(two or more values above 
thresholds): fasting 5.9 mmol/l (105 mg/dl), 1-
hour 10.6 mmol/l (190 mg/dl), 2-hour 9.2 mmol/l 
(165 mg/dl) and 3-hour 8.1 mmol/l (145 mg/dl) 
Same as universal group 
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Diagnosis criteria reference National Diabetes Data Group criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
564/18504 (3.0%) 547/18504 (3.0%) 
Sensitivity 100% (reference) 97%=547/564 
Specificity 0% (reference) 10.1%=(1832-17)/(18504-564) 
5.3 Other information 
Screening only women≥ 25 years old would have detected 90.4% of GDM cases, whereas the addition of the remaining 3 screening criteria combined 
would have detected only an additional 6.6% of cases. Screening only women≥ 25 years old would have exempted 17.8% women. Screening only women≥ 
30 years old alone would have detected 65.8% of GDM cases, and exempted 48.8% women. 
6. Authors conclusion 
The 1997 American Diabetes Association selective screening guidelines would miss relatively small proportion (3%) of GDM women in our population. 
However, implementation of these guidelines would decrease the number of screens by only 10% while adding significant complexity to the screening 
process. 
7. Reviewer’s conclusion 
This is a well reported study. The study additionally analysed the significance of each of the four risk factors for predicting GDM, and found age is the most 
significant risk factor for GDM in their population. The cut-off value of 25 years old is more appropriate than 30 years old as age criteria in their 
population.  
 
 
(5) Data extraction result for Di Cianni et al. (2003)  
1. Study details 
Study ID: 07 
First author surname: Di Cianni 
Year of publication: 2003 
Country and city: Italy, Pisa 
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Study design: Retrospective cohort study 
Study setting: Diabetes Section of the Department of Endocrinology and Metabolism of the University of Pisa 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women consecutively referred to the Diabetes Section of the Department of Endocrinology and Metabolism of 
the University of Pisa 
Time of study: Between 1 June 1995 to 31 December 2001 
Funding: Information not available 
2. Aim of the study 
 This study aims to evaluate the GDM prevalence and the presence of risk factors for GDM, as well as to compare universal versus selective screening to 
validate the ADA’s recommendations in their population. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 3950 
Number of participants consented/included 3806 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
3662 (144 women with GCT positive didn’t go for OGTT test) 
Characteristics of participants 
Mean age (years) 31.1±4.7 (15-50)  
Mean BMI (kg/m
2
) 22.5±3.7 (15.6-48.8) 
Ethnicity Caucasian 
Participants with a family history of diabetes among first-degree relatives  18.1% 
4. Selection criteria for high-risk women 
Reference of criteria 2002 American Diabetes Association (ADA) GDM screening guidelines  
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age Yes (≥25) 
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Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  3950 3950 (same cohort) 
Selection   
Number of high risk women  3714 
Number of low risk women  236 
Screening   
Number of women undertook screening 3950 3714 
Time of screening 24-28 weeks of gestation (the obstetrician could 
request the GCT at 14-18 weeks for women at 
risk, and if the GCT is negative, it will be further 
performed at 24-28 weeks) 
Same as universal group 
Screening test 50g GCT: ≥7.8 mmol/l at 1 hour Same as universal group 
Screening criteria reference Recommendations of the Regional Public Health 
Authority, and the Fourth International Workshop 
Conference on GDM 
Same as universal group 
Number of women screened positive (%) 1389 (35.2%) 1355 
Diagnosis   
Number of women undertook diagnosis 1221 (Among the 1389 GCT+ women, 24 were 
diagnosed as GDM directly, 144 dropped out) 
1355 
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Time of diagnosis One week after 50g GCT Same as universal group 
Diagnosis test 50g GCT ≥11 mmol/l allowed a direct diagnosis 
of GDM 
100g OGTT(two or more values above 
thresholds): fasting 5.9 mmol/l (105 mg/dl), 1-
hour 10.6 mmol/l (190 mg/dl), 2-hour 9.2 mmol/l 
(165 mg/dl) and 3-hour 8.1 mmol/l (145 mg/dl) 
Same as universal group 
Diagnosis criteria reference Carpenter and Coustan’s criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
308/3806 (8.1%) 303/3806(8.0%) 
Sensitivity 100% (reference) 98.4%=303/308 
Specificity 0% (reference) 6.6%=(236-5)/(3806-308) 
 
5.3 Other information 
None. 
6. Authors conclusion 
At present, universal screening remains a good instrument to identify women with GDM at least in Italian with a large percentage of women at 
medium/high risk for GDM. 
7. Reviewer’s conclusion 
This is a well reported study. The study additionally performed OGTT among 391 randomly selected GCT negative women, and diagnosed 25 more GDM 
women. However, to keep GDM prevalence calculation consistent, these 25 GDM women were excluded for the calculation of GDM prevalence (Only the 
308 GDM women who were diagnosed under the normal procedure of GCT positive followed by OGTT were calculated).  
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(6) Data extraction result for Hadaegh et al. (2005)  
1. Study details 
Study ID: 09 
First author surname: Hadaegh 
Year of publication: 2005 
Country and city: Iran, Bandar Abbas 
Study design: Prospective cohort study 
Study setting: Obstetrics clinics in various parts of Bandar Abbas city in southern Iran 
Number of centres: many 
Inclusion and exclusion criteria: Pregnant women consecutively referred to the obstetrics clinics were included. Women with any of the following 
characteristics were excluded from the study: (1) previous history of diabetes; (2) use of drugs that affect glucose metabolism, such as corticosteroids; (3) 
diagnosis of chronic liver disease, endocrine disorders (such as hyperthyroidism), or connective tissue disorders; and (4) presence of major medical 
conditions, such as persistent hypertension. 
Time of study: Between March 2002 to March 2004  
Funding: Information not available 
2. Aim of the study 
 This study aims to estimate and report the prevalence of GDM in pregnant women of Bandar Abbas, a city in southern Iran. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 800 
Number of participants consented/included 700 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
600 (100 women who had GCT positive results did not undergo the 3-hour 
OGTT mainly because of personal reasons. No significant differences were 
found in age, BMI, or blood pressure between those pregnant women who 
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underwent the OGTT and those who did not) 
Characteristics of participants 
Mean age (years) 24.9±5.3  
Mean BMI (kg/m
2
) BMI≥25 kg: 48.9% in normal women and 67.7% in GDM women 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  9.2% in normal women and 12.9% in GDM women 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age Yes (≥25) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  800 800 (same cohort) 
Selection   
Number of high risk women  552 
Number of low risk women  248 
Screening   
Number of women undertook screening 800 552 
Time of screening 24-28 weeks of gestation  Same as universal group 
214 
 
Screening test 50g GCT: ≥130 mg/dl at 1 hour Same as universal group 
Screening criteria reference N/A Same as universal group 
Number of women screened positive (%) 221/700 (31.6%) 157 
Diagnosis   
Number of women undertook diagnosis 221 157 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT(two or more values above 
thresholds): fasting 95 mg/dl, 1-hour 180 mg/dl, 
2-hour 155 mg/dl and 3-hour 140 mg/dl 
Same as universal group 
Diagnosis criteria reference Carpenter and Coustan’s criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
62/700 (8.9%) 55/700 (7.9%) 
Sensitivity 100% (reference) 88.7%=55/62 
Specificity 0% (reference) 32.7%=(248-7)/(800-62) 
5.3 Other information 
Of the 800 participants, 100 women who had a positive GCT results did not undergo OGTT, which could lead to underestimation of GDM prevalence. To 
avoid this, the predicted prevalence of GDM in these women was calculated, and the overall GDM prevalence was estimated to be 11.4% (91 of 800) under 
the Carpenter and Coustan’s criteria of GDM diagnosis. 
6. Authors conclusion 
Screening for GDM in all pregnant women in Bandar Abbas seems necessary, regardless of the presence of risk factors for GDM. 
7. Reviewer’s conclusion 
This is a well reported study. The study analysed the GDM prevalence using the National Diabetes Data Group and the Carpenter and Coustan criteria, 
respectively. However, as the sensitivity was calculated using the Carpenter and Coustan criteria, only data under the Carpenter and Coustan criteria were 
extracted. 
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(7) Data extraction result for Helton et al. (1997)  
1. Study details 
Study ID: 10 
First author surname: Helton 
Year of publication: 1997 
Country and city: USA, Chapel Hill 
Study design: Retrospective cohort study 
Study setting: A university-based family practice centre 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women who received prenatal care and gave birth at the centre during the study period, and had no personal 
history of diabetes. 
Time of study: Between January 1988 to December 1993  
Funding: The study was supported by a University of North Carolina Department of Family Medicine Faculty Research Development Grant. 
2. Aim of the study 
This study aims to reassess the value of universal screening of all pregnant patients with a 50g GCT. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 595 
Number of participants consented/included 526 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
457 (Among these excluded 69 women, 51 were either not screened by the 
GCT test or had no record of a screening result, and 18 were those who had a 
GCT positive results but did not undergo OGTT) 
Characteristics of participants 
Mean age (years) 27 (15-46) 
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Mean BMI (kg/m
2
) N/A 
Ethnicity 60% non-Hispanic white, 35% black, 5% other races 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 6 
Maternal age Yes (≥35) 
Obesity Yes (weight ≥200lb) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome Yes 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  595 595 (same cohort) 
Selection   
Number of high risk women  189 
Number of low risk women  406 
Screening   
Number of women undertook screening 544 189 
Time of screening 24-28 weeks of gestation  Same as universal group 
Screening test 50g GCT: ≥140 mg/dl at 1 hour Same as universal group 
Screening criteria reference The American College of Obstetricians and 
Gynecologists (ACOG) criteria 
Same as universal group 
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Number of women screened positive (%) 76/544 (12.8%) N/A 
Diagnosis   
Number of women undertook diagnosis 58 (18 GCT positive women did not undergo 
OGTT) 
N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT(two or more values above 
thresholds): fasting 105 mg/dl, 1-hour 190 mg/dl, 
2-hour 165 mg/dl and 3-hour 145 mg/dl 
Same as universal group 
Diagnosis criteria reference National Diabetes Data Group (NDDG) criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
13/595 (2.2%) 9/595 (1.5%) 
Sensitivity 100% (reference) 69.2%=9/13 
Specificity 0% (reference) 69.1%=(406-4)/(595-13) 
5.3 Other information 
None. 
6. Authors conclusion 
Screening only those women at risk for GDM is a reasonable approach to identify the disease in a low-risk population. 
7. Reviewer’s conclusion 
The specificity of 69.1% which could exempt 69.1% non-GDM women from screening was outstanding. Although 30.8% GDM women would be missed 
by selective screening, however, the absolute value of missing 4 GDM women of 595 pregnant women is small in this low risk population (GDM 
prevalence was 2.2%). It is considered rational that the author concluded selective screening was a preferable alternative to universal screening in low risk 
population. 
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(8) Data extraction result for Jimenez-Moleon et al. (2002)  
1. Study details 
Study ID: 12 
First author surname: Jimenez-Moleon 
Year of publication: 2002 
Country and city: Spain, Granada 
Study design: Retrospective cohort study 
Study setting: San Cecilio University Hospital of Granada (SCUH) 
Number of centres: 1 
Inclusion and exclusion criteria: Criteria for inclusion in the study were: (a) having regular residence and medical attention within the area of referral of 
the SCUH, (b) having a singleton pregnancy, (c) making a first visit to the doctor before week 28 of gestation and (d) gestational age at delivery ≥28 weeks. 
The exclusion criteria were: primary diabetes (type 1 or type 2) or carbohydrate intolerance diagnosed before gestation, a pregnancy not under medical 
control and pregnancies and deliveries involving a high obstetric risk which, under other circumstances, would not have been attended to in the SCUH. 
Time of study: Between 1 January and 31 December 1995 
Funding: The study was supported was supported in part by the Fondo de Investigaciones Sanitarias (Fund for Health Research in Spain). 
2. Aim of the study 
This study aims to determine the prevalence of GDM and its variations depending on the presence of risk factors, and to evaluate how the GDM screening 
strategies applied might modify the observed prevalence in the population. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 2574 
Number of participants consented/included 1962 (76.2%) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1350 (for the other 612 women, screening was definitely not done in 425 and 
was not known in 187 women) 
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Characteristics of participants 
Mean age (years) 80.3%≥ 25 years, 41.8%≥ 30 years 
Mean BMI (kg/m
2
) 12.3%≥27 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  14.8% 
4. Selection criteria for high-risk women 
Reference of criteria The American Diabetes Association (ADA) criteria and the American College 
of Obstetrics and Gynecologists (ACOG) criteria, respectively (The only 
different between the two criteria is the age threshold). 
Type of criteria Risk factor ≥1 
Number of risk factors used 10 
Maternal age Yes (≥25 for ADA criteria and ≥30 for ACOG criteria) 
Obesity Yes (BMI ≥27) 
Family history of diabetes among first-degree relatives Yes  
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome Yes (two or more miscarriages, perinatal mortality or congenital 
malformations) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Chronic hypertension 
 Polyhydramnios 
 Hpertension induced by the pregnancy 
 Suspected large fetus for gestational age 
5.1 Comparison of universal versus selective screening (under ACOG criteria for selecting high risk women) 
 Universal screening Selective screening 
Number of participants  2574 2574 (same cohort) 
Selection   
Number of high risk women  1436 
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Number of low risk women  1138 
Screening   
Number of women undertook screening 1962 1162 
Time of screening 24-28 weeks of gestation  For women with risk factors, performed at the first 
medical visit during pregnancy, and if negative then 
repeated after week 24 of gestation 
Screening test 50g GCT: ≥7.8 mmol/l at 1 hour Same as universal group 
Screening criteria reference N/A Same as universal group 
Number of women screened positive (%) 294/1962 (15.0%) N/A 
Diagnosis   
Number of women undertook diagnosis 259 (80% of 294 women with GCT+ underwent 
OGTT) 
N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 5.8 mmol/l, 1-hour 
10.6mmol/l, 2-hour 9.2mmol/l and 3-hour 
8.1mmol/l 
Same as universal group 
Diagnosis criteria reference The National Diabetes Data Group critieria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
65/2574 (2.5%) 58/2574 (2.3%) 
Sensitivity 100% (reference) 89.2%=58/65 
Specificity 0% (reference) 45.1%=(1138-7)/(2574-65) 
5.2 Comparison of universal versus selective screening (under ADA criteria for selecting high risk women) 
 Universal screening Selective screening 
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Number of participants  2574 2574 (same cohort) 
Selection   
Number of high risk women  2174 
Number of low risk women  400 
Screening   
Number of women undertook screening 1962 1704 
Time of screening 24-28 weeks of gestation  For women with risk factors, performed at the first 
medical visit during pregnancy, and if negative then 
repeated after week 24 of gestation 
Screening test 50g GCT: ≥7.8 mmol/l at 1 hour Same as universal group 
Screening criteria reference N/A Same as universal group 
Number of women screened positive (%) 294/1962 (15.0%) N/A 
Diagnosis   
Number of women undertook diagnosis 259 (80% of 294 women with GCT+ underwent 
OGTT) 
N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT(two or more values above 
thresholds): fasting 5.8 mmol/l, 1-hour 
10.6mmol/l, 2-hour 9.2mmol/l and 3-hour 
8.1mmol/l 
Same as universal group 
Diagnosis criteria reference The National Diabetes Data Group critieria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
65/2574 (2.5%) 63/2574 (2.4%) 
Sensitivity 100% (reference) 96.9%=63/65 
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Specificity 0% (reference) 15.9%=(400-2)/(2574-65) 
5.3 Other information 
None. 
6. Authors conclusion 
Selective GDM screening under ADA criteria did not have any apparent benefits. Selective screening is desirable only when fairly restrictive criteria are 
applied in defining the gravidae at risk and, therefore, a significant proportion of the population is exempt from screening. 
7. Reviewer’s conclusion 
The study evaluated the specificity and selectivity of the selective screening using the ADA criteria (age cut-off 25 years or over) and the ACOG criteria 
(age cut-off 30 years or older) respectively. The only difference of the two selection criteria is the age cut-off. As a result, the specificity (45.1% and 15.9%, 
respectively) and the selectivity (89.2% and 96.9%, respectively) changed considerably. 
 
 
(9) Data extraction result for Lavin (1985)  
1. Study details 
Study ID: 13 
First author surname: Lavin 
Year of publication: 1985 
Country and city: USA, Akron (Ohio) 
Study design: Prospective cohort study 
Study setting: the prenatal clinic of the University of Cincinnati Medical Center 
Number of centres: 1 
Inclusion and exclusion criteria: Women who were not known to be diabetic before the onset of pregnancy during a 25-month period 
Time of study: Information not available 
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Funding: Information not available 
2. Aim of the study 
This study aims to evaluate whether screening only the high-risk women is appropriate and to determine if universal screening for abnormal carbohydrate 
metabolism in pregnancy could be feasibly implemented in a busy, working prenatal clinic. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 2077 
Number of participants consented/included 2077 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
2077 
Characteristics of participants 
Mean age (years) N/A 
Mean BMI (kg/m
2
) N/A 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 9 
Maternal age No 
Obesity Yes 
Family history of diabetes among first-degree relatives Yes (A family member with diabetes) 
Personal history of GDM Yes 
A prior macrosomic infant Yes (>4000g) 
History of adverse obstetric outcome Yes (previous delivery of an unexplained stillborn infant, previous  
delivery of an infant with significant congenital malformations, a history of 
recurrent abortion) 
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Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Monilial vaginitis 
Glucosuria 
Polyhydramnios 
An infant suspected of being large for gestational age 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  2077 2077 (same cohort) 
Selection   
Number of high risk women  959 
Number of low risk women  1118 
Screening   
Number of women undertook screening 2077 959 
Time of screening 28-32 weeks of gestation for non-risk women; at 
the initial visit and again at 28 weeks of gestation 
for the at-risk women 
At the initial visit and again at 28 weeks of gestation 
Screening test 50g GCT: ≥150 mg/dl at 1 hour Same as universal group 
Screening criteria reference O'Sullivan et al., and the American Diabetes 
Association Workshop-Conference on Gestational 
Diabetes 
Same as universal group 
Number of women screened positive (%) 137 (6.6%) 69 (7.2%) 
Diagnosis   
Number of women undertook diagnosis 137 69 
Time of diagnosis N/A N/A 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 105 mg/dl, 1-hour 190 mg/dl, 
Same as universal group 
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2-hour 165 mg/dl and 3-hour 145 mg/dl) 
Diagnosis criteria reference O'Sullivan et al., and the American Diabetes 
Association Workshop-Conference on Gestational 
Diabetes 
Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
30/2077 (1.4%) 14/2077 (0.7%) 
Sensitivity 100% (reference) 46.7%=14/30 
Specificity 0% (reference) 53.8%=(1118-16)/(2077-30) 
5.3 Other information 
The results of the study have been reported previously (Lavin et al., 1982), and were summarised in this article. The previous article (Lavin et al., 1982) 
was not accessible, thus could not identify any possible information about the time of study and the characteristics of participants, which might be available 
in that article. 
6. Authors conclusion 
The study results reemphasize the inadequacy of screening only those patients with traditional risk factors for GDM and demonstrate the feasibility of 
implementing a program of universal glucose screening among a large obstetric population. 
7. Reviewer’s conclusion 
The author divided the cohort into risk women and non-risk women. However, it was still a one-cohort study. If screening high-risk women only, it could 
exempt 53.8% non-GDM women from screening, but would miss more than half (53.3%) of the GDM cases. It is rationale for the author to conclude that 
screening only high-risk women for GDM in their population was inadequate.  
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(10) Data extraction result for Naylor et al. (1997)  
1. Study details 
Study ID: 17 
First author surname: Naylor 
Year of publication: 1997 
Country and city: Canada, Toronto 
Study design: Retrospective cohort study 
Study setting: Three teaching hospitals in Toronto 
Number of centres: 3 
Inclusion and exclusion criteria: All consenting pregnant women without known diabetes mellitus, 24 years of age or older, presenting before 24 weeks’ 
gestation, had singleton deliveries, had both the screening and diagnosis tests, and had complete data during the study period were included. Women who 
delivered before 28 weeks’ gestational were excluded. 
Time of study: Between September 1989 to March 1992 
Funding: The study was supported by an operating grant (02650) from the Ontario Ministry of Health 
2. Aim of the study 
This study aims to test the hypothesis that the efficiency of screening could be enhanced by considering women’s risks of GDM on the basis of their clinical 
characteristics. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 3152  
Number of participants consented/included 3131 (99.3%) (divided into two groups: 1560 as derivation group and 1571 was 
validation group) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
3110 (The other 21 either did not have singleton deliveries or data were 
insufficiently complete for analysis) 
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Characteristics of participants 
Mean age (years) 51.3% ≥ 30 (for the derivation group) 
Mean BMI (kg/m
2
) 47.2% ≥ 22 (for the derivation group) 
Ethnicity 81.5% White, 5.3% Black, 9.0% Asian, 4.3% others 
Participants with a family history of diabetes among first-degree relatives  14.5% 
4. Selection criteria for high-risk women 
Reference of criteria A risk score system derived from their derivation group (1560 women) using 
the rounded odds ratios of the risk factors  
Type of criteria A risk score system (women with scores of 0 to 1 were not screened but the 
reminder were all screened) 
Number of risk factors used 3 
Maternal age Yes (scored 0 if age ≤30; scored 1 if age within 31-34; scored 2 if age ≥35) 
Obesity Yes (scored 0 if BMI ≤22; scored 2 if BMI within 22.1-25.0; scored 3 if BMI 
≥25.1) 
Family history of diabetes among first-degree relatives No 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes (scored 0 if black; scored 5 if Asian; scored 2 if others) 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1560 (derivation group) 1560 (same cohort) 
Selection   
Number of high risk women  1016 
Number of low risk women  544 
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Screening   
Number of women undertook screening 1560 1016 
Time of screening 26 weeks’ gestation (±1 week) Same as universal group 
Screening test 50g GCT: ≥ 140 mg/dl for women scored 2-3; ≥ 
128 mg/dl for women scored ＞3 at 1 hour 
Same as universal group 
Screening criteria reference N/A  N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis 28 weeks’ gestation (±1 week) Same as universal group 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 5.8 mmol/l (105 mg/dl), 1-
hour 10.5 mmol/l (190 mg/dl), 2-hour 9.2 mmol/l 
(165 mg/dl) and 3-hour 8.0 mmol/l (145 mg/dl) 
Same as universal group 
Diagnosis criteria reference N/A Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
32/1560 (2.1%) 29/1560 (1.9%) 
Sensitivity 100% (reference) 90.6%=29/32 
Specificity 0% (reference) 35.4%=(544-3)/(1560-32) 
5.3 Other information 
For the derivation group, apart from the 50g GCT thresholds extracted as above, the author also examined the efficacy of selective screening using different 
50g GCT thresholds, namely, test threshold of 140 mg/dl for scores 2–3, 130 mg/dl for scores ＞3). The GDM diagnosed would be 27  
Funding: Information not available 
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6. Authors conclusion 
Consideration of women’s clinical characteristics allows efficient selective screening for GDM. 
7. Reviewer’s conclusion 
The specificity was not directly reported from the study, but calculated by the reviewer from the data of the derivation group (32 GDM cases detected in the 
universal screening group of usual care, and 29 cases detected in the selective screening group using 140 mg/dl threshold for women scored 2-3 and 
128mg/dl threshold for women scored >3). Because of this reason, the reviewer only extracted the data from the derivation group (1560 women) where 
specificity could be calculated, data from the validation group (1571) were not extracted. This study was the first study which used a risk score system 
rather than presence/absence of risk factors for selective screening of GDM. This study also showed that the sensitivity of selective screening could change 
according to the different thresholds of the 50g GCT screening test.  
 
 
(11) Data extraction result for Sacks et al. (1987)  
1. Study details 
Study ID: 18 
First author surname: Sacks 
Year of publication: 1987 
Country and city: USA, California 
Study design: Prospective cohort study 
Study setting: Kaiser Foundation Hospital, Bellflower, California 
Number of centres: 1 
Inclusion and exclusion criteria: All pregnant women who delivered at the study period, had at least one glucose screening test during pregnancy, and had 
the presence or absence of risk factors ascertained. 
Time of study: Between July 1, 1984 and June 30, 1985 
2. Aim of the study 
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This study aims to test the hypothesis that the efficiency of screening could be enhanced by considering women’s risks of GDM on the basis of their clinical 
characteristics. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 4519 
Number of participants consented/included 4116 (91.1%)  
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
3713 (For the other 403 women, 370 didn’t have glucose screening test, 33 
didn’t have the profile of risk factors) 
Characteristics of participants 
Mean age (years) 26.4 
Mean BMI (kg/m
2
) N/A 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 5 (previous pregnancies complicated by congenital malformations, stillbirth, or 
neonatal death were group as ‘history of adverse obstetric outcome’) 
Maternal age Yes (≥25) 
Obesity Yes (pre-pregnancy weight ≥150 pounds) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant Yes 
History of adverse obstetric outcome Yes (including previous pregnancies complicated by congenital malformations, 
stillbirth, or neonatal death) 
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Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  4116 4116 (same cohort) 
Selection   
Number of high risk women  3180 
Number of low risk women  936 
Screening   
Number of women undertook screening 4116 4116 (same cohort) 
Time of screening At or beyond 24 weeks of gestation At the time of prenatal registration (initial clinic 
visit) 
Screening test 50g GCT: ≥ 135 mg/dl  Same as universal group 
Screening criteria reference N/A  N/A 
Number of women screened positive (%) 991 874 
Diagnosis   
Number of women undertook diagnosis N/A (11-21% women screened positive didn’t go 
for OGTT) 
N/A 
Time of diagnosis Approximately 18 days after the 50g GCT Same as universal group 
Diagnosis test 75g OGTT (If the fasting plasma glucose ≥ 
120 mg/dL, the test was discontinued. If a 
subsequent fasting plasma glucose ≥105 mg/dL, 
the patient was considered a GDM) 
Same as universal group 
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Diagnosis criteria reference The Second International workshop-Conference 
on Gestational Diabetes, with one modification 
Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
138/4116 (3.4%) 134/4116 (3.3%) 
Sensitivity 100% (reference) 97.1%=134/138 
Specificity 0% (reference) 23.4%=(936-4)/(4116-138) 
5.3 Other information 
For pregnant women with risk factors, the GDM screening test was undertaken in early pregnancy (at the time of prenatal registration). Among patients 
whose early screening values were elevated and whose initial OGTT were normal, the odds of being classified ultimately as a GDM were 7.3 times that of 
patients whose initial screening tests were normal. 
6. Authors conclusion 
Selective screening based on risk factors may enhance detection of diabetes early in gestation, and might be considered in designing a cost-effective 
screening programme for GDM. 
7. Reviewer’s conclusion 
Although the screening test for high risk pregnant women were conducted in early pregnancy (not during 24-28 weeks of gestation), the author had 
examined that screening test undertaken at this time point is effective as well (the figure of 7.3 times in the ‘Other information’). In this study, it is rationale 
that the author concluded selective screening during early pregnancy is a good approach. 
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(12) Data extraction result for Teh et al. (2011)  
1. Study details 
Study ID: 19 
First author surname: Teh 
Year of publication: 2011 
Country and city: Australia, Victoria 
Study design: Retrospective cohort study 
Study setting: A tertiary referral hospital (Monash Medical Centre, Victoria) 
Number of centres: 1 
Inclusion and exclusion criteria: Women of singleton pregnancies (without pre-existing diabetes mellitus) giving birth in 2007 from the Birthing 
Outcomes System. 
Time of study: Year 2007 
Funding: The study was supported by a grant from the Novo Nordisk Regional Diabetes Scheme 
2. Aim of the study 
This study aims to review risk profiles of women with GDM and to evaluate international GDM screening recommendations. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 2880 
Number of participants consented/included 2880 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
2880 
Characteristics of participants 
Mean age (years) 33.3 ± 5.2 (GDM women); 30.3 ± 5.5 (Non-GDM women) 
Mean BMI (kg/m
2
) 28.2 ± 8.3 (GDM women); 25.3 ± 6.4 (Non-GDM women) 
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Ethnicity 56.9% were born overseas, 32.7% were from Asian countries 
Participants with a family history of diabetes among first-degree relatives  39.8%  
4. Selection criteria for high-risk women 
4.1 UK NICE selection criteria 
Reference of criteria UK NICE 
Type of criteria Risk factor ≥1 
Number of risk factors used 5 
Maternal age No 
Obesity Yes (BMI ≥30) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (≥4500g) 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes (family origin with a high prevalence of diabetes including South Asian, 
black Caribbean, Middle Eastern) 
Others None 
4.2 US ADA selection criteria 
Reference of criteria US ADA 
Type of criteria Risk factor ≥1 
Number of risk factors used 6 
Maternal age Yes (≥25) 
Obesity Yes (abnormal body weight) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
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A prior macrosomic infant No 
History of adverse obstetric outcome Yes 
Member of an ethnic or racial group with a high prevalence of GDM   Yes (from a high-risk ethnic ⁄ racial group of diabetes, e.g. Hispanic American, 
Native American, Asian American, African American, Pacific Islander) 
Others History of abnormal glucose metabolism 
4.3 Australian ADIPS selection criteria 
Reference of criteria Australian ADIPS (universal screening is recommended, the selective 
screening criteria is for resource limited settings) 
Type of criteria N/A 
Number of risk factors used 7 
Maternal age Yes (≥30) 
Obesity Yes  
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes (Past history of GDM or glucose intolerance) 
A prior macrosomic infant No 
History of adverse obstetric outcome Yes  
Member of an ethnic or racial group with a high prevalence of GDM   Yes (Belonging to high-risk ethnic group, e.g. Australian Indigenous, 
Polynesian, South Asian ⁄ Indian) 
Others Glycosuria 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  2880 2880 (same cohort) 
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Selection   
Number of high risk women  1695/2880 (NICE criteria); 2340/2880 (ADA 
criteria); 2121/2880 (ADIPS criteria) 
Number of low risk women  1185/2880 (NICE criteria); 540/2880 (ADA 
criteria); 759/2880 (ADIPS criteria) 
Screening   
Number of women undertook screening 2880 2880 (same cohort) 
Time of screening 26-28 weeks of gestation 26-28 weeks of gestation 
Screening test 75g GCT: ≥ 8.0 mmol/l at 1 hour Same as universal group 
Screening criteria reference The guidelines of the Australian Diabetes in 
Pregnancy Society 
Same as universal group 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis N/A N/A 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting 5.5 mmol/l, 2-hour 8.0 mmol/l 
Same as universal group 
Diagnosis criteria reference The guidelines of the Australian Diabetes in 
Pregnancy Society 
Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
250/2880 (8.7%) 232/2880 (8.1%) (NICE criteria); 250/2880 (8.7%) 
(ADA criteria); 247/2880 (8.6%) (ADIPS criteria) 
Sensitivity 100% (reference) 92.7%=232/250 (NICE criteria); 100%=250/250 
(ADA criteria); 98.6%=247/250 (ADIPS criteria) 
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Specificity 0% (reference) 44.4%=(1185-18)/(2880-250)=(NICE criteria); 
2.1%(540-0)/(2880-250)(ADA criteria); 
28.7%=(759-3)/(2880-250)=(ADIPS criteria) 
5.3 Other information 
None. 
6. Authors conclusion 
Current selective screening guidelines have high sensitivity but low specificity and offer little over universal screening. 
7. Reviewer’s conclusion 
The advantage of the study is that the author examined three different selective screening criteria, the UK NICE criteria, the US ADA criteria, and the 
Australian ADIPS criteria, respectively. All the three selective screening approach gave low specificity and high sensitivity (except the NICE criteria had 
lower sensitivity of 92.7% but still high). The three specificities reported in this table were based on the definition of specificity in the review, and were 
slightly different from the specificities reported by the author. 
 
 
(13) Data extraction result for Van Leeuwen et al. (2010)  
1. Study details 
Study ID: 20 
First author surname: Van Leeuwen 
Year of publication: 2010 
Country and city: Netherlands, Utrecht 
Study design: Prospective cohort study 
Study setting: University Medical Centre in Utrecht in the Netherlands  
Number of centres: 1 
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Inclusion and exclusion criteria: All women with a singleton pregnancy who reported for prenatal care during a period of 2 years were invited to 
participate in this study. Women with known pre-gestational diabetes mellitus and women who were first seen after 20 weeks of gestation were excluded 
from the study. 
Time of study: N/A 
Funding: The study was supported by a grant from Novo Nordisk, Alphen aan den Rijn, the Netherlands and by grant 917.46.346 in the VIDI-program of 
ZonMW, The Hague, the Netherlands. 
2. Aim of the study 
This study aims to develop a clinical prediction rule that can help the clinician to identify women at high/low risk for GDM early in pregnancy in order to 
improve the efficiency of GDM screening. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 995 
Number of participants consented/included 995 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
995 
Characteristics of participants 
Mean age (years) N/A 
Mean BMI (kg/m
2
) N/A 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria Their own clinical prediction model 
Type of criteria Risk factor ≥1 
Number of risk factors used 4 
Maternal age No 
Obesity Yes (linear relationship between 22-30) 
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Family history of diabetes among first-degree relatives Yes (among first- and second-degree relatives) 
Personal history of GDM Yes 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  995 995 (same cohort) 
Selection   
Number of high risk women  428 
Number of low risk women  567 
Screening   
Number of women undertook screening 995 995 (same cohort) 
Time of screening 24-28 weeks of gestation Same as universal group 
Screening test Random plasma glucose and 50g GCT: screened 
positive if random plasma glucose ≥6.8mmol/l or 
50g GCT ≥ 7.8mmol/l at 1 hour 
Same as universal group 
Screening criteria reference N/A  N/A 
Number of women screened positive (%) 114 N/A 
Diagnosis   
Number of women undertook diagnosis 122 (94 women screened positive and 28 women 
who are a subgroup that OGTT was performed 
N/A 
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irrespective of the screening tests) 
Time of diagnosis Within one week of the screening tests Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting 7.0 mmol/l, 2-hour 7.8 mmol/l 
Same as universal group 
Diagnosis criteria reference World Health Organisation criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
46/995 (4.6%) 35/995 (3.5%) 
Sensitivity 100% (reference) 76.1%=35/46 
Specificity 0% (reference) 58.6%=(567-11)/(995-46) 
5.3 Other information 
To estimate the proportion of diseased women who were not identified by the screening tests (false negative fraction), in order to correct for verification 
bias, the study performed OGTT in a subset of 28 women with two negative screening test results. Subsequently, the study used multiple imputation to 
estimate the results of OGTT in all women in whom no OGTT was performed (24 women out of 873 women who screened negative would be diagnosed as 
GDM), based on the results of the two screening tests as well as on patient characteristics. 
6. Authors conclusion 
The use of a clinical prediction model is an accurate method to identify women at increased risk for GDM, and could be used to select women for additional 
testing for GDM. 
7. Reviewer’s conclusion 
The author used a clinical prediction model for selecting high risk women for GDM, which could be more accurate than the use of absence/presence of risk 
factors. The author concluded selective screening by the prediction model could be used, however, the sensitivity of 76% means it could still miss 24% of 
GDM women, the conclusion needs to be more carefully considered.  
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(14) Data extraction result for Williams et al. (1999)  
1. Study details 
Study ID: 21 
First author surname: Williams 
Year of publication: 1999 
Country and city: USA, Ann Arbor (Michigan) 
Study design: Retrospective cohort study 
Study setting: University of Michigan 
Number of centres: 1 
Inclusion and exclusion criteria: All deliveries at the University of Michigan during the study period 
Time of study: Between 1987 and 1997 
Funding: Information not available 
2. Aim of the study 
This study aims to estimate the percentage of pregnant women who would not be screened and the percentage of women with GDM who would possibly 
remain undiagnosed if the American Diabetes Association’s (ADA’s) new selective screening recommendations are used rather than universal screening for 
GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 25118 
Number of participants consented/included 25118 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
25118 
Characteristics of participants 
Mean age (years) N/A 
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Mean BMI (kg/m
2
) N/A 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria The ADA recommendation (1997) 
Type of criteria Risk factor ≥1 
Number of risk factors used 4 
Maternal age Yes (≥25) 
Obesity Yes (BMI≥27, defined by the study) 
Family history of diabetes among first-degree relatives Yes (among first- and second-degree relatives) 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes (Hispanic, Native American, Asian, African-American) 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  25118 25118 (same cohort) 
Selection   
Number of high risk women  N/A 
Number of low risk women  N/A 
Screening   
Number of women undertook screening 25118 25118 (same cohort) 
Time of screening 24-28 weeks of gestation Same as universal group 
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Screening test 50g GCT: ≥140mg/dl at 1 hour Same as universal group 
Screening criteria reference The Second International Workshop-Conference 
on Gestational Diabetes 
Mellitus 
Same as universal group 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis N/A Same as universal group 
Diagnosis test 100g OGTT (two or more values above 
thresholds): fasting 105 mg/dl, 1-hour 190 mg/dl, 
2-hour 165 mg/dl, 3-hour 145 mg/dl 
Same as universal group 
Diagnosis criteria reference National Diabetes Data Group criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
200/25118 (0.8%) 192/25118 (0.8%) 
Sensitivity 100% (reference) 96.0%=192/200 
Specificity 0% (reference) 11.1% (estimated from a random sample of 171 
women) 
5.3 Other information 
The author explained why the incidence of GDM in the study appeared low—that’s because the population of women with GDM that they studied and the 
population delivering at the University of Michigan were not identical. Many women who delivered at their institution received care, including testing for 
GDM, at off-site clinics, and records from those clinics were not available for review. 
6. Authors conclusion 
If the new ADA selective screening recommendations are used, few women with GDM will be missed (4%) but approximately 90% of pregnant women 
will still need to be screened for GDM. 
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7. Reviewer’s conclusion 
The author did not conclude directly whether they recommend the ADA selective screening approach or not. The selective screening could only exempt 
11.1% of the women from screening, thus from the reviewer’s view it did not offer much over universal screening. It is also worthwhile to notice that the 
specificity of 11.1% was estimated from a random sample of 171 women, not from the whole cohort of 25118 women   
 
 
(15) Data extraction result for Zoller et al. (1988)  
1. Study details 
Study ID: 22 
First author surname: Zoller 
Year of publication: 1988 
Country and city: USA, Rockford 
Study design: Prospective cohort study 
Study setting: Teaching hospitals 
Number of centres: Information not available 
Inclusion and exclusion criteria: All patients entering the obstetrical clinics at their teaching hospitals during the study period 
Time of study: Between August 1, 1984, and July 30, 1985 
Funding: Information not available 
2. Aim of the study 
This study aims to determine the validity of screening all patients and to determine the cost effectiveness of such a screening program. 
3. Participants 
Number of participants (One cohort of universal screening) 
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Number of participants invited/considered 363 
Number of participants consented/included 363 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
363 
Characteristics of participants 
Mean age (years) 21.3 (13-43) 
Mean BMI (kg/m
2
) N/A 
Ethnicity 59% white and 41% non-white 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women 
Reference of criteria Reference: Gabbe SG (1980). Effects of identifying a high risk population. 
Diabetes Care. 3: 486-8. 
Type of criteria Risk factor ≥1 
Number of risk factors used 8 (10 if ‘history of adverse obstetric outcome’ is deemed as three RFs) 
Maternal age No 
Obesity Yes (weight ≥90.72kg) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome Yes (stillbirth, precious infant with congenital malformation, history of three or 
more spontaneous abortions) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Glucosuria 
 Polyhydramnios 
 Intrauterine growth consistent with large gestational aged infant 
5. Comparison of universal versus selective screening 
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 Universal screening Selective screening 
Number of participants  363 363 (same cohort) 
Selection   
Number of high risk women  140 
Number of low risk women  223 
Screening   
Number of women undertook screening 363 363 (same cohort) 
Time of screening 24-28 weeks of gestation Same as universal group 
Screening test 50g GCT: ≥140mg/dl at 1 hour Same as universal group 
Screening criteria reference N/A N/A 
Number of women screened positive (%) 52 N/A 
Diagnosis   
Number of women undertook diagnosis 52 N/A 
Time of diagnosis At a later time after the screening test Same as universal group 
Diagnosis test 100g OGTT  Same as universal group 
Diagnosis criteria reference O'Sullivan's diagnostic criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
10/363 (2.8%) 4/363 (1.1%) 
Sensitivity 100% (reference) 40%=4/10 
Specificity 0% (reference) 61.5%=(223-6)/(363-10) 
5.3 Other information 
For universal screening, the total cost for screening and follow-up was $5,190.00. The average cost per patient screened was $14.30, and the cost per case of 
GDM diagnosed was $519.00. 
6. Authors conclusion 
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In order to identify GDM, all pregnant patients must be screened. Universal screening was found to be simple and cost effective. 
7. Reviewer’s conclusion 
The sensitivity and specificity of selective screening was calculated by the reviewer from the data, the author did not calculate them directly. It is rationale 
for the author to recommend universal screening from the fact that there was no significant difference between the risk group and non-risk group for the 
number of abnormal OGTTs. The author concluded universal screening was cost-effective, however, it is hard to conclude this only with the average cost 
per patient screened and cost per case of GDM diagnosed for the universal screening approach. 
 
 
 
Appendix 5.2 Study characteristics of the 13 effectiveness studies with a one-step test 
 
(16) Data extraction result for Capula et al. (2013) 
1. Study details 
Study ID: 23 
First author surname: Capula 
Year of publication: 2013 
Country and city: Italy, Catanzaro 
Study design: Retrospective cohort study 
Study setting: the Complex Operative Structure of Endocrinology-Diabetology, Pugliese-Ciaccio Hospital, Catanzaro, Calabria, Italy 
Number of centres: 1 
Inclusion and exclusion criteria: All consecutive pregnant women attending the clinic during the study period were included. Women with pre-existing 
type 1 or type 2 DM, as defined by ADA criteria, with active chronic systemic disease, and with multifetal gestation were excluded. 
Time of study: Between May 2010 and December 2012 
Funding: The study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 
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2. Aim of the study 
This study aims to determine the effectiveness of the recent Italian guidelines, which excludes women <35 years old, without risk factors from GDM 
screening, with respect to the IADPSG criteria. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 2448 
Number of participants consented/included 2448 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
2448 
Characteristics of participants 
Mean age (years) 30.8±3.2 for GDM women; 29.3±3.5 for non-GDM women 
Mean BMI (kg/m
2
) 22.8±1.9 for GDM women; 21.4±2.0 for non-GDM women 
Ethnicity All Caucasian 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women  
Reference of criteria New Italy guidelines for GDM screening (July, 2011) 
Type of criteria Risk factor ≥1 
Number of risk factors used 6 
Maternal age Yes (≥35) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes 
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Others No 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  2448 2448 (same cohort) 
Selection   
Number of high risk women  1910 
Number of low risk women  538 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1910 1910 
Time of diagnosis 24-28 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT 
 
Same as universal group 
Diagnosis criteria reference The IADPSG criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
674/2448 (27.5%) 503/2448 (20.5%) 
Sensitivity 100% (reference) 74.6%=503/674 
Specificity 0% (reference) 20.1%=(538-171)/(2448-674) 
5.3 Other information 
The author assessed the maternal and neonatal outcomes in women <35 years without risk factors, and found among these non-risk women, GDM women 
had significantly more adverse outcomes than non-GDM women in many maternal and neonatal measures.  
The author also compared the maternal and neonatal outcomes between GDM women with and without risk factors. The lack of differences further 
indicated the importance of identifying and treating all pregnants with GDM. 
6. Authors conclusion 
Italian recommendations failed to identify 7.0% of women with GDM, under the IADPSG criteria. The risk for adverse hyperglycaemic-related outcomes is 
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similar in low-risk and high-risk GDM women. It is suggested to limit OGTT to 1 hour, while extending the test to all pregnant women. 
7. Reviewer’s conclusion 
The prevalence of GDM decreased from 27.5% to 20.5% when screening only high-risk women using the IADPSG diagnosis criteria. The sensitivity is 
74.6%, that 25.4% of the GDM women were missed by the selective diagnosis approach. It is rationale for the author to recommend GDM diagnosis among 
all pregnants. The advantage of the study is that the author additionally compared the adverse hyperglycaemic-related outcomes between GDM and non-
GDM in the non-risk group, and between GDM women with and without risk factors. Both results further strengthened the necessity to undertake GDM test 
for all pregnant women.  
 
 
(17) Data extraction result for Chong et al. (2014) 
1. Study details 
Study ID: 24 
First author surname: Chong 
Year of publication: 2014 
Country and city: Singapore, Singapore 
Study design: Prospective cohort study 
Study setting: the KK Women’s and Children’s Hospital (KKH) and National University Hospital (NUH) in Singapore 
Number of centres: 2 
Inclusion and exclusion criteria: Pregnant women 18 years and above, who were in their first trimester were recruited from the two hospitals during the 
study period. Women who were on chemotherapy, psychotropic drugs or those with type 1 diabetes were excluded. 
Time of study: Between June 2009 and September 2010 
Funding: The study is supported by the Translational Clinical Research (TCR) Flagship Program on Developmental Pathways to Metabolic Disease funded 
by the National Research Foundation (NRF). Additional funding is provided by the Singapore Institute for Clinical Sciences – A*STAR. 
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2. Aim of the study 
This study aims to assess GDM screening approaches in Asian ethnic groups in a single multi-ethnic population, especially to compare the performance of a 
high-risk screening approach to universal screening for detecting GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1247  
Number of participants consented/included 1136 (91.1%; the remaining 111 subjects either declined OGTT or missed their 
26–28 weeks clinic visit) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1136 
Characteristics of participants 
Mean age (years) 30.7±5.1 
Mean BMI (kg/m
2
) 22.7±4.4 
Ethnicity 56.7% Chinese, 25.5% Malay and 17.8% Indian 
Participants with a family history of diabetes among first-degree relatives  29.4% 
4. Selection criteria for high-risk women  
Reference of criteria UK NICE guideline 
Type of criteria Risk factor ≥1 
Number of risk factors used 5 
Maternal age No 
Obesity Yes (BMI >30) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (weight ≥4.5kg) 
History of adverse obstetric outcome No 
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Member of an ethnic or racial group with a high prevalence of GDM   Yes (South Asians, black Caribbean, Middle Eastern. South Asian includes 
India, Pakistan and Bangladesh) 
Others No 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1136 1136 (same cohort) 
Selection   
Number of high risk women  496 
Number of low risk women  640 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1136 496 
Time of diagnosis 26-28 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting ≥7.0 mmol/l, 2-hour ≥7.8 mmol/l (blood 
glucose levels were only collected twice to 
minimize subject burden) 
 
Same as universal group 
Diagnosis criteria reference 1999 WHO criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
215/1136 (18.9%) 111/1136 (9.8%) 
Sensitivity 100% (reference) 51.6%=111/215 
Specificity 0% (reference) 58.2%=(640-104)/(1136-215) 
5.3 Other information 
For women of three ethnic groups, 48.4% (104/215) GDM cases would be missed by selective screening. In detail, 66.7% (90/135) Chinese GDM women, 
40.0% (14/35) Malay GDM women, and none Indian GDM women would be missed by the selective approach. None Indian GDM cases were missed 
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because Indian belongs to the high-risk ethnic group and all would be screened by selective approach anyway. 
6. Authors conclusion 
Risk factors failed to detect half the GDM cases in Asian women. The study suggests that universal screening for GDM should be instituted in the 
Singapore population, particularly for Chinese and Indian women. 
7. Reviewer’s conclusion 
The selective screening approach based on GDM risk factors would miss nearly half (48.4%) of the GDM cases. It is rationale for the author to recommend 
universal screening in the Singapore population. The advantage of the study is that it compared the effect of the selective screening approach among the 
three Asian ethnic groups, and assessed the risk factors for GDM in the three groups. 
 
 
 
(18) Data extraction result for Corrado et al. (2014) 
1. Study details 
Study ID: 25 
First author surname: Corrado 
Year of publication: 2014 
Country and city: Italy, Messina 
Study design: Retrospective cohort study 
Study setting: the Clinic of Diabetes and Pregnancy of the University of Messina 
Number of centres: 1 
Inclusion and exclusion criteria: Consecutive pregnant women referred to the clinic during the study period were included. Women with pre-pregnancy 
diabetes were excluded. 
Time of study: Between 1
 
May 2010 and 31 October 2011 
Funding: Information not available 
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2. Aim of the study 
This study aims to compare in the population the universal screening test recommended by the IADPSG panel and the ADA versus the selective screening 
proposed by the UK NICE but modified by the Italian National Institute of Health. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1028 
Number of participants consented/included 1015 (13 were excluded: 12 had no complete information on the RFs or the 
first-trimester FPG values, one had pre-pregnancy diabetes) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1015 
Characteristics of participants 
Mean age (years) 32.0±4.8 for GDM women; 30.5±5.4 for non-GDM women 
Mean BMI (kg/m
2
) 25.7±4.7 for GDM women; 23.7±6.8 for non-GDM women 
Ethnicity All Caucasian 
Participants with a family history of diabetes among first-degree relatives  40.7% for GDM women; 22.1% for non-GDM women 
4. Selection criteria for high-risk women  
Reference of criteria Selective screening proposed by the UK NICE but modified by the Italian 
National Institute of Health 
Type of criteria Risk factor ≥1 
Number of risk factors used 5 
Maternal age Yes (≥35) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (birth weight >4500g) 
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History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others No 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1015 1015 (same cohort) 
Selection   
Number of high risk women  591 
Number of low risk women  424 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1015 591 
Time of diagnosis 24-28 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting ≥92 mg/dl, 1-hour≥180 mg/dl, 2-hour 
≥153 mg/dl 
Same as universal group 
Diagnosis criteria reference IADPSG and ADA recommendation Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
113/1015 (11.3%) 87/1015 (8.6%) 
Sensitivity 100% (reference) 77.0%=87/113 
Specificity 0% (reference) 44.1%=(424-26)/(1015-113) 
5.3 Other information 
The author assessed the associations between GDM and the risk factors used in the Italian Institute of Health guidelines. Except maternal age (≥35), all 
other risk factors were associated with developing GDM. The highest predictive value was confirmed for previous GDM.  
6. Authors conclusion 
More information on the clinical impact of selective screening could be obtained by a strict analysis of treatment, perinatal outcome and follow-up of an 
adequate sample size of ‘‘missed’’ GDM. 
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7. Reviewer’s conclusion 
The study found that selective screening using the risk factors stated in the Italian Institute of Health guidelines would exempt 44.1% women from 
screening, while detect 77% of GDM cases (23% would be missed). Normally it would be concluded that selective screening was not recommended. 
However, the author was very cautious and concluded that only future study of an adequate sample size examining treatment, perinatal outcome and follow-
up of the ‘‘missed’’ GDM may answer the question of selective or universal screening. This ‘pending’ conclusion is rationale.  
 
 
(19) Data extraction result for Cosson et al. (2013)  
1. Study details 
Study ID: 04 
First author surname: Cosson 
Year of publication: 2013 
Country and city: France, Paris 
Study design: Retrospective cohort study 
Study setting: Obstetrics department of university hospital (Jean Verdier Hospital) 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women with no known diabetes and with all risk factors known 
Time of study: Between 2002 and 2010 
Funding: Information not available 
2. Aim of the study 
 This study aims to evaluate a selective screening strategy for GDM based on the presence of risk factors. 
3. Participants 
Number of participants (One cohort of universal screening) 
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Number of participants invited/considered 18775 
Number of participants consented/included 18775 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
87.5% of 18775 women (it is estimated from 2011’s data that nearly 12.5% 
women didn’t undertaking the screening) 
Characteristics of participants 
Mean age (years) 29.7±5.8  
Mean BMI (kg/m
2
) 24.1±4.9 
Ethnicity Multi-ethnicity: Europe (29.1%), North Africa (27.8%) and sub-Saharian 
Africa (20.8%), and Pakistan, India, and Sri Lanka (5.1%). 
Participants with a family history of diabetes among first-degree relatives 20.4% 
4. Selection criteria for high-risk women 
Reference of criteria Expert panel for French guidelines 
Type of criteria Risk factor ≥1 
Number of risk factors used 5 
Maternal age Yes (≥35) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (details N/A) 
History of adverse obstetric outcome None 
Member of an ethnic or racial group with a high prevalence of GDM   None 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  18775 18775 (same cohort) 
Selection   
Number of high risk women   10975 
Number of low risk women  7800 
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Screening   
Number of women undertook screening None (undertook OGTT directly) Same as universal group 
Time of screening None  Same as universal group 
Screening test None  Same as universal group 
Screening criteria reference None Same as universal group 
Number of women screened positive (%) None Same as universal group 
Diagnosis   
Number of women undertook diagnosis 18775 10975 
Time of diagnosis 15 weeks of gestation for high-risk women; 24-28 
weeks of gestation for all women not diagnosed as 
GDM at 15 weeks 
Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting 5.3 mmol/l, 2-hour 7.8 mmol/l 
Same as universal group 
Diagnosis criteria reference The fasting value was based on previous French 
recommendations; the 2-hour value was based on 
WHO criteria. 
Same as universal group 
Number of women diagnosed positive-GDM 
women (%) (GDM prevalence) 
2710/18775(14.4%) 1770/18775 (9.4%) 
Sensitivity 100% (reference) 65.3%=1770/2710 
Specificity 0% (reference) 42.7%=(7800-940)/(18775-2710) 
5.3 Other information 
None. 
6. Authors conclusion 
The selective screening would miss one-third of the women with GDM who, even without risk factors, had more events than women without GDM. This 
study stands against the present selective screening currently proposed in the French guidelines. 
7. Reviewer’s conclusion 
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The estimated 12.5% women who did not undertake OGTT test might affect the accuracy of the study results of GDM prevalence, sensitivity, and 
specificity. Based on a sensitivity of 65.3%, it is rationale for the authors to stand against the selective screening approach. 
 
 
(20) Data extraction result for Jensen et al. (2003)  
 
1. Study details 
Study ID: 11 
First author surname: Jensen 
Year of publication: 2003 
Country and city: Denmark, Copenhagen/ Aarhus/ Odense 
Study design: Prospective cohort study 
Study setting: Four Danish centres: the University Hospitals of Copenhagen (Copenhagen County Hospital and Rigshospitalet), Aarhus, and Odense. 
Number of centres: 4 
Inclusion and exclusion criteria: Pregnant women who consecutively registered during the study period were included. Exclusion criteria were as follows: 
pre-existing diabetes mellitus, age younger than 18 years, delivery or migration before 30 weeks, and first booking later than 30 weeks of gestation, as well 
as women with incomplete data.  
Time of study: Between 1999 to 2000  
Funding: The study was supported by the Faculty of Health Sciences, University of Southern Denmark, the NOVO Foundation, the Danish Diabetes 
Association, Handelsgartner Ove Villiam Buhl Olesen og ægtefælle fru E. Buhl Olesens Mindelegat, Direktør Ib Henriksens fond, Poul og Erna Sehested 
Hansens fond, Fonden til Lægevidenskabens Fremme, the Danish Medical Research Council, and the Grant Committee of the Consultancy, Odense 
University Hospital. 
2. Aim of the study 
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This study aims to evaluate a simple screening model for GDM on the basis of five pre-defined clinical risk indicators. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 5235 
Number of participants consented/included 2292 (For the other 2943 women, 326 did not speak Danish, 377 could not be 
contacted despite repeated efforts, and 2240 declined to undergo testing) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
2292 
Characteristics of participants 
Mean age (years) 30.0 (27.0-33.4) 
Mean BMI (kg/m
2
) 22.7 (20.7-25.4) 
Ethnicity 81% white, 19% others 
Participants with a family history of diabetes among first-degree relatives  14.3% 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 5 
Maternal age No 
Obesity Yes (BMI ≥27) 
Family history of diabetes among first-degree relatives Yes (among parents, children, grandparents, and siblings) 
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Glucosuria: +2 or greater on a BM-Test Strip (Boehringer Mannheim, 
Germany) (equivalent to 5.6 mmol/L) 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
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Number of participants  2292 2292 (same cohort) 
Selection   
Number of high risk women  1898 
Number of low risk women  3337 
Screening   
Number of women undertook screening No screening test was performed No screening test was performed 
Time of screening N/A N/A 
Screening test N/A N/A 
Screening criteria reference N/A N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis 2292 1468 
Time of diagnosis Performed in women with either previous GDM 
or more than one risk factors, and during 28-32 
weeks of gestation for all women with risk factors 
unless already diagnosed with GDM and also in 
non-risk group 
Same as universal group 
Diagnosis test 75g OGTT(one or more values above thresholds): 
fasting 6.1 mmol/l (111 mg/dl), 2-hour 9.0 mmol/l 
(164 mg/dl) 
Same as universal group 
Diagnosis criteria reference Fasting thresholds referred to the World Health 
Organization criteria for diabetes outside 
pregnancy. 2-hour thresholds referred to the 
Diabetic Pregnancy Study Group of the European 
Association for the Study of Diabetes (DPSG) 
Same as universal group 
Number of women diagnosed positive-GDM 124/5235 (2.4%) 100/5235 (1.9%) 
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women (%) 
Sensitivity 100% (reference) 80.6%=100/124 
Specificity 0% (reference) 64.8%=(3337-24)/(5235-124) 
5.3 Other information 
The prevalence of GDM and the sensitivity were calculated based on the diagnosed GDM cases plus the expected GDM cases from the 2943 (56%) women 
who did not undergo OGTT. 
6. Authors conclusion 
Under ideal conditions, sensitivity of the selective screening model was comparable with universal screening. The model could avoid two thirds of all 
pregnant women from the screening and diagnostic testing. 
7. Reviewer’s conclusion 
In the study, 56% of participants didn’t undergo OGTT, which could cause potential bias to the estimated GDM prevalence and sensitivity. Different from 
other studies, the risk factors used for selective screening included glucosuria but did not include maternal age. The selection of high risk women was 
deemed as screening, followed by OGTT diagnosis test. No screening test (such as 50g GCT) was performed.  
 
 
(21) Data extraction result for Moses et al. (1995)  
1. Study details 
Study ID: 15 
First author surname: Moses 
Year of publication: 1995 
Country and city: Australia, Illawarra area of New South Wales (near the city of Wollongong) 
Study design: Prospective cohort study 
Study setting: The prenatal clinics at Wollongong Hospital 
Number of centres: 1 
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Inclusion and exclusion criteria: All women attending the prenatal clinic at Wollongong hospital.  
Time of study: Between January 1993 and June 1994 
Funding: The study was funded by the Illawarra Area Health Service 
2. Aim of the study 
This study aims to determine what proportion of women with GDM by the Australasian Diabetes in Pregnancy Society (ADIPS) criteria would be missed if 
selective screening as used. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1209 
Number of participants consented/included 1185 (98.0%) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1161 (For the other 24 women, data about the BMI were absent in 19 women 
and the family history was not recorded in 5 women) 
Characteristics of participants 
Mean age (years) 26.7%≥ 30 years old 
Mean BMI (kg/m
2
) 15.1%≥ 30 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  15.3% 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age Yes (≥30) 
Obesity Yes (BMI ≥30) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
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Member of an ethnic or racial group with a high prevalence of GDM   No 
Others None 
 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1185 1185 (same cohort) 
Selection   
Number of high risk women  543 
Number of low risk women  642 
Screening   
Number of women undertook screening No screening test was performed No screening test was performed 
Time of screening N/A N/A 
Screening test N/A N/A 
Screening criteria reference N/A N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis 706 (59.6% of the 1185 women undertook the 
OGTT test) 
N/A 
Time of diagnosis At the beginning of the third trimester Same as universal group 
Diagnosis test 75g OGTT: 2-hour ≥ 8.0 mmol/l (in the first 6 
months of the study period); fasting≥ 5.5 mmol/l 
and/or 2-hour ≥ 8.0 mmol/l (in the following 12 
months of the study period) 
Same as universal group 
Diagnosis criteria reference The Australasian Diabetes in Pregnancy Society 
(ADIPS) criteria 
Same as universal group 
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Number of women diagnosed positive-GDM 
women (%) 
79/1185 (6.7%) 48/1185 (4.1%) 
Sensitivity 100% (reference) 60.8%=48/79 
Specificity 0% (reference) 55.2%=(642-31)/(1185-79) 
5.3 Other information 
None. 
6. Authors conclusion 
This study supports the ADIF'S recommendation that there should be universal testing. 
7. Reviewer’s conclusion 
No screening test was performed, GDM was diagnosed directly by the 75g OGTT test. In the study, only 706 (59.6%) of the 1185 participants underwent 
the diagnosis test, which could lead to potential bias in the estimate of GDM prevalence and the sensitivity of selective screening. 
 
 
 
(22) Data extraction result for Moses et al. (1998)  
1. Study details 
Study ID: 16 
First author surname: Moses 
Year of publication: 1998 
Country and city: Australia, Illawarra area of New South Wales (near the city of Wollongong) 
Study design: Retrospective cohort study 
Study setting: The prenatal clinics at Wollongong and Shellharbour hospitals 
Number of centres: 2 
Inclusion and exclusion criteria: All pregnant women attending the prenatal clinics at Wollongong and Shellharbour hospitals. Only the data from 
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singleton pregnancies have been included 
Time of study: Between January 1993 and June 1994 
Funding: Information not available 
2. Aim of the study 
This study aims to determine the GDM prevalence in women with low-risk factors and to see if the pregnancy outcomes of women with GDM from a low-
risk group were diff e rent from the outcomes of other women with GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 2907 
Number of participants consented/included 2907 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
2907 
Characteristics of participants 
Mean age (years) 27.0±5.0 (for Caucasian women) 
Mean BMI (kg/m
2
) 24.1±5.9 (for Caucasian women) 
Ethnicity 91.1% Caucasian (72.7% Australian, 18.4% European), 0.7% Aboriginal, 0.7% 
Pacific Islander, 3.1% Asian, 4.4% others 
Participants with a family history of diabetes among first-degree relatives  14.6% 
4. Selection criteria for high-risk women 
Reference of criteria N/A  
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age Yes (≥25) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives No 
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Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   Yes (non-Caucasian ethnic origin) 
Others None 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  2907 2907 (same cohort) 
Selection   
Number of high risk women  2334 
Number of low risk women  573 
Screening   
Number of women undertook screening No screening test was performed No screening test was performed 
Time of screening N/A N/A 
Screening test N/A N/A 
Screening criteria reference N/A N/A 
Number of women screened positive (%) N/A N/A 
Diagnosis   
Number of women undertook diagnosis N/A N/A 
Time of diagnosis At the beginning of the third trimester Same as universal group 
Diagnosis test 75g OGTT: 2-hour ≥ 8.0 mmol/l Same as universal group 
Diagnosis criteria reference The Australasian Diabetes in Pregnancy Society Same as universal group 
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(ADIPS) criteria 
Number of women diagnosed positive-GDM 
women (%) 
183/2907 (6.3%) 167/2907 (5.7%) 
Sensitivity 100% (reference) 91.3%=167/183 
Specificity 0% (reference) 20.4%=(573-16)/(2907-183) 
5.3 Other information 
The study additionally assessed the figures of specificity and sensitivity using different selection and diagnosis criteria. If the BMI thresholds changed from 
＜25 to ＜ 27, then the low risk women would increase from 573 to 652, and the GDM diagnosed would decrease from 167 to 149, the new specificity and 
sensitivity would be 22.4% (↑) and 81.4% (↓), respectively. If the 2-hour glucose level of GDM diagnosis changed from ≥ 8.0 mmol/l to ≥ 9.0 mmol/l, then 
the GDM cases would decrease from 167 to 75, and 6 cases would be from the 573 low risk women, the new sensitivity would be 92% (similar to the old 
sensitivity of 91.3%).  
6. Authors conclusion 
The pregnancy outcomes of women with GDM from a low-risk group are similar to the outcomes of other women with GDM. Selective screening needs 
further evaluation in different populations before it can be endorsed. 
7. Reviewer’s conclusion 
The study included 2907 women from Wollongong and Shellharbour hospitals, but didn’t report the number of women who actually underwent the OGTT 
diagnosis test. From a precious study of the author (Moses et al., 1995) including 1185 women from Wollongong hospital of the same study period, only 
706 (59.6%) of the 1185 women undertook the OGTT test. The non-compliance with the test could cause potential bias in the estimate of GDM prevalence 
and sensitivity. The advantage of the study is that the author additionally assessed the figures of specificity and sensitivity using different selection and 
diagnosis criteria (BMI thresholds changed from ＜25 to ＜ 27; the 2-hour glucose level of GDM diagnosis changed from ≥ 8.0 mmol/l to ≥ 9.0 mmol/l), 
and found the sensitivity and specificity would change according to the different criteria used. 
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(23) Data extraction result for Ostlund & Hanson (2003) 
1. Study details 
Study ID: 27 
First author surname: Ostlund & Hanson 
Year of publication: 2003 
Country and city: Sweden, Orebro 
Study design: Prospective cohort study 
Study setting: Maternal health centres and delivery departments in Orebro County 
Number of centres: Information not available 
Inclusion and exclusion criteria: All pregnant non-diabetic women attending maternal health care in Orebro County in Sweden during the study period 
Time of study: Between 1 July 1994 and 30 June 1996 
Funding: The study was supported by grants from the General Maternity Hospital Foundation and Research Committee of Orebro County Council 
2. Aim of the study 
This study aims to determine prevalence of GDM, and the value of traditional anamnestic risk factors for predicting GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 4918 
Number of participants consented/included 3616 (73.5%) agreed to perform the OGTT 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
3616 
Characteristics of participants 
Mean age (years) 27.9±4.8 
Mean BMI (kg/m
2
) 23.8±4.1 
Ethnicity 11.2% Nonnordic origin 
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Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women  
Reference of criteria Recommendation from the Swedish National Board of Health and Welfare in 
1997 
Type of criteria Risk factor ≥1 
Number of risk factors used 4 
Maternal age No 
Obesity Yes (weight ≥90 kg) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others No 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  3616 3616 (same cohort) 
Selection   
Number of high risk women  571 
Number of low risk women  3045 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 3616 571 
Time of diagnosis 28-32 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting ≥6.7 mmol/l, 2-hour ≥9.0 mmol/l.  
GDM include IGT and DM. IGT was diagnosed if 
Same as universal group 
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fasting <6.7 mmol/l and 2-hour between 9.0–11.0 
mmol/l; DM was diagnosed if fasting ≥6.7 mmol/l 
or 2-hour ≥11.1 mmol/l. 
Diagnosis criteria reference The World Health Organization (1980) Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
61/3616 (1.7%) 29/3616 (1.1%) 
Sensitivity 100% (reference) 47.5%=29/61 
Specificity 0% (reference) 84.8%=(3045-32)/(3616-61) 
5.3 Other information 
Random B-glucose was analysed every fourth to six week. If random B-glucose was ≥9.0 mmol/l an OGTT was carried out immediately. If this was in early 
pregnancy, an OGTT was repeated in 28–32 weeks of gestation. 
The sensitivity and specificity using the four risk factors are 47.5% and 84.8%, respectively. Adding ethnicity (Nonnordic) to these risk factors increased 
the sensitivity to 60.7% and decreased the specificity to 74.8%. While further adding maternal age (≥25 years) increased the sensitivity to 93.4%, however, 
the specificity decreased to 20.3%. 
6. Authors conclusion 
Using traditional risk factors as an indicator to perform an OGTT gives a low sensitivity to detect GDM and even DM especially among primiparas. 
7. Reviewer’s conclusion 
The study analysed the sensitivity and specificity under three different selection criteria. Using the four traditional risk factors gave a high specificity 
(84.8%) but low sensitivity (47.5%). Adding ethnicity as a risk factor didn’t change much (74.8% and 60.7%, respectively). While further adding maternal 
age as a risk factor gave a high sensitivity (93.4%) but unfortunately low specificity (20.3%). It is reasonable for the author to conclude that using 
traditional risk factors gives a low sensitivity and there is a need for other screening models.  
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(24) Data extraction result for Pintaudi et al. (2014) 
1. Study details 
Study ID: 28 
First author surname: Pintaudi 
Year of publication: 2014 
Country and city: Italy, Messina 
Study design: Retrospective cohort study 
Study setting: the Clinic of Diabetes and Pregnancy of the University of Messina 
Number of centres: 1 
Inclusion and exclusion criteria: Consecutive pregnant women referred to the clinic during the study period were included. Women with pre-pregnancy 
diabetes were excluded. 
Time of study: Between 1
 
May 2010 and 31 October 2011 
Funding: The study did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector 
2. Aim of the study 
This study aims to assess the predictive value of risk factors (RFs) for GDM established by selective screening (SS) and to identify subgroups of women at 
a higher risk of developing GDM. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1028 
Number of participants consented/included 1015 (13 were excluded: 12 had no complete information on the RFs or the 
first-trimester FPG values, one had pre-pregnancy diabetes) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1015 
Characteristics of participants 
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Mean age (years) 32.0±4.8 for GDM women; 30.5±5.4 for non-GDM women 
Mean BMI (kg/m
2
) 25.7±4.7 for GDM women; 23.7±6.8 for non-GDM women 
Ethnicity All Caucasian 
Participants with a family history of diabetes among first-degree relatives  40.7% for GDM women; 22.1% for non-GDM women 
4. Selection criteria for high-risk women  
Reference of criteria RECPAM model: risk factors identified by the RECursive Partitioning and 
AMalgamation (RECPAM) method 
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age No 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others FPG >4.4 mmol/l 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1015 1015 (same cohort) 
Selection   
Number of high risk women  641 
Number of low risk women  374 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1015 641 
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Time of diagnosis 24-28 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (one or more values above thresholds): 
fasting ≥5.1 mmol/l, 1-hour≥10.0 mmol/l, 2-hour 
≥8.5 mmol/l.  
Same as universal group 
Diagnosis criteria reference IADPSG recommendation Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
113/1015 (11.3%) 101/1015 (10.0%) 
Sensitivity 100% (reference) 89.0%=101/113 
Specificity 0% (reference) 40.1%=(374-12)/(1015-113) 
5.3 Other information 
The author conducted the RECPAM analysis to identify women at different risks of developing GDM. The study compared the effectiveness of selective 
screening using RECPAM model and SS criteria. The application of SS criteria would result in the execution of OGTT in 591 (58.3%) of women, and 26 
(23.0%) GDM cases would be missed due to the absence of any RF. The RECPAM model, however, would reduce by over 50% (23.0 vs 10.6%) the 
number of undiagnosed GDM cases when compared with the current SS approach, at the expense of 50 additional OGTTs required. 
The RFs used in the SS criteria are: age ≥35 years, BMI ≥25, FPG values between 5.6 and 6.9 mmol/l during pre-pregnancy or in the first trimester of 
pregnancy, previous GDM, previous macrosomia (≥4500g), family history of diabetes (first-degree relative with diabetes), and origin of family from areas 
with a high prevalence of diabetes.  
6. Authors conclusion 
A selective screening approach based on our RECPAM model results in a significant reduction in the number of undetected GDM cases compared with the 
current selective screening approach using SS critieria. 
7. Reviewer’s conclusion 
The selective screening approach using the RECAPM model would exempt 40.1% pregnant women from the OCTT and still diagnose 89.0% of GDM 
cases. Compared with the selective screening approach using traditional RFs, it increased the sensitivity from 77.0% (87/113) to 89.0% at the cost of only 
50 more OGTTs. It is rationale for the author to recommend the RECAPM model. The advantage of the study is that the author employed the RECAPM 
method to identify the RFs significantly associated with GDM in the population, and produced a more accurate selective screening model than the 
traditional one.   
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(25) Data extraction result for Savona-Ventura et al. (2013) 
1. Study details 
Study ID: 29 
First author surname: Savona-Ventura 
Year of publication: 2013 
Country and city: 11 Mediterranean countries 
Study design: Prospective cohort study 
Study setting: Centres among 11 Mediterranean countries 
Number of centres: Information not available 
Inclusion and exclusion criteria: Each participating centre from the 11 countries recruited a convenience sample of 75–200 pregnant women attending 
routine prenatal care during the study period. The participants were not known to have any form of carbohydrate metabolism disorder before their current 
pregnancy (i.e. T1DM, T2DM, or maturity-onset diabetes of the young). 
Time of study: Between August 1, 2010, and May 31, 2011 
Funding: The study was funded by a financial grant from the Mediterranean Group for the Study of Diabetes, which is supported by an unrestricted 
educational grant from Servier. 
2. Aim of the study 
This study aims to determine whether clinical risk assessment for GDM may preclude the need for universal screening with an OGTT in situations of 
economic restraint. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1368 
Number of participants consented/included 1368 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1368 
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Characteristics of participants 
Mean age (years) Eastern Mediterranean countries (28.9±6.1), northern Mediterranean countries 
(30.3±5.3), Maghreb countries (30.2±5.8) 
Mean BMI (kg/m
2
) Maternal BMI during the third trimester: Eastern (28.2±5.3), northern 
(28.5±4.9), Maghreb countries (27.6±4.7) 
Ethnicity 64 women (4.7%) were born in countries outside the Mediterranean region, 13 
of these 64 women had 1 or both parents of Mediterranean origin 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women  
Reference of criteria From the results of the risk factors analysis in this current study 
Type of criteria FBG >5.0 mmol/L or maternal obesity with age ≥30 
Number of risk factors used 3 
Maternal age Yes (≥30) 
Obesity Yes (pre-pregnancy BMI ≥25 or a 3rd trimester BMI ≥30) 
Family history of diabetes among first-degree relatives No 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others FBG >5.0 mmol/L 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1368 1368 (same cohort) 
Selection   
Number of high risk women  466 
Number of low risk women  902 
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Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1368 466 
Time of diagnosis 24-32 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT 
 
Same as universal group 
Diagnosis criteria reference The American Diabetes Association (ADA) 
criteria (2003) 
Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
119/1368 (8.7%) 96/1368 (7.0%) 
Sensitivity 100% (reference) 80.7%=96/119 
Specificity 0% (reference) 70.4%=(902-23)/(1368-119) 
5.3 Other information 
The author calculated the sensitivity and specificity using nine different combinations of risk factors (see Table 2 in the original article). Apart from the 
reported combination of risk factors, another important combination was FBG >5.0 mmol/L or age ≥30 years or diastolic BP ≥80 mmHg. Under this 
combination, the sensitivity and specificity was 96.6% and 34.5%, respectively. 
6. Authors conclusion 
Use of a composite model to prescreen women for GDM risk may reduce the need for universal screening with the OGTT among centres facing health-cost 
pressures. 
7. Reviewer’s conclusion 
The figures of specificity in this study were re-calculated by the reviewer using the definition of specificity in the review. Although the author assessed the 
sensitivity and specificity under nine different combinations of risk factors, the author’s conclusion was made based on the first combination which was 
FBG >5.0 mmol/L or maternal obesity with age ≥30 (sensitivity and specificity was 80.7% and 65.9%, respectively). It is rationale for the author to 
recommend selective screening under this combination for the areas of economic restraint. 
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(26) Data extraction result for Shamsuddin et al. (2001) 
1. Study details 
Study ID: 30 
First author surname: Shamsuddin 
Year of publication: 2001 
Country and city: Malaysia, Cheras 
Study design: Prospective cohort study (reported as cross-sectional study by the author) 
Study setting: Antenatal clinic at the Hospital Universiti Kebangsaan Malaysia (HUKM) 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women at ≥24 weeks’ gestation who were attending the antenatal clinic in HUKM. Known cases of diabetes 
mellitus or GDM already diagnosed elsewhere prior to the first antenatal visit in HUKM were excluded. 
Time of study: Between June 1999 and January 2000 
Funding: Information not available 
2. Aim of the study 
This study aims to assess the prevalence and association of frequently used screening risk factors for GDM, and to compare the validity and cost of 
universal screening with risk factor screening. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 896 
Number of participants consented/included 835 (93.2% responded) 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
768 (For the other 67 women, laboratory results of 50 mothers could not be 
traced and another 17 mothers were excluded due to incomplete data) 
Characteristics of participants 
Mean age (years) N/A (0.3% <20; 85% between 20-24; 14.7% ≥35) 
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Mean BMI (kg/m
2
) N/A 
Ethnicity 58.3% Malays, 35.0% Chinese, 5.0% Indians, 1.7% Others 
Participants with a family history of diabetes among first-degree relatives  N/A 
4. Selection criteria for high-risk women  
Reference of criteria N/A 
Type of criteria Risk factor ≥1 
Number of risk factors used 9 
Maternal age Yes (≥35) 
Obesity Yes  (maternal weight ≥80kg) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (≥4000g) 
History of adverse obstetric outcome Yes (birth with congenital anomalies, intrauterine deaths, neonatal death, 
previous polyhydramnios, spontaneous abortion) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Urinary tract infection 
 Vaginal discharge and pruritis vulvae 
 Glycosuria 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  768 768 (same cohort) 
Selection   
Number of high risk women  513 
Number of low risk women  255 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 768 513 
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Time of diagnosis ≥ 24 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (one value above threshold): 2-hour 
7.8mmol/l 
Same as universal group 
Diagnosis criteria reference N/A Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
191/768 (24.9%) 138/1368 (10.1%) 
Sensitivity 100% (reference) 72.2%=138/191 
Specificity 0% (reference) 35.0%=(255-53)/(768-191) 
5.3 Other information 
Among all these traditional risk factors used for the selective screening, only previous history of GDM and maternal age were significantly associated with 
prevalence of GDM in this population. The study also evaluated the cost of universal and selective screening, which were 12.6 RM and 11.15 RM to 
identify a case of GDM, respectively. 
6. Authors conclusion 
Risk factor screening scored poorly in predicting GDM. Cost analysis of universal compared with traditional risk factor screening showed a negligible 
difference. Thus universal screening appears to be the most reliable method of diagnosing GDM. 
7. Reviewer’s conclusion 
The specificity in this study was re-calculated by the reviewer using the definition of specificity in the review, which was the proportion of low-risk women 
who could be exempted from the GDM screening/diagnosis. The selective screening used a series of traditional risk factors but only identified 72.2% of the 
GDM cases. It is reasonable for the author to recommend universal screening to improve GDM detection in their population. 
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(27) Data extraction result for Shirazian et al. (2009) 
1. Study details 
Study ID: 31 
First author surname: Shirazian 
Year of publication: 2009 
Country and city: Iran, Tehran 
Study design: Retrospective cohort study (a secondary analysis on the ongoing prospective study) 
Study setting: Javaheri General Hospital and four private obstetric clinics  
Number of centres: 5 
Inclusion and exclusion criteria: Pregnant women with the diagnosis of diabetes before pregnancy, presence of comorbid conditions and whose 
gestational age was more than 28 weeks at first prenatal visit were excluded from the study. 
Time of study: Between May 2005 and May 2008 
Funding: The study was supported by Islamic Azad University, Tehran Medical Branch grant 
2. Aim of the study 
This study aims to determine the influence of risk factors on incidence of GDM in Iranian population. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 971 
Number of participants consented/included 971 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
924 (47 women did not complete OGTT) 
Characteristics of participants 
Mean age (years) N/A (29.2% ≤24; 40.2% between 25-29; 30.6% >30) 
Mean BMI (kg/m
2
) N/A (49.4% ≤24.9; 36.6% between 25.0-29.9; 14.0% >30) 
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Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  22.0% 
4. Selection criteria for high-risk women  
Reference of criteria Risk factors used was identified from the current study 
Type of criteria Risk factor ≥1 
Number of risk factors used 3 
Maternal age Yes (≥25) 
Obesity Yes (BMI ≥25) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant No 
History of adverse obstetric outcome No 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others No 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  924 924 (same cohort) 
Selection   
Number of high risk women  798 
Number of low risk women  126 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 924 798 
Time of diagnosis 24-28 weeks of gestation Same as universal group 
Diagnosis test 75g OGTT (two or more values above 
thresholds): fasting 5.3 mmol/l (95 mg/dl), 1-hour 
Same as universal group 
283 
 
10.0 mmol/l (180 mg/dl), 2-hour 8.6 mmol/l (155 
mg/dl) 
Diagnosis criteria reference American Diabetes Association (ADA) criteria Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
68/924 (7.4%) 67/924 (7.3%) 
Sensitivity 100% (reference) 98.5%=67/68 
Specificity 0% (reference) 14.6%=(126-1)/(924-68) 
5.3 Other information 
The author established a risk score system using the odds ratios of GDM risk factors. Pregnant women were stratified into 6 different score risk groups, 
scoring from 0 to 6. However, the low-risk group was directly defined as the group who scored 0, without further exploration of the other groups scored 1-6. 
The sensitivity, specificity, and the conclusion was calculated or made based on this definition of low-risk group.  
6. Authors conclusion 
Age, BMI, and family history of diabetes were independent risk factors in developing GDM. Concerning these factors, we do not miss substantial number 
of GDM cases with selective screening. 
7. Reviewer’s conclusion 
The selective screening approach exempted 14.6% women from the GDM diagnosis and missed 1.5% of GDM women. It is rationale for the author to 
conclude that selective screening will not miss substantial number of GDM cases in Iranian people using their selection criteria. However, the proportion of 
GDM women exempted from the GDM diagnosis test was also low. The author didn’t make a conclusion about whether or not to recommend selective 
screening. 
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(28) Data extraction result for Wagaarachchi et al. (2001) 
1. Study details 
Study ID: 32 
First author surname: Wagaarachchi 
Year of publication: 2001 
Country and city: Sri Lanka, Colombo 
Study design: Prospective cohort study 
Study setting: Antenatal clinics at the Castle Street Hospital for Women, Colombo 
Number of centres: 1 
Inclusion and exclusion criteria: Pregnant women attending antenatal clinics at the hospital during the study period were included. Women with pre-
existing diabetes were excluded from the study 
Time of study: 22 months (details not available) 
Funding: The study was supported by grants from the Sri Lanka College of Obstetricians and Gynaecologists and Les Laboratories Survier, Novo Nordisk 
Limited. 
2. Aim of the study 
This study aims to determine what proportion, if any, of women with GDM would be missed if testing was confined to clinical risk factors in an Asian 
population. 
3. Participants 
Number of participants (One cohort of universal screening) 
Number of participants invited/considered 1096 
Number of participants consented/included 1096 
Number of participants in the end after those missed/excluded/lost to 
follow-up at a later stage 
1004 (who had both tests performed and completed the study) 
Characteristics of participants 
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Mean age (years) N/A (21.6% ≥35) 
Mean BMI (kg/m
2
) N/A (11.1% ≥30) 
Ethnicity N/A 
Participants with a family history of diabetes among first-degree relatives  13.3% 
4. Selection criteria for high-risk women  
Reference of criteria N/A 
Type of criteria Risk factor ≥1 
Number of risk factors used 6 
Maternal age Yes (≥35) 
Obesity Yes (BMI ≥30) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM No 
A prior macrosomic infant Yes 
History of adverse obstetric outcome Yes (history of unexplained perinatal loss) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others Presence of grand multiparity 
5. Comparison of universal versus selective screening 
 Universal screening Selective screening 
Number of participants  1004 1004 (same cohort) 
Selection   
Number of high risk women  461 
Number of low risk women  543 
Diagnosis (one-step diagnosis only)   
Number of women undertook diagnosis 1001 461 
Time of diagnosis 24-28 weeks of gestation Same as universal group 
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Diagnosis test 75g OGTT  Same as universal group 
Diagnosis criteria reference The World Health Organisation Criteria (1980) Same as universal group 
Number of women diagnosed positive-GDM 
women (%) 
41/1004 (4.1%) 24/1004 (2.4%) 
Sensitivity 100% (reference) 58.5%=24/41 
Specificity 0% (reference) 54.6%=(543-17)/(1004-41) 
5.3 Other information 
Of the six risk factors used for the selective screening, only maternal age (≥35 years) and obesity (BMI ≥30) were significantly associated with developing 
GDM. 
6. Authors conclusion 
GDM is common in Asian women, and screening should be performed on every pregnant woman, rather than on selective basis as indicated by risk factors. 
7. Reviewer’s conclusion 
In the study, the selective screening approach using six risk factors would exempt about half of the women (54.6%) from the OGTT test, but would also 
miss around half GDM women (58.5%). It is rationale for the author to recommend universal screening. One point is that among the six risk factors, only 
two (maternal age and obesity) were found to be significantly associated with GDM. If use only these two risk factors and use different cut-offs (other than 
35 for age and 30 for obesity), there is possibility that the conclusion might change due to the altered specificity and sensitivity.  
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Appendix 5.3 Study characteristics of the cost-effectiveness study  
 
 Data extraction result for Poncet et al. (2002) 
1. Study details 
Study ID: 33 
First author surname: Poncet 
Year of publication: 2002 
Country: France 
Analytical framework (type of model): Decision analysis and cost-effectiveness analysis 
Perspective: Health system 
Study population: Pregnant women undertaking GDM screening and diagnosis at hospital 
Funding: The study was supported by grants from the Programme Hospitalier de Recherche Clinique 1997 (PHRC-Health ministry) 
2. Aim of the study 
This study aims to compare three strategies for GDM screening, in terms of cost-effectiveness. 
3. Intervention and comparator 
Intervention S1: Screening of high-risk pregnant women with 50g GCT followed by 100g OGTT 
S2: Screening of all pregnant women with 50g GCT followed by 100g OGTT 
S3: Screening of all pregnant women with a one-step 75g OGTT 
Comparator S0: No screening 
Details of 
screening and 
diagnosis tests 
50g GCT: 1-hour ≥7.2 mmol/l (Carpenter and Coustan criteria) 
100g OGTT (two or more values above thresholds): fasting ≥5.3 mmol/l, 1-hour ≥10.0 mmol/l, 2-hour ≥8.6 mmol/l, 3-hour ≥7.8 
mmol/l (Carpenter and Coustan criteria) 
75g OGTT (one or more values ≥ thresholds): fasting ≥5.5 mmol/l, 2-hour ≥8.0 mmol/l (World Health Organization criteria) 
288 
 
4. Selection criteria for high-risk women  
Reference of criteria N/A 
Type of criteria Risk factor ≥1 
Number of risk factors used 6 
Maternal age Yes (≥35) 
Obesity Yes (BMI ≥27) 
Family history of diabetes among first-degree relatives Yes 
Personal history of GDM Yes 
A prior macrosomic infant Yes (≥ 4000g) 
History of adverse obstetric outcome Yes (pre-eclampsia, foetal death after 3 months of gestation) 
Member of an ethnic or racial group with a high prevalence of GDM   No 
Others No 
5. Clinical effectiveness 
Effectiveness measures The outcome measures of effectiveness were macrosomia, prematurity, perinatal mortality, and 
hypertensive disorders rates. 
Source of effectiveness data The effectiveness estimations were extracted from a literature analysis based on Medline data using 
relevant keywords. Thirty-eight articles, published between 1973 and 1998 were finally retained and 
used to calculate the effectiveness. 
6. Cost data 
Economic measures The costs accounted for screening tests, obstetrical cares, management of GDM, if any, delivery cares, 
and sick leave, starting from the 24
th
 week of gestation till discharge from maternity. The long-term 
consequences of GDM after delivery were not considered. 
Source for resource consumption To estimate the various costs, they conducted a prospective study of 120 pregnancies between 15 
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February and 11 April 1999, in a public hospital of the Rhone-Alpes region (Lyon Sud Hospital-
Hospices Civils de Lyon). They relied also on expert opinions and literature data as complements. 
Reference of cost (health care system) The costs were evaluated according to the official French health insurance system (Assurance Maladie) 
criteria. 
The costs were estimated using the French key-letters costing system. Hospitalisation costs were 
evaluated using ISA points (synthetic activity index) per GHM (homogenous group of patients, the 
French version of diagnosis related group). In 1997, the ISA point value as Euros 1.94. Costing of sick 
leave was estimated from the daily allowance for sick leave paid by the official French health insurance 
system. 
Currency used Costs estimated in euros 
Years to which costs apply 1997 (Costing up-dating was not necessary because all costs were calculated within 3 months) 
7. Cost-effectiveness 
Outcome measures used in economic evaluations ICER 
Modelling summary A model of decision analysis was used to estimate the cost-effectiveness ratios (CERs) of the three 
alternative screening strategies versus the strategy of ‘no screening’. Based on the CERs, the estimation 
of the ICERs of each screening strategy with no screening was produced and compared. 
Cost-effectiveness outcomes The ICERs of S1 are 21069.52 (macrosomia), 9953.24 (prematurity), 7871.55 (perinatal mortality), and 
28674.90 (hypertension disorders). 
The ICERs of S2 are 23135.36 (macrosomia), 10965.20 (prematurity), 8663.83 (perinatal mortality), 
and 31898.74 (hypertension disorders). 
The ICERs of S3 are 68933.79 (macrosomia), 37320.89 (prematurity), 29444.16 (perinatal mortality), 
and 94506.04 (hypertension disorders). 
ICERs of S2 were 1.10-1.11 times of S1. ICERs of S3 were 3.27-3.75 times of S1. 
Sensitivity analysis Sensitivity analysis for the key variables was performed. 
6. Other information 
The sensitivity analysis showed that: (1) Changing the values of the events and the values of the main outcome measures within the range found in the 
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literature did not change of results of the ICERs; (2) Changing the values of the costs within the ranges [Euros 3811.23-6860.21] changed the ICERs values. 
Above the thresholds of Euros 5488.16, that is a relative variation of 9.5%, the strategy of screening of all pregnant women with a 75g OGTT (S3) was 
proved to be the most cost-effective. 
7. Authors conclusion 
The costs per case prevented reflect a favourable cost-effectiveness ratio for screening of high-risk pregnant women by 50g GCT. 
8. Reviewer’s conclusion 
The ICER, that is cost to obtain one unit of additional effectiveness, was 1.10-1.11 times more expensive of S2, and 3.27-3.75 times more expensive of S3, 
compared with S1. It is rationale for the author to conclude that S1 (selective screening) was the most cost-effective strategy among the three screening 
strategies. It is worthwhile to notice that the conclusion was not outstandingly robust, since sensitivity analysis showed changing the values of the costs 
could change the ICERs and the conclusion (S3 could be the most cost-effective strategy under certain circumstances). It is also worthwhile to notice that 
the outcome measures used are short-term outcomes before discharge from the hospital. The author also pointed out the future need for cost-effectiveness 
estimation on a long-term basis.   
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Appendix 6. Q sorting from −3 (Agree least) to +3 (Agree most) for the 32 
Q statements 
 
Agree Least                                                                         Agree Most       
-3 -2 -1 0 1 2 3 
              
              
 
          
 
 
          
 
  
      
  
  
      
  
   
  
   
   
  
    
 
Appendix 7. The 32 Q statements for the Q methodology study 
 
1. The OGTT is convenient 
2. Having blood drawn three times within 2 hours OGTT is too much 
3. The duration of 2 hours for the OGTT test is too long 
4. The time from having the OGTT test to collecting the result was satisfactory 
5. I feel it is more convenient to collect my GDM diagnosis result during my next 
visit to the hospital, rather than waiting for several hours to collect it on that day 
6. I prefer face-to-face notification of the GDM diagnosis result when I come to the 
hospital rather than being telephoned when the result comes out 
7. It was easy to find the scan machine for collecting my GDM diagnosis result 
8. The GDM diagnosis result sheet was NOT understandable 
9. I was satisfied with the doctor’s explanation when I gave my GDM diagnosis 
result sheet to him/her to review 
10. I wish I had been given more information about GDM and GDM diagnosis 
before I had the OGTT 
11. I wish I had been given more information about GDM and GDM diagnosis after 
I had the OGTT 
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12. I am NOT satisfied with the GDM information I received from the doctors/nurses 
at the hospital 
13. I am satisfied with the GDM information I received from the weekly lectures for 
pregnant women at the hospital 
14. I am NOT satisfied with the GDM information I received from the 
leaflet/bulletin board at the hospital 
15. I would prefer to receive GDM information from weekly lectures for pregnant 
women at the hospital 
16. I would prefer to receive GDM information from an education leaflet provided 
by the hospital 
17. I would NOT prefer to receive GDM information from the hospital bulletin board 
18. I would NOT prefer to search for GDM information (from internet, TV, 
magazines, books, etc.) by myself 
19. I would prefer my family (parents, husband/partner) or my friends to search for 
GDM information for me 
20. I would prefer to learn about GDM from talking to women who have or had 
GDM 
21. Testing for GDM is very important and necessary 
22. The OGTT should be conducted for all pregnant women 
23. I feel it is a burden to undergo the OGTT 
24. I was confused about the OGTT 
25. I was unhappy with the OGTT 
26. I am satisfied with the whole process of being tested for GDM 
27. I am satisfied with the support I received throughout the OGTT procedure 
28. I was treated with dignity and respect by staff in the hospital throughout the 
whole OGTT procedure 
29. The doctor who gave the OGTT to me was NOT knowledgeable and informative 
30. The doctor who did the OGTT listened to my concerns and listened to what I 
needed 
31. Sometimes I felt afraid to ask the hospital staff relevant advice about OGTT and 
GDM 
32. All necessary explanations and advice about OGTT were given by hospital staff 
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Appendix 8. Screenshots illustration of the FlashQ programme 
 
1. Instruction： 
 
 
2. Q statements and Q sorting: 
 
2.1Select ‘Disagree’, ‘Neutral’, or ‘Agree’ for each of the 32 statements 
 
 
2.2 Rank over the preferences to get a pyramid of (dis)agreements 
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3. Provide reasons for the most agreed and disagreed statements: 
 
 
4. Provide background information and additional comments: 
 
 
5. Submit data and finish the FlashQ study: 
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Appendix 9. An instruction sheet for completing the FlashQ 
 
Thank you very much for participating in the study. Here are some 
instructions for you before you start! 
1)  Your study number is: ______ (You will need this information in the last 
section of the study). 
2) The study aims to explore pregnant women’s attitudes, views, and experience 
of the gestational diabetes mellitus (GDM) diagnosis. The study is developed 
using the FlashQ software.  
3) Please use the laptop computer in the meeting room to complete the FlashQ 
study. The study will take about 15-20 minutes. However, you can take as 
long as you wish to complete the study. 
4) Please simply follow the instructions on the FlashQ to complete. If you have 
any questions or queries during the process, please do not hesitate to contact 
the researcher at the other side of the room. 
5) When you finish the study, please notify the researcher at the other side of 
the room. You will receive a small souvenir of the University of Warwick 
from the researcher.  
 
Thanks again for your precious time!  
 
*If you have any further queries, or if you want to discuss the results of the study, 
please do not hesitate to contact the researcher. Contact information: Qing Fang 
(PhD student), Warwick Medical School, the University of Warwick, Coventry CV4 
7AL, United Kingdom. Email: Q.Fang@warwick.ac.uk. Contact number: 0086-
15810470049 (China); 0044-2476 574505 (United Kingdom).   
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Appendix 10. Full ethical approval letter for the Q methodology study 
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Appendix 11. Table for flagging significant factor loadings (Quick lookup 
table – is it significant?) 
 
Source: http://jeffar.es/category/q-methodology/ 
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Appendix 12. Screenshot for dragging the Q statements into the Q 
pyramid 
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Appendix 13. The list of potential GDM risk factors under investigation 
in the nested case-control study 
Potential GDM risk factors planned to be investigated Version 
(electronic, 
paper, 
calculated, or 
N/A) 
1 Maternal age (years) E 
2 BMI (kg/m
2
) 
* BMI is calculated as weight (kg)/(height(m))2 
C 
3 Family history of diabetes (no family history, father, mother, brother, 
sister, grandfather, grandmother) 
E + P 
4 History of GDM (Yes or No) N/A 
5 History of macrosomia (Yes or No) E + P 
6 Unsuccessful pregnancy history (no history, fetal death, stillbirth, 
abortion, fetal anomaly) 
E 
7 Gestational weight gain (kg)  
*Weight gain between pre-pregnancy and OGTT test. 
P 
8 Polycysticovary syndrome (PCOS) (Yes or No) 
*PCOS is diagnosed if the patient has all of the following: (1) oligoovulation, (2) signs 
of androgen excess (clinical or biochemical), (3) other entities are excluded that would 
cause polycystic ovaries. 
P 
9 Waist circumference (pre-pregnancy) (cm) P 
10 Height (cm) E 
11 Mother’s birth weight (kg) N/A 
12 High blood pressure during first trimester(hypertension, 
prehypertension, or normal) 
*Reference value: 120/80 mmHg (normal), 120–139/80–89 mmHg (prehypertension), 
and140 and/or 90 mmHg or use of antihypertensive medications (hypertension). 
P 
13 Family history of hypertension (Yes or No) E + P 
14 Irregular menstruation (Yes or No) 
*Irregular menstruation is a menstrual disorder whose manifestations include irregular 
cycle lengths as well as metrorrhagia (vaginal bleeding between expected periods). 
E 
15 Vulvovaginal candidiasis (Yes or No) 
*Vulvovaginal candidosis is the presence of Candida in addition to vaginal 
inflammation. The presence of yeast is typically diagnosed in one of three ways: 
microscopy, microbial culture, and antigen tests. 
E + P 
16 Triglycerides (above or normal) 
*Reference value:0.4-1.7mmol/l. 
N/A 
17 Total cholesterol (above or normal) 
*Reference value:3.35-6.45mmol/l. 
N/A 
18 α-thalassaemia (Yes or No) 
*α -thalassaemiais a form of thalassemia involving the genes HBA1and HBA2. α -
thalassaemiais due to impaired production of 1,2,3, or 4 alpha globin chains, leading to 
a relative excess of beta globin chains.  
N/A 
19 Hemoglobin (above or normal) 
*Reference value: 110-150g/L 
E + P 
20 Elevated serum ferritin level (above or normal) 
*Reference value: 6.6－28.3 pmol/l. 
E + P 
21 Maternal Smoking (Yes or No) E 
22 Occupation (unemployed; employed) E 
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23 Education level (below college; college or above) N/A 
24 Family income (<¥5000⁄ month; ≥ ¥5000⁄ month) N/A 
25 Hepatitis B virus carrier (HBsAg+) (Yes or No) E + P 
26 Previous deliveries E 
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Appendix 14. Full ethical approval letters for the case-control study 
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Appendix 15. A full list of cut-off scores and corresponding sensitivities and specificities of the ROC curve 
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Appendix 16. Sensitivity and specificity with the two different cut-off 
scores 
3.1 Figures with a cut-off score of 0.32 
  IADPSG screening 
GDM Non-GDM Total 
Risk scoring 
algorithm 
( with a cut-off 
score of 0.32) 
Positive 
(≥0.32 as having 
high risk of 
GDM) 
245 (True positive) 211 (False 
positive) 
456 
Negative 
(<0.32 as having 
low risk of 
GDM) 
27 (False negative) 67 (True negative) 97 
Total 272 278 553 
1. Sensitivity=TP/(TP + FN)=245/272=90% 
2. Specificity=TN/(TN + FP)=67/278=24% 
3. Sensitivity is the proportion of GDM who are correctly diagnosed out by using the risk 
scoring algorithm with the IADPSG diagnosis approach. 
4. Specificity is the proportion of non-GDM who are classified as low risk women and avoid 
the IADPSG diagnosis approach. 
 
3.2 Figures with a cut-off score of 0.37 
  IADPSG screening 
GDM Non-GDM Total 
Risk scoring 
algorithm 
( with a cut-off 
score of 0.37) 
Positive 
(≥0.37 as having 
high risk of 
GDM) 
218 (True positive) 153 (False 
positive) 
371 
Negative 
(<0.37 as having 
low risk of 
GDM) 
54 (False negative) 125 (True 
negative) 
179 
Total 272 278 550 
1. Sensitivity=TP/(TP + FN)= 218/272=80% 
2. Specificity=TN/(TN + FP)=125/278=45% 
3. Sensitivity is the proportion of GDM who are correctly diagnosed out by using the risk 
scoring algorithm with the IADPSG diagnosis approach. 
4. Specificity is the proportion of non-GDM who are classified as low risk women and avoid 
the IADPSG diagnosis approach. 
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